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Key messages  
This health technology assessment (HTA) summarises and supplements 
a 2019 Canadian HTA on the effectiveness and safety of micro-invasive 
glaucoma surgery (MIGS) versus other treatment options. Further, it 
contains cost-effectiveness analysis based on the Canadian HTA, in ad-
dition to patient partners’ considerations, organizational and ethical 
considerations relevant to discussions of MIGS’ role in Norwegian rou-
tine care.  
 
The Canadian evidence, which included 32 studies and 24 comparisons, 
was inconclusive due to very low to low certainty.  
 
Our supplementary findings show that: 
• MIGS with Hydrus Microstent combined with cataract surgery 
reduces intraocular pressure (IOP) at 24 months, compared with 
cataract surgery alone (high-certainty evidence) 
• MIGS with iStent inject combined with cataract surgery probably 
reduces IOP at 24 months, compared with cataract surgery alone 
(moderate-certainty evidence) 
• For other techniques there is either no or little difference between 
the MIGS and control interventions, or it is uncertain whether there 
is a difference in effectiveness 
• Neither MIGS procedures, nor alternative surgical strategies appear 
to be at high risk of adverse events 
• Lifetime total cost for glaucoma treatment ranged from NOK 30 000 
to NOK 83 000 per patient, depending on treatment strategy  and 
baseline disease stage. The incremental Quality adjusted life years 
(QALYs) for MIGS between comparators ranged between – 0.080 
and 0.057  
• MIGS is suitable as a outpatient surgery without hospital admission. 
Clinicians need training. Clear criteria for patient selection shuld be 
developed. Experts predict that the number of MIGS procedures 
may increase to twice as many in 2024 than today 
• The clinical evidence on MIGS is limited. The main reason for this is 
the lack of comparative studies. Our health economic evaluation 
shows some scenarios where MIGS may be cost-effective, 
depending on comparator and disease stage. Our analysis puts 
individuals with glaucoma in severity class 1.  
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 7  Executive summary 
Executive summary 
 
Background 
Glaucoma is a substantial public health problem, with a large negative impact on qual-
ity of life and the utilization of health care resources. Glaucoma refers to a group of eye 
conditions with a characteristic pattern of progressive damage to the optic nerve. 
Raised intraocular pressure (IOP) is the best characterized risk-factor, but IOP can also 
be normal. Globally, glaucoma is considered the leading cause of irreversible vision loss 
and one of the leading causes of blindness overall. There are approximately 77,000 
Norwegian individuals with a glaucoma diagnosis. The incidence is expected to in-
crease because of demographic changes and because the disease can now be diagnosed 
at earlier stages than before. Minimally invasive glaucoma surgery (MIGS) represents a 
class of new surgical procedures and devices to address this issue. Experts suggest 
MIGS may result in shorter procedure and recovery times than traditional surgical pro-
cedures, and that MIGS make it possible to offer treatment at an earlier stage of glau-
coma. The indications for each MIGS procedure depend on its mechanism of action and 
the individual patient’s target IOP and concomitant eye diseases. MIGS procedures and 
devices can be used alone or in conjunction with cataract surgery. The procedure is al-
ready offered in many public hospitals in Norway. 
 
Objective 
The objectives of this health technology assessment (HTA) were to: 1) supplement the 
evidence of (effectiveness and safety ) of MIGS in an HTA published by the Canadian 
Agency for Drugs and Technologies in Health (CADTH) in January, 2019, 2) conduct a 
health economic evaluation of MIGS from a Norwegian health care perspective, and 3) 
assess organizational and ethical aspects of MIGS in a Norwegian setting.  
 
Method 
Clinical effectiveness and safety 
We have summarized CADTH’s HTA evidence of effectiveness and safety, and adapted 
CADTH’s methods in the conduct of our supplementary review of more recent studies. 
CADTH carried out systematic literature searches in August and November 2017, while 
our updated searches were carried out in August 2019 and November 2020. Searches 
were run in electronic medical databases, such as MEDLINE, EMBASE, CINAHL and 
Cochrane Central Register of Controlled Trials, using peer-reviewed search strategies. 
Two reviewers independently selected studies meeting our inclusion criteria. Likewise, 
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two reviewers independently judged the included studies’ risk of bias. One reviewer ex-
tracted predefined data, and another reviewer checked the data extraction. The pri-
mary outcome in CADTH’s HTA was quality of life, and intraocular pressure in the Nor-
wegian Institute of Public Health (NIPH) HTA supplementary review. When possible, 
mean differences with 95 % confidence intervals were calculated, and effect estimates 
were pooled for similar comparisons.  When pooling was not possible, findings were re-
ported narratively. One reviewer assessed the certainty of the evidence with the 
GRADE approach, and a second reviewer checked the assessments. 
 
Health economic evaluation 
We based our health economic analysis on the previous HTA carried out by CADTH. We 
developed six different decision analytic cost-effectiveness models in TreeAge Pro, to 
estimate incremental cost utility rate (ICER). The models provide insight into costs, 
health effects, survival, and disease stage. The analysis was carried out from a modified 
Norwegian health care perspective. We have estimated absolute shortfall for patients 
with glaucoma. We handled uncertainties in model parameters by assigning probability 
distributions to the parameters and performing probabilistic sensitivity analysis (PSA), 
designed as a Monte Carlo simulation. We also performed one-way sensitivity analyses 
for each of the six models to explore potential impact of uncertainty in single parame-
ters. In addition, we estimated the budget impact of introducing MIGS as a routine 
treatment option in Norway for patients with glaucoma. 
 
Organizational aspects 
In order to evaluate the organizational consequences related to the implementation of 
MIGS and a potential increase in volume of MIGS performed in Norwegian hospitals, we 
asked clinical experts from five of the state-run hospitals that perform MIGS in Norway, 
to answer a questionnaire regarding their present capacity and procedure used: patient 
selection, procedures and ongoing trials.  
 
Ethical perspectives 
We analysed central ethical implications of MIGS implementation, and the analysis was 
proceeded in three major steps: First, brief description of the situation, alternative ac-
tions and solutions, and the involved stakeholders. Second, analysis of the ethical chal-
lenges and possible consequences in terms of the four principles: benefit, harm, auton-
omy and justice. 
 
Results 
Clinical effectiveness and safety 
 
CADTH HTA 
CADTH’s HTA included 35 publications from 32 studies; 10 randomized trials and 22 
non-randomised studies. The evidence included 24 specific comparisons: one compari-
son of a MIGS versus another MIGS, six comparisons of a MIGS combined with cataract 
surgery versus cataract surgery alone, nine comparisons of a MIGS combined with cata-
ract surgery versus filtration surgery combined with cataract surgery, six comparisons 
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of a MIGS combined with filtration surgery versus filtration surgery alone, two compar-
isons of a MIGS versus pharmacotherapy, and one comparison of a MIGS versus laser 
therapy. CADTH’s authors considered all the included studies to have some risk of bias. 
 
As shown in the table below with summary of findings by comparison and outcomes 
(reproduced with kind permission from CADTH), there was largely no statistically sig-
nificant difference between intervention and comparator and this can be explained  be-
cause the heterogeneity in interventions and comparisons did not allowed pooling. . 
The evidence was considered very low or low certainty across comparisons and out-
comes. 
  
 
NIPH supplementary review  
We identified and included eight studies (seven randomised trials and one non-ran-
domised study) that compared a MIGS procedure alone or in combination with cataract 
surgery, with another MIGS procedure or non-MIGS procedures. None of the additional 
found studies could be pooled with study results in the CADTH HTA. 
 
As showed in the summary of findings table below, there was high-certainty evidence 
of lower IOP with Hydrus in combination with cataract surgery than with cataract sur-
gery alone, and moderate-certainty evidence of lower unmedicated IOP with iStent in-
ject in combination with cataract surgery than with cataract surgery alone. Otherwise, 
there was no or little difference between the MIGS and interventions in control groups, 
or the certainty of the evidence was too low to make a judgement. 
 
The evidence for the safety of MIGS was inconclusive across the comparisons, but there 
appeared to be little or no risk of complications associated with any of the treatment 
options. There also appears to be no standarized method to measure safety.  
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Summary of findings: Intraocular pressure (IOP) 
Effectiveness of MIGS for open-angle glaucoma in adults 
Patient or population: adults with open-angle glaucoma  
Intervention: MIGS alone or in combination with other procedure 
Comparison: other MIGS or other procedure  
Comparison 
Anticipated absolute effects* 
MD (95% CI)  № of participants  (studies)  
Certainty of the 
evidence 
(GRADE)  
Comments 
 Intraocular pressure [mm 
Hg] 
   
 
 
One MIGS procedure versus another MIGS procedure   
Hydrus vs 2x iStent  
MD 1.9 lower 
(2.91 lower to 0.89 lower)  
148 
(1 RCT)  
⨁⨁◯◯ 
LOW a,b 
Follow-up: 12 months 
One MIGS procedure versus another procedure (non-MIGS) 
iStent+phaco vs 
phaco alone  
 
MD 1.9 lower 
(3.32 lower to 0.48 lower)  
48 
(1 observational study)  
⨁◯◯◯ 
VERY LOW b,c 
Follow-up: 12 months 
iStent inject+phaco 
vs phaco alone  
 
MD 0.7 lower 
(1.27 lower to 0.13 lower)  
570 
(2 RCTs)  
⨁⨁⨁◯ 
MODERATE a 
Follow-up: 24 months 
Hydrus+phaco vs 
phaco alone  
 
MD 1.8 lower 
(2.73 lower to 0.87 lower)  
331 
(1 RCT)  
⨁⨁⨁⨁  
HIGH 
Follow-up: 24 months 
Trab360+phaco vs 
phaco alone  
 
MD 2.8 lower 
(5.49 lower to 0.11 lower)  
18 
(1 RCT)  
⨁◯◯◯ 
VERY LOW b,d 
Follow-up: 24 months 
Gold MicroShunt vs 
Ahmed glaucoma 
valve  
 
MD 0.7 lower 
(2.71 lower to 1.31 higher)  12 
(1 RCT)  
⨁◯◯◯ 
VERY LOW b,e 
Follow-up: 5 years 
iTrack+phaco vs fil-
tration sur-
gery+phaco  
 
MD 1.7 lower 
(3.29 lower to 0.11 lower)  59 
(1 RCT)  
⨁◯◯◯ 
VERY LOW b,f 
Follow-up: 12 months 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the rela-
tive effect of the intervention (and its 95% CI).  
 
CI: Confidence interval; MD: Mean difference; phaco: phacoemulsification (cataract surgery)  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, 
but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the esti-
mate of effect  
Explanations 
a. Possible risk of performance bias in personnel  
b. Wide confidence interval and/or sub-optimal information size 
c. Serious bias due to confounding  
d. High risk of performance and detection bias. 
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e. High risk of attrition bias; unclear risk of bias in most other domains.  
f. High risk of selection, performance and attrition bias; unclear risk of detection and reporting bias. 
 
 
Health economic evaluation 
The lifetime total cost per patient for glaucoma treatment ranged between NOK 30 000 
and NOK 84 000 depending on the treatment strategy and patient’s baseline disease 
stage. The incremental quality adjusted life years (QALYs) for MIGS between compara-
tors ranged between – 0.080 and 0.057.  
 
Organizational aspects 
MIGS surgery is done at many public hospitals in Norway in addition to a few private 
clinics. There is a lack of formalised indications for the use of MIGS in Norway. MIGS is 
suitable for outpatient surgery without hospital admission. Ophthalmologists need spe-
cific MIGS training to perform the surgery (certification). The MIGS-procedures have a 
shorter learning curve than traditional glaucoma surgery, and has in other countries 
also been implemented by non-glaucoma specialists / general cataract surgeons for this 
reason (i.e. some benefit in terms of regional accessibility in Norway can be expected).  
MIGS procedures require less follow-up than traditional surgery, so there may be fewer 
post-intervention controls per patient in the hospital. Finally, a better treatment option 
may also lead to more patients being operated. The need for glaucoma surgery may in-
crease due to increased population growth in the relevant age group. Experts predict 
that the demand for MIGS procedures will increase annually from today to twice as 
many by 2024. 
 
Ethical perspectives 
There are potential benefits of MIGS. The central ethical concerns of MIGS implementa-
tion are, in terms of justice, to guarantee patients equal access to treatment, regardless 
of ability to pay, place of residence, social status, or cultural background. The chal-
lenges for patient autonomy seem manageable, if patients can be thoroughly informed 
about risks of and alternatives to a given MIGS procedure.  
 
Discussion 
The strengths of CADTH’s and our health technology assessments include updated sys-
tematic searches in electronic databases, pre-specified inclusion and exclusion criteria, 
double independent screening of identified records, independent assessments of risk of 
bias in included studies, systematic data extraction and reporting, and assessments of 
the certainty of the evidence. We believe we have identified most eligiblie studies that 
were not included in CADTH’s HTA, thus providing a useful supplement.  
 
We had to make several assumptions to develop the six health economic models, lead-
ing to some uncertainty surrounding our economic results. MIGS is a heterogeneous 
group of devices with potentially different costs, risk profiles and relative treatment ef-
fects. We replicated the model from CADTH with respect to model structure and effi-
cacy data. The input is adjusted according to Norwegian conditions.  
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It is important to ask whether the introduction of MIGS will lead to a change in Norwe-
gian practice. According to our clinical experts, the impact on practice will be limited. 
Our health economic evaluation is consistent with other evaluations on health econom-
ics, among others the CADTH report, regarding uncertainty around estimates due to 
lack of data. Cost components may be different in different countries. 
 
To obtain high quality documentation for the myriad of possible MIGS comparisons, 
there is a need for more well-designed randomised trials, with larger numbers of par-
ticipants and longer follow-up. Further, detailed micro-costing of MIGS procedures may 
allow for greater certainty in the true absolute and incremental costs of MIGS to better 
inform the potential economic value of MIGS. For patients and clinicians, it would be 
helpful if evidence-based guidelines were developed or applied to a Norwegian setting 
in addition to local and/or national registrers.  
 
Studies on the most used MIGS procedures in Norway (as iStent, Xen, Preserflo) are in-
cluded, but might not be well documented in this report, as some relevant clinical com-
parisons have not been conducted yet (to our knowledge). The evaluation of effect and 
cost-effectiveness might therefore have some limits. 
 
 
Conclusion 
MIGS with Hydrus Microstents combined with cataract surgery reduces intraocular 
pressure (IOP) at 24 months, compared to cataract surgery alone.  MIGS with Hydrus 
Microstents probably reduces IOP at 12 months, compared to MIGS with 2x iStents. For 
other comparisons and outcomes, it is uncertain whether there is a difference in IOP re-
duction. Neither MIGS procedures nor alternative surgical strategies appear to be at 
high risk of adverse events, and it is uncertain whether complications occur more or 
less frequently in either category. Definitive conclusions on the cost-effectiveness of 
MIGS are uncertain, given the uncertainty in the analysis. The economic evaluation pro-
vided some scenarios where MIGS might be cost-effective, depending on comparator 
and disease stage. 
 
The clinical evidence on MIGS is limited. The main reason for this is the lack of compar-
ative studies. Our health economic evaluation shows some scenarios where MIGS may 
be cost-effective, depending on comparator and disease stage. Our analysis puts indi-
viduals with glaucoma in severity class 1. 
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Hovedbudskap 
Denne metodevurderingen (HTA) oppsummerer og sup-
plerer en kanadisk HTA fra 2019 om effekt og sikkerhet 
ved minimal-invasiv glaukomkirurgi (MIGS). Videre gjorde 
vi kost-nytteanalyser basert på den kanadiske HTAen, i til-
legg til brukerperspektiv, organisatoriske og etiske vurde-
ringer som er relevante i en diskusjon om hvorvidt MIGS 
bør være et rutinetilbud i norsk praksis.     
 
Det kanadiske kunnskapsgrunnlaget, som omfattet 32 stu-
dier og 24 sammenlikninger, var usikkert på grunn av 
svært lav til lav tillit til resultatene. Våre supplerende funn 
viser at:  
• MIGS med Hydrus Microstent kombinert med 
kataraktkirurgi reduserer intraokulært trykk (IOP) etter 24 
måneder, sammenliknet med kataraktkirurgi alene (høy tillit 
til resultatet) 
• MIGS med iStent inject og kataraktkirurgi reduserer trolig 
IOP etter 24 måneder, sammenliknet med kataraktkirurgi 
alene (middels tillit til resultatet) 
• Det er usikkert hvorvidt det er noen forskjell i effekt mellom 
MIGS og kontrollgruppene for andre sammenligninger 
• Det ser ikke ut til å være noen betydelig forskjell mellom 
MIGS og kontrollgruppene i risiko for uønskede 
hendelser/skader 
• Total livstidskostnad per pasient for glaukombehandling ble 
estimert mellom 30 000 norske kroner og 83 000 norske 
kroner avhengig av behandlingsstrategi og sykdomsstadie 
ved start. Inkrementell QALY for MIGS sammenlignet med 
komparatorer var mellom – 0.080 og 0.057  
•  MIGS egner seg for poliklinisk kirurgi. Øyeleger må ha 
opplæring for å utføre MIGS. Det bør utvikles klare kriterier 
for pasientseleksjon. Eksperter predikerer en dobling av 
antall MIGS prosedyrer i 2024 enn antallet i dag 
• Kunnskapsgrunnlaget for effekt og sikkerhet om MIGS er 
begrenset. Hovedgrunnen er mangel på sammenliknende 
studier. Vår helseøkonomiske vurdering viser at MIGS kan 
være kostnadseffektive, avhengig av sammenliknng og 
sykdomsutvikling. Vår analyse setter individer med glaukom 
i gruppe for alvorlighetsgrad 1.  
Tittel: 
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Sammendrag 
Bakgrunn 
Glaukom er et betydelig folkehelseproblem med stor påvirkning på livskvalitet for pasi-
enter og pårørende. Pasienter med glaukom har behov for betydelig hjelp fra helsetje-
nestene. Glaukom refererer til en sykdomsgruppe som kjennetegnes av en progressiv 
ødeleggelse av synsnerven i et karakteristisk mønster. Økt intraokulært trykk (IOP) er 
den best beskrevne risikofaktoren, men IOP kan også være normalt. Globalt betraktes 
glaukom som den vanligste årsaken til irreversibelt synstap og en av de vanligste årsa-
kene til blindhet. I Norge er om lag 77 000 individer diagnostisert med glaukom. Insi-
densen er forventet å øke på grunn av demografiske endringer og fordi tilstanden nå 
kan diagnostiseres tidligere enn før. Minimal-invasiv glaukomkirusrgi (MIGS) er en ny 
gruppe av kirurgiske prosedyrer og utstyr. Ifølge eksperter kan MIGS gi kortere prose-
dyre- og restitusjonstider sammenlignet med tradisjonelle kirurgiske prosedyrer, noe 
som gjør det mulig å utføre MIGS på et tidligere sykdomsstadium. Indikasjonene for 
hver enkelt MIGS-prosedyre varierer med virkningsmekanisme og pasientens individu-
elle mål for intraokulært trykk (IOP). MIGS-prosedyrer og -utstyr kan utføres alene el-
ler i kombinasjon med katarakt kirurgi. Inngrepet tilbys allerede på mange offentlige 
sykehus i Norge. 
 
Mål 
Hensikten med denne metodevurderingen var å 1) supplere kunnskapsgrunnlaget for 
effekt og sikkerhet av MIGS sammenliknet med andre behandlingsstrategier i en meto-
devurdering (HTA) publisert av the Canadian Agency for Drugs and Technologies in 
Health (CADTH) i januar 2019, 2) undersøke kostnadseffektiviteten ved MIGS opp mot 
prioriteringskriteriene gjeldende i norsk helsetjeneste: nytte-, ressursbruk- og alvorlig-
hetskriteriet, og 3) vurdere organisatoriske konsekvenser og etiske aspekter relatert til 
bruk av MIGS i Norge.  
 
Metode 
Klinisk effekt og sikkerhet 
Vi har oppsummert kunnskapsgrunnlaget i CADTH-HTAen og tilpasset CADTHs meto-
der i utføringen av vår supplerende gjennomgang av nyere studier. CADTH søkte syste-
matisk etter litteratur i august og november 2017, mens våre oppdateringssøk ble gjen-
nomført i august 2019 og november 2020. Søkene ble kjørt ved hjelp av fagfellevur-
derte søkestrategier i elektroniske medisinske databaser som MEDLINE, EMBASE, 
CINAHL og Cochrane Central Register of Controlled Trials. 
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To forskere valgte, uavhengig av hverandre, ut studier som møtte inklusjonskriteriene. 
Videre vurderte to forskere uavhengig av hverandre også risiko for skjevheter i de ink-
luderte studiene. Én forsker hentet ut forhåndsbestemte data, og en annen forsker sjek-
ket datauthentingen. Hovedutfallet i CADTH-HTAen var livskvalitet, mens det var intra-
okkulært trykk i FHIs supplerende gjennomgang. Der det var mulig ble gjennomsnitts-
forskjeller med 95% konfidensintervall beregnet, og effektestimater for like sammen-
ligninger slått sammen. Til slutt vurderte en forsker tilliten til resultatene ved hjelp av 
GRADE-tilnærmingen, og en annen forsker sjekket vurderingene. 
 
Helseøkonomisk evaluering 
Vi baserte vår helseøkonomiske analyse på en tidligere HTA utført av CADTH. Vi utvik-
let seks ulike beslutnings-analytiske kostnadseffektivitets modeller i TreeAge Pro for å 
estimere ICER. Modellene gir innsikt i kostnader, helseeffekter, overlevelse og syk-
domsstadie. Analysen ble utført ut ifra et modifisert norsk helsetjenesteperspektiv. Vi 
har estimert absolutt prognosetap for pasienter med glaukom. Vi håndterte usikkerhet 
i modell-parametere ved å tildele sannsynlighetsfordelinger til parameterene og ut-
førte «probabilistic sensitivity analysis» (PSA), utformet som Monte Carlo simuleringer. 
Vi utførte også enveis sensitivitetsanalyser for hver av de seks modellene for å under-
søke potensiell påvirkning til usikkerheten på enslige parametere. I tillegg, estimerte vi 
budsjett konsekvens ved å introdusere MIGS som en rutine behandlingsalternativ i 
Norge for pasienter med glaukom. 
 
Organisatoriske aspekter 
For å evaluere organisatoriske konsekvenser relatert til implementering av MIGS og en 
potensiell økning i volum av MIGS utført i norske sykehus, ba vi kliniske eksperter ved 
fem offentlige sykehus som utfører MIGS svare på et spørreskjema knyttet til deres ka-
pasitet og prosedyrer.  
 
Etiske perspektiver 
Vi analyserte sentrale etiske implikasjoner av MIGS implementering. Analysen ble ut-
ført ved å kort beskrive situasjonen, alternative strategier, løsninger og involverte in-
teressenter. Etiske utfordringer og mulige konsekvenser ble deretter analysert gjen-
nom de fire prinsippene: velferd, ikke skade, autonomi, og rettferdighet.  
 
Resultat 
Klinisk effekt og sikkerhet 
 
CADTH-HTAen  
CADTH-HTAen inkluderte 35 publikasjoner fra 32 studier; 10 randomiserte forsøk og 
22 ikke-randomiserte studier. Kunnskapsgrunnlaget omfattet 24 spesifikke sammen-
likninger: én sammenlikning av én type MIGS versus en annen MIGS, seks sammenlik-
ninger av MIGS kombinert med kataraktkirurgi versus kataraktkirurgi alene, ni sam-
menlikninger av MIGS kombinert med kataraktkirurgi versus filtrasjonskirurgi kombi-
nert med kataraktkirurgi, seks sammenlikninger av MIGS kombinert med filtrasjons-
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kirurgi versus filtrasjonskirurgi alene, to sammenlikninger av MIGS versus medikamen-
tell behandling og en sammenlikning av MIGS versus laserbehandling. CADTH-forfat-
terne vurderte at det var risiko for skjevheter i samtlige studier.  
 
Som vist i oppsummeringstabellen nedenfor (gjengitt med vennlig tillatelse fra 
CADTH), viste funnene at det i all hovedsak ikke var noen statistisk signifikant forskjell 
mellom intervensjon- og kontrollgruppe, eller en statistisk test av forskjell manglet. 
CADTH-forfatterne hadde svært lav til lav tillit til resultatene. 
 
 
FHIs supplerende systematiske oversikt 
Vi inkluderte åtte studier (sju randomiserte og én ikke-randomisert studie) som sam-
menliknet MIGS-prosedyren alene eller i kombinasjon med kataraktkirurgi versus et 
annet behandlingsalternativ. Ingen av resultatene i den supplerende oversikten kunne 
slås sammen med resultatene i CADTH-HTAen.  
 
Som vist i tabellen med oppsummering av resultater nedenfor, var det intraokulære 
trykket lavere med Hydrus Microstent + kataraktkirurgi enn med kataraktkirurgi alene, 
og med iStent inject + kataraktkirurgi sammenliknet med kataraktkirurgi alene. Det var 
ellers ingen eller liten forskjell mellom MIGS og kontrollgruppene, eller det var usikkert 
om det var noen forskjell i effekt.  
 
Kunnskapsgrunnlaget for sikkerhet var usikkert på tvers av sammenlikningene, men 
det så ikke ut til at noen av behandlingsalternativene innebar høy risiko for komplika-
sjoner. 
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Oppsummering av resultater: Intraokulært trykk (IOP) 
Effekt av MIGS for åpenvinklet glaukom hos voksne 
Pasient eller populasjon: voksne med åpenvinklet glaukom  
Intervensjon: MIGS alene eller i kombinasjon med annen prosedyre 
Komparator: annen MIGS eller annen prosedyre  
Komparator 
Forventet absolutte effekter* 
MD (95% KI) MIGS № av deltakere  
(studier)  
Sikkerhet av evi-
densen 
(GRADE)  
Kommentarer 
 IOP (mm Hg) 
En type MIGS versus 
en annen type MIGS 
 
 
   
Hydrus vs 2x iStent  
MD 1,9 lavere 
(2,91 lavere til 0,89 la-
vere)  
148 
(1 RCT)  
⨁⨁◯◯ 
LAV a,b 
Oppfølging: 12 måneder 
MIGS versus en an-
nen prosedyre 
 
 
   
iStent+phaco vs 
phaco alene  
 
MD 1,9 lavere 
(3,32 lavere til 0,48 la-
vere)  
48 
(1 observasjons 
studie)  
⨁◯◯◯ 
VELDIG LAV b,c 
Oppfølging: 12 måneder 
iStent inject+phaco 
vs phaco alene  
 
MD 0,7 lavere 
(1,27 lavere til 0,13 la-
vere)  
570 
(2 RCTer)  
⨁⨁⨁◯ 
MIDDELS a 
Oppfølging: 24 måneder 
Hydrus+phaco vs 
phaco alene  
 
MD 1,8 lavere 
(2,73 lavere til 0,87 la-
vere)  
331 
(1 RCT)  
⨁⨁⨁⨁ 
HØY  
Oppfølging: 24 måneder 
Trab360+phaco vs 
phaco alene  
 
MD 2,8 lavere 
(5,49 lavere til 0,11 la-
vere)  
18 
(1 RCT)  
⨁◯◯◯ 
VELDIG LAV b,d 
Oppfølging: 24 måneder 
Gold MicroShunt vs 
Ahmed glaucoma 
valve  
 
MD 0,7 lavere 
(2,71 lavere til 1,31 høy-
ere)  
12 
(1 RCT)  
⨁◯◯◯ 
VELDIG LAV b,e 
Oppfølging: 5 år 
iTrack+phaco vs fil-
tration sur-
gery+phaco  
 
MD 1,7 lavere 
(3,29 lavere til 0,11 la-
vere)  
59 
(1 RCT)  
⨁◯◯◯ 
VELDIG LAV b,f 
Oppfølging: 12 måneder 
*Risikoen i intervensjonsgruppen (og dens 95% konfidens intervall) er basert på antatt risiko i komparator gruppen og den relative ef-
fekten hos intervensjonen (og dens 95% KI).  
 
KI: Konfidens intervall; MD: Gjennomsnittlig forskjell; phaco: phacoemulsification (katarakt kirurgi)  
GRADE Arbeids Gruppes grader av sikkerhet 
Høy sikkerhet: Vi er veldig sikre på at sann effekt ligger nært effekt estimatene 
Moderat sikkerhet: Vi er moderat sikker på effekt estimatene: Den sanne effekten er sannsynlig nært effekt estimatene, men det er en 
mulighet for at den er betydelig forskjellig 
Lav sikkerhet: Vår tillit til effekt estimatene er begrenset: Den sanne effekten kan være betydelig forskjellig fra effekt estimatene 
Veldig lav sikkerhet: Vi har veldig liten tillit til effekt estimatene: Den sanne effekten er sannsynligvis betydelig forskjellig fra effekt estima-
tene  
 
Forklaringer 
a. Mulig risiko for utførelsesskjevhet (personnell). 
b. Bredt konfidensintervall og/eller subpotimal utvalgsstørrelse. 
c. Alvorlig skjevhet på grunn av konfundering. 
d. Høy risiko for utførelses- og oppdagelsesskjevhet . 
e. Høy risiko for frafallsskjevhet; uklar risiko for skjevheter i de fleste av domenene i en av studiene.  
f. Høy risiko for seleksjons-, utførelses- og frafallsskjevhet; uklar risiko for oppdagelses- og rapporteringsskjevhet..  
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Helseøkonomisk evaluering 
I et livstidsperspektiv er total-kostnaden for glaukombehandling estimert til mellom 30 
000 og 83 000 norske kroner per pasient, avhengig av behandlingsstrategi og pasien-
tens sykdomsstadie ved start. Inkrementell QALY for MIGS sammenlignet med kompa-
ratorer lå mellom – 0.080 og 0.057. 
 
Organisatoriske aspekter 
I Norge er MIGS kirurgi organisert på et regionalt nivå, og utføres på mange offentlige 
sykehus og i noe grad ved iFocus og Volvat-Orbita sine privatklinikker. Spesifikke krite-
rier for seleksjon av hvilke pasienter som kan eller ikke kan dra nytte av en spesifikk 
MIGS er ikke utviklet, etter hva Folkehelseinstituttet kjenner til. MIGS foretas som poli-
klinisk kirurgi uten sykehusinnleggelse. Øyeleger trenger opplæring for å utføre MIGS. 
MIGS prosedyre krever mindre oppfølging enn tradisjonell kirurgi, noe som kan føre til 
færre kontroller per pasient ved sykehus. På en annen side kan nye og bedre behand-
lingsalternativ lede til at flere pasienter tilbys operasjon. Behovet for glaukomkirurgi 
kan øke på grunn av økt populasjonsvekst i den relevante aldersgruppen eller utvidet 
pasientgrunnlag. Eksperter anslår at antall MIGS prosedyrer vil øke årlig til dobbelt så 
mange i 2024 enn i dag. 
 
Etiske perspektiver 
Hvis Beslutningsforum RHF sier ja til å innføre MIGS blir det viktig å garantere pasien-
ter lik tilgang til behandling, uavhengig av betalingsevne, bosted, sosial status, eller kul-
turell bakgrunn. Det blir også viktig å sikre at alternativer forblir tilgjengelig for pasien-
ter som ikke kan dra nytte av tilgjengelige MIGS prosedyrer.  
 
Diskusjon 
Denne metodevurderingen er basert på oppdaterte systematisk søk i elektroniske data-
baser, forhåndsbestemte inklusjons- og eksklusjonskriterier, uavhengig screening av 
identifiserte artikler, uavhengige vurderinger av risiko for skjevheter i inkluderte stu-
dier, systematisk datauttak og -rapportering, og vurderinger av tilliten på dokumenta-
sjonen. Vi tror at vi har identifisert de mest relevante studiene som ikke var inkludert i 
CADTH sin metodevurdering, og at disse utgjør et godt supplement.  
 
Vi gjorde flere antakelser for å kunne utføre seks helseøkonomiske modeller, noe som 
førte til usikkerhet rundt de økonomiske resultatene. MIGS er en heterogen gruppe 
med utstyr med potensiellt forskjellige kostnader og varierende behandlingseffekt. Vi 
repliserte modellene fra CADTH med tanke på modellstruktur og effektdata, og kan ha 
oversett viktige variabler. Data er tilpasset etter norske forhold. Hvis MIGS blir introdu-
sert i Norge, er et viktig spørsmål på hvilken måte nåværende praksis blir endret. Ifølge 
våre kliniske eksperter vil det ikke ha en stor påvirkning på organiseringen. Vår helse-
økonomiske vurdering er konsistent med andre evalueringer av helseøkonomi, blant 
annet CADTH rapporten, med tanke på usikkerhet rundt estimatene på grunn av 
mangel på data. Kostnadskomponenter kan være forskjellige i ulike land. 
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For å oppnå høy tillit til dokumentasjonen for de utallige mulige MIGS sammenlig-
ningene, er det behov for mer spesifikke designete randomiserte studier. Videre kan en 
detaljert mikrokostnadstilnærming til MIGS-prosedyrene gi høyere sikkerhet i sann ab-
solutt og inkrementell kostnad for MIGS til å bedre informere om potensiell økonomisk 
verdi av MIGS. 
 
Studier vedrørende de mest brukte MIGS prosedyrer i Norge (som iStent, Xen, Preser-
flo) er inkludert, men ikke nødvendigvis godt dokumentert i denne rapporten. Det 
mangler, så vidt vi vet, relevante, sammenliknende kliniske studier. Evalueringen av ef-
fekt og kostnadseffektivitet vil derfor ikke være helt representativ eller dekkende.  
 
 
Konklusjon 
Hydrus Microstent i kombinasjon med kataraktkirurgi reduserer intraokulært trykk 
(IOP) ved 24 måneder, sammenlignet med kataraktkirurgi alene. Hydrus Microstent re-
duserer trolig intraokulært trykk (IOP) ved 12 måneder, sammenlignet med 2x iStent. 
For andre sammenligninger er det usikkert om det er en forskjell i IOP reduksjon. Hver-
ken MIGS-prosedyrene eller andre kirurgiske strategier ser ut til å innebære høy risiko 
for uønskede hendelser, og det er usikkert hvorvidt MIGS-prosedyrene færre eller flere 
komplikasjoner sammenliknet med andre prosedyrer. Kostnadseffektiviteten av MIGS 
er usikker. Den økonomiske evalueringen ga noen scenarioer hvor MIGS kan være kost-
nadseffektiv, men dette avhenger av komparator og sykdomsstadie. 
 
Kunnskapsgrunnlaget for effekt og sikkerhet om MIGS er begrenset. Hovedgrunnen er 
mangel på sammenliknende studier. Vår helseøkonomiske vurdering viser at MIGS kan 
være kostnadseffektivte, avhengig av sammenliknng og sykdomsutvikling. Vår analyse 
setter individer med glaukom i gruppe for alvorlighetsgrad 1. 
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Preface 
The Division of Health Services at the Norwegian Institute of Public Health (NIPH) re-
ceived a commission from The Commissioning Forum for The Regional Health Authori-
ties (RHA Forum), in the National System for Managed Introduction of New Health 
Technologies within the Specialist Health Service in Norway, to undertake a Health 
Technology Assessment (HTA) on Minimally Invasive Glaucoma Surgery (MIGS) for pa-
tients with glaucoma. 
 
On June 21st, 2018, Glaukos Corporation submitted a proposal for a new national HTA 
regarding the use of a trabecular bypass MIGS device implantation with iStent Inject in 
patients with primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary 
glaucoma (1). The RHA Ordering Forum assessed the proposal, together with a horizon 
scanning report (2), on September 24th 2018, and commissioned NIPH to conduct a 
single HTA (i.e., the assessment of a single MIGS device). Because there were several 
suppliers of MIGS devices, a single HTA was deemed not appropriate, and on October 
22th 2018 the RHA Forum instead commissioned NIPH to conduct a multiple HTA to 
assess relative effect, safety, cost-effectiveness of all MIGS devices for treatment of indi-
viduals with glaucoma in Norway (3;4). 
 
In this HTA, NIPH have collaborated with clinical experts and patient partners, with 
specialist knowledge of competence within glaucoma. 
Project management and participants* 
Project leader: Ulrikke Højslev Lund, Health Economist 
Responsible for the project:  Liv Merete Reinar, Deputy Department Director (from Oct 2020) 
Øyvind Melien, Former Department Director (until Oct.  2020) 
Internal project participants: Julia Bidonde, Researcher (on leave) 
Hege Kornør, Department Director 
Beate Charlotte Fagerlund, Health Economist 
Lien Nguyen, Information Specialist 
Elisabeth Hafstad, Information Specialist 
Martin Lerner, Senior Advisor 
Bjarne Robberstad, Health Economist 
External clinical experts: 
 
 
 
 
 
External patient partners: 
Jon Henrik Tveit, MD, Oslo University Hospital 
Marit Fagerli, MD, St. Olav Hospital University Hospital 
Hildegunn Halvorsen, MD, Haukeland University  
Hospital 
Are Lindland, MD, Sorlandet Hospital 
 
Asle Haukaas, Board Member, Norwegian Glaucoma Association 
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* The project group, that consisted of both internal and external participants, started its activities 
at the end of May 2019. The NIPH had an introductory meeting with the project group 14th of June 
2019. 
 
The internal project group at NIPH would like to extend a large thank you to our clinical 
experts, patient partners, external ethicist, external reviewers and internal reviewers 
who all provided valuable insights and comments to the draft report. Further, we want 
to thank Blerta Avdiu for participating as an internship student in health economics in 
this project during spring 2019. We also want to thank Vigdis Underland for checking 
our data extraction in Appendix 7, characteristics of studies included in NIPH supple-
mentary review. 
 
NIPH have based this HTA on a published MIGS HTA conducted by Canadian Agency for 
Drugs and Technologies in Health (CADTH) published in January 2019. We contacted 
CADTH and agreed on collaborating in this process, and we would like to thank for the 
opportunity to re-use and adapt parts of their HTA (5). 
 
We have attached a progress log for this HTA in appendix 1. 
 
Declaration of interest: None of the authors, contributors or peer reviewers state any 
conflicts of interest. 
 
NIPH assumes final responsibility for the content of this report.   
 
   
Kåre Birger Hagen 
Director of Reviews and 
Health Technology Assess-
ments 
Liv Merete Reinar 
Deputy Department Direc-
tor, Reviews and Health 
Technology Assessments 
Ulrikke Højslev Lund 
Project lead and Senior Ad-
viser health economics 
 
 
 
 
 
 
External ethicist: 
Mette Mellem, Low Vision Teacher, Norwegian Association of 
the Blind and Partially Sighted 
Arne Tømta, Low Vision Teacher, Norwegian Association of the 
Blind and Partially Sighted 
 
Lars Øystein Ursin, Associate Professor, Department of Public 
Health and Nursing, Norwegian University of Science and Tech-
nology 
Internal reviewers: Kjetil Gundro Brurberg, Department Director, NIPH 
External reviewers: Alexander Thrane, MD, PhD, Consultant, Haukeland University 
Hospital 
Turid Skei Tønset, MD Consultant, «Seksjon for Fremre seg-
ment, Øyeavdelingen Ullevål», Oslo University Hospital 
Eline Aas, Associate Professor, University of Oslo 
 22  Abbreviations 
Abbreviations 
Abbreviation Term 
ACG Angle closure glaucoma 
AS Absolute shortfall 
CADTH Canadian Agency for Drugs and Technologies in Health 
CEA Cost-effectiveness analysis 
CEAC Cost-effectiveness acceptability curve 
CI Confidence interval 
CUA Cost-utility analysis 
dB Decibels 
ECP Endoscopic Cyclophotcoagulation 
GRADE Grading of Recommendations Assessment, Development and Evaluation 
HRQoL Health-related quality of life 
HTA Health Technology Assessment 
ICER Incremental cost effectiveness ratio 
ICUR Incremental cost utility ratio 
IOP Intraocular pressure 
MD Mean difference 
MIGS Minimally Invasive Glaucoma Surgery 
NICE National Institute for Clinical Excellence 
NIPH Norwegian Institute of Public Health 
NOK Norwegian kroner 
OAG/POAG Open Angle Glaucoma/Primary Open Angle Glaucoma 
OR Odds ratio 
PICO Population Intervention Comparator Outcome 
PSA Probabilistic sensitivity analysis 
QALY Quality-adjusted life-year 
QoL Quality of life 
RCT Randomized controlled trial 
RHA Regional Health Authority 
RR Relative risk / risk ratio 
SR Systematic review 
VF Visual field 
WTP Willingness-to-pay 
 
 23  Objectives 
Objectives 
The purpose of this HTA was to support well-informed decisions in health care that will 
lead to improved quality of services. This HTA responds to the question of what is the 
optimal use of MIGS devices and procedures for adults with open-angle glaucoma? In 
this HTA, we aimed to evaluate the clinical effectiveness, safety, cost-effectiveness, or-
ganizational consequences and ethical perspectives of MIGS in patients with glaucoma. 
We compared MIGS with current treatment options, against the prioritization criteria 
applicable in the Norwegian health care: the benefit, the resource use, and the severity 
criterion (6). 
 
The specific objectives of this HTA were to: 
 
1) Supplement the evidence of clinical effectiveness and safety from a recent HTA 
by the Canadian Agency for Drugs and Techologies in Health (CADTH) (5), with 
regard to selected MIGS procedures versus each other or another comparator 
(i.e., pharmacotherapy, laser therapy, filtration surgery, cataract surgery), both 
as a stand-alone procedure or performed in combination with cataract surgery, 
in the treatment of open-angle glaucoma. 
 
2) Conduct a health economic evaluation, ascertaining cost-effectiveness of MIGS 
compared with conventional treatment options in patients with glaucoma, in a 
Norwegian health care perspective. We quantify the severity criterion by 
calculating absolute shortfall for individuals with glaucoma that receive 
conventional care. We also assess the impact of introduction of MIGS as routine 
treatment for patients with glaucoma on the Norwegian health care budget. 
 
3) Assess organisational challenges and consequences linked to establishing MIGS 
as a treatment option in Norway. 
 
4) Assess potential ethical issues raised by the use of MIGS in treatment of 
glaucoma in Norway. 
 
We include patient partners’ in the external advisory team in order to understand their 
own perspectives and experiences regarding glaucoma treatment and healthcare ser-
vices, as well as the perspectives of their caregivers.  
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Background 
Glaucoma is a disease with great impact on quality of life for patients and relatives; it 
represents a substantial public health problem and reports an increasing prevalence. 
As a result of this, patients with glaucoma  utilize more health care resources (7). 
 
Glaucoma 
Glaucoma refers to a group of eye conditions, in which there is a characteristic pattern 
of progressive damage to the optic nerve (the nerve for vision), which can lead to irre-
versible visual loss and potentially blindness (8). Since there are many other non-glau-
comatous diseases that also can affect the optic nerve, it is often the pattern in which it 
affects the appearance of the nerve clinically (excavation), on scans and on visual field 
testing that establishes the diagnosis. Optic nerve damage can develop over time if 
there is an imbalance between the production and drainage of eye fluid (aqueous hu-
mor). Ocular drainage principally ocurrs in the area between iris and cornea where 
various disease processes can impair fluid outflow and the eye pressure consequently 
increases (9). In a healthy eye the outflow of aqueous humor occurs by two main 
routes: The first is the trabecular outflow tract, which is located at the angle of the ante-
rior chamber of eye, where the trabeculum is a “filter-like” structure providing the pri-
mary resistance for pressure-dependent egress of fluid from the eye into a modified cir-
cular lymphatic vessel called Schlemm’s canal, and from there to the venous circulation. 
The second is the uveoscleral tract, where aqueous humor passes in a pressure-inde-
pendent manner across the iris root and cilliary muscle into the supracilliary and su-
prachoroidal spaces, and then drain into the venous circulation. 
 
Glaucoma is a slowly progressing disease, sometimes called the “silent thief of sight”. 
Glaucoma remains the leading cause of blindness worldwide, after cataracts (7) Be-
cause central vision often remains intact as the disease progresses, irreversible harm 
can result before the patient notices “tunnel vision” or other types of visual impair-
ment. Up to 50% of people in the industrialised world are unaware of their glaucoma 
condition and are therefore not receiving appropriate treatment (10). Early diagnosis 
and treatment could help prevent permanent visual defects and blindness.  (8;11). 
(7)(7). Status of the visual field is often used as the most important reference when dis-
cussing disease stages in glaucoma. A discrete-levels staging system modified from the 
Hodapp-Parrish classification has been used for several years. Glaucoma usually affects 
both eyes, but often manifests in an asymmetrical fashion. One eye may have advanced 
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glaucomatous damage, while the other eye has very little or none (12). According to Pe-
ters et al., there is a 26.5% risk of blindness in one eye after 10 years and a 5.5% for bi-
lateral blindness. After 20 years the risks are 38.1% and 13.5% respectively (13).  
 
The causes of glaucoma remain unknown. However, some factors have been identified 
to possibly increase the risk of developing and the progression of the disease. Examples 
of such risk factors include: high intraocular pressure (IOP; i.e., pressure inside the 
eye), increasing age, family history of glaucoma, ethnicity, eye injuries, long-term corti-
sone treatment for other reasons, diabetes, hypertension, hypothyroidism and cardio-
vascular disease. IOP is the most important and modifiable risk factor (12;14). Accord-
ing to The European Glaucoma Society, these factors associated with the progression of 
established glaucoma have been analyzed in several trials: Early Manifest Glaucoma 
Trial (EMGT), Collaborative Initial Glaucoma Treatment Study (CIGTS), Collaborative 
Normal Tension Glaucoma Study (CNTGS), and Advanced Glaucoma Intervention Study 
(AGIS) (12). 
 
Intraocular pressure (IOP) 
IOP in the general population is normally distributed with a right skew, and the average 
in adult populations has been estimated at 15-16 mmHg (measured in millimeters of 
mercury), with a standard deviation of about 3.0 mmHg. Normal IOP has been defined 
as two standard deviations above normality (i.e., 21 mmHg), and an IOP above this 
level is considered to be elevated (12). Twenty to 30% of people with glaucoma do not 
have elevated eye pressures. IOP can become elevated when there is an imbalance be-
tween production and drainage of the fluid that nourishes the lens and cornea, known 
as aqueous humour. Clinical trials and epidemiological studies have shown that ele-
vated IOP is a major risk factor for developing glaucoma, and that optimal control of 
IOP slows glaucoma progression and thus reduces the risk of optic nerve damage 
(7;15;16). The risk of developing glaucoma for those with IOP measurements of 26 
mmHg or greater is estimated to be 12 times higher than for those with IOP within nor-
mal level (12). Further, for every 1 mm Hg increase in IOP, there is a 10% increased 
risk of both development of glaucoma and disease progression (17). This is also the 
case for patients with normal IOP at diagnosis.  
 
Often, clinicians set a target IOP as a long-term treatment goal when they are working 
with patients suffering from glaucoma. A target IOP could be defined as the IOP level at 
which clinicians believe that further glaucomatous optic neuropathy is unlikely to oc-
cur. The determination of a target IOP differs between patients, and the target IOPs 
change constantly depending on whether the glaucoma shows signs of progression. 
Thus, the target IOP is where the rate of disease progression is acceptable, as there is 
almost always some progression (e.g. 0.1-0.3 dB/year on visual field). The determina-
tion of target IOP is based upon several factors, such as the stage of disease, the base-
line untreated IOP level, and the presence of risk factors for the development of glau-
coma or its progression (12). 
 
 26  Background 
Incidence and prevalence 
Glaucoma affects approximately 66.8 million people worldwide, and in Norway, ap-
proximately 77,000 individuals are treated for glaucoma annually (1.5 % of the Norwe-
gian population) (18). Glaucoma is most common among the elderly population and the 
incidence increases with age. It is estimated that 2.2% of the population aged 40 and 
over have glaucoma; the estimated prevalence of the whole population is 0.9% (19). 
The incidence of glaucoma is expected to increase in the coming years because of de-
mographic changes that result in an ageing population and an increase in life expec-
tancy, as well as better awareness of the disease and better diagnostic procedures (20). 
 
Types of glaucoma 
There are several types of glaucoma; the two main types are open-angle glaucoma 
(OAG) and angle-closure glaucoma (ACG), which are both defined by an IOP greater 
than 21 mmHg (21). Although elevated IOP is often associated with the disease, ele-
vated IOP is not necessary for the diagnosis, and a signficiant proportion of patients 
have normal tension glaucoma (NTG). OAG or ACG depend on whether the drainage 
channels for aqueous humour in the front of the eye appear open or closed. OAG is a 
chronic and progressive condition and occurs when the system responsible for drain-
ing fluid from the eye (i.e., Schlemm’s canal and the trabecular meshwork (TM)) is ana-
tomically open but functioning sub-optimally. On the other hand, ACG occurs when the 
fluid draining system is anatomically blocked. ACG can both be acute and chronic. In 
acute ACG, the disease may be painful and emergency care can be necessary. More of-
ten the ACG is chronic, progressive, and without symptoms. Globally, OAG and ACG ac-
count for about half of all glaucoma cases, where OAG represents the more common 
form of glaucoma with approximately 80% of the patient proportion. However, NTG is 
less easy to detect and might be underreported. The main reason to distinguish the two 
types from each other is the initial therapeutic approach (i.e., iridotomy or iridectomy), 
differences in optimal timing and amenability to other interventions (e.g. cataract sur-
gery), and the possible late complications or the complications occuring when these  in-
idviduals with glaucoma  undergo filtration surgery (5;7). 
 
Cataract 
Cataract is an opacification of the lens inside the eye, which leads to impaired vision. 
Symptoms may include blurry or double vision, faded colors, halos around light, and 
difficulties seeing at night. Cataracts are often due to aging but may also occur due to 
trauma or radiation exposure, be present from birth, or occur following eye surgery for 
other problems. Risk factors include diabetes, smoking, alcohol, corticosteroid use and 
prolonged exposure to sunlight. Cataract normally develops slowly and can affect one 
or both eyes, and cause half of all cases of blindness and 33% of visual impairment 
worldwide (22). Annually, about 38,000 age-related cataract surgeries are carried out 
in Norway (23).  
 
Cataract may naturally coexist with glaucoma, have a causative effect on glaucoma, or 
may be a result of glaucoma surgery. Patients with both cataracts and glaucoma require 
special considerations, and several recent studies indicate that cataract surgery can 
also play a role in the management of glaucoma (24). 
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Glaucoma management 
There is no curative treatment for glaucoma and vision loss from glaucoma is irreversi-
ble. The goal of current treatment is to address the only known reversible risk factor 
for glaucoma, IOP, and thereby to minimize disease progression and prevent further 
nerve damage and loss of vision (ref). The most common treatment (e.g. eye drops or 
MIGS)  seeks to lower IOP by either reducing the production of aqueous humour or en-
hancing its drainage (5;25). By achieving a significant and sustained decrease in IOP the 
subsequent risk of disease progression is reduced and the patient’s health-related qual-
ity of life (HRQoL) is preserved (8). Quality of life is closely linked with visual function, 
but can also be influenced by choice of treatment (e.g. eye drops, laser, filtering sur-
gery). Choice of treatment is often dependent on the stage of the disease (26). Patients 
with early and moderate glaucoma often have good visual function and modest reduc-
tion in quality of life. On the other hand, quality of life is considerably reduced if both 
eyes have advanced visual function loss (12).(26)(26) Major risk factors for glaucoma 
blindness are age and the stage of the disease at diagnosis. As such, treatment should 
be individualized to the rate of progression (RoP) and needs of each patient (12). 
 
Current diagnostic and treatment pathways in Norway 
The European Glaucoma Society (EGS) updates its guidelines for glaucoma regularly, 
including patient examination, and treatment principles and options, and the Norwe-
gian glaucoma society follow these guidelines (12). 
 
All patients receiving eye care should undergo a clinical examination and be examined 
for glaucoma risk factors to rule out the disease. Consideration of risk factors (risk as-
sessment) may be important, it may help to identify individuals who can be targeted for 
early detection and to guide management decisions about the initiation and escalation 
of treatment in patients with established glaucoma. Methods used to diagnose glau-
coma in Norway? are based on patient examination including among other things to-
nometry (methods of measurement for IOP), ophtalmoscopy (examining/assessing the 
optic nerve), imaging of the optic neve (optical coherence tomography, OCT), perimetry 
(to examine the visual field (VF)) and gonioscopy (to inspect the anterior chamber an-
gle). Patients that are diagnosed with glaucoma should have follow-up consultations 
with an ophthalmologist where the regularity of tests is dependent on the glaucoma 
stage, rate of progression and other factors. Disease progression in glaucoma differs 
greatly between patients. Determining the rate of VF progression is the standard for 
monitoring disease progression and the EGS guidelines recommend three VF tests per 
year during the first two years after diagnosis to determine the disease progression 
rate. The frequency of testing may be reduced after two years for patients that have no 
progression. Progression rate might be influenced by the type of glaucoma. It is also im-
portant to ensure that patients are able to follow up with therapy (12). 
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The initial treatment (first line treatment) for most forms of glaucoma upon diagnosis 
is topical medication (antiglaucoma drugs) with an IOP-lowering eye drop as mono-
therapy or a combination with eye drops with different mechanisms of action (pharma-
cotherapy). Selective laser trabeculoplasty (SLT) might also be an option (27). How-
ever, laser therapy is not recommended for some individuals with glaucoma because of 
contraindications. With more severe cases of glaucoma, and when pharmacotherapy 
and laser treatment have failed to result in adequate IOP, a final step is to offer glau-
coma surgery. The most common glaucoma surgery, stated as the gold standard, is tra-
beculectomy, followed by tube/shunt implantation. Both providing an alternate drain-
age for the eye fluid into the subconjunctival space, and thus lowering IOP. The down-
side of these surgeries is that they are more complex interventions with a considerable 
risk of serious complications, longer recovery time and potentially lifelong discomfort 
to the patient. The success rate for these surgical procedures decreases with repeated 
surgery. Continued pharmacotherapy is usually required after both laser therapy and 
surgery (12;28;29).  
 
To NIPHs knowledge, glaucoma surgery typically is performed at public hospitals,  and 
not at all or in very few private clinics  in Norway today (28). 
 
Minimally Invasive Glaucoma Surgery (MIGS) 
MIGS (Minimally Invasive Glaucoma Surgery- I am sure MIGS acronym has been intro-
duced already) is a potential surgical alternative to current treatment of glaucoma that 
seeks to reduce IOP. MIGS represents a class of various new surgical procedures and 
devices developed since the early 2000s to provide a minimally invasive surgical ap-
proach to glaucoma treatment that limits damage to the conjunctiva (28;30;31). Ex-
perts suggest that, in addition to causing minimal or no damage to the conjunctiva, 
MIGS may also result in shorter procedure times and patient recovery times than tradi-
tional surgical procedures. The approach of a MIGS procedure is either ab-interno 
(from inside of the eye) or ab-externo (from outside of the eye) (5). 
 
As of October 2019, NIPH was aware of 15 MIGS devices and procedures in use. The in-
dications for each specific MIGS-procedure can vary depending on its mechanism of ac-
tion and the individual patient’s target IOP. MIGS can be used as a stand-alone proce-
dure or in conjunction with cataract surgery, possibly with a higher success rate than 
traditional glaucoma surgery in combination with cataract surgery (28). MIGS can be 
categorized by recipient reservoir, as Schlemm’s canal/trabecular meshwork (TM), su-
prachoroidal space or subconjunctival space, according to where fluid is redirected 
during the procedure (30): 
 
Schlemm’s canal / Trabecular meshwork (TM) 
Increasing trabecular outflow by bypassing the TM using a device 
• iStent  
• iStent inject 
• Hydrus 
Increasing trabecular outflow by bypassing the TM using tissue ablation/removal 
• Trabectome  
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• Kahook Dual Blade  
Increasing trabecular outflow by bypassing the TM via 360º suture 
• GATT (Gonioscopy Assisted Transluminal Trabeculotomy)  
• iTrack  
• Visco360  
• Trab360  
 
Suprachoroidal space  
• Solx Gold Shunt  
• iStent Supra 
• Aquashunt 
 
Aqueous humor reduction 
• Endoscopic cyclophotocoagulation (ECP)  
 
Recently, there has been a growing demand for use of MIGS both in Norway and glob-
ally. To the best of our knowledge, several hospitals (Oslo University Hospital, Sør-
landet Hospital, Haukeland University Hospital, Stavanger, St.Olav Hospital- University 
Hospital Trondheim, Ålesund Hospital, Molde Hospital, University Hospital of North 
Norway, Drammen hospital, Elverum Hospital and probably more) in Norway currently 
offer some type of MIGS to individuals with glaucoma. In addition to these hospitals, the 
private iFocus and Volvat-Orbita private clinics  offer  some MIGS surgeries (28). 
According to the clinical experts the choice of type of MIGS is often dependent on the 
stage of the disease, target pressure, tolerance/intolerance/allergy to drops. iStent and 
Hydrus is typically recommended for the mild and moderate stages of glaucoma and 
Xen (MIGS+ or hybrid MIGS) for more severe cases.  
 
Cataract surgery in combination with glaucoma treatment or alone 
When there is a visually significant cataract and glaucoma surgery is indicated, cataract 
surgery and glaucoma surgery procedures can be performed combined or sequentially. 
Cataract surgery may be combined with one of several glaucoma surgeries including 
trabeculectomy, glaucoma drainage devices, canaloplasty, and other MIGS. The MIGS 
procedures are especially suited for combining with cataract surgery since they can 
usually be performed by using the same incision through which the cataract is re-
moved. However, they rely on the eye’s natural drainage system and may not get the 
eye pressure to a low enough level for some patients (24).  
 
Existing research syntheses 
In January 2019, CADTH published a health technology assessment of MIGS. The con-
clusion from the CADTH report on optimal use of MIGS is that there is insufficient evi-
dence on clinical effectiveness and safety of MIGS versus comparators and there is no 
definitive evidence on which specific MIGS might be preferable. Although pointing at 
limitations in the evidence base, MIGS is suggested to have a potential role in the treat-
ment of adult patients with glaucoma if some factors are considered and disclosed to 
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patients. Factors which include, among others, the diversity of MIGS options, surgeon’s 
experience and health care system related issues such as geographical location and fi-
nancial considerations (5).   
In addition there are four relevant systematic reviews published in the past 5 years. 
They are all published Cochrane systematic reviews (15;32-34). 
The aim of Zhang and colleagues’ systematic review from 2015 (15) was to compare 
the effectiveness and safety of combined glaucoma and cataract surgery with cataract 
surgery alone. The review included nine RCTs, with a total of 655 participants (657 
eyes), and follow-up periods ranging from 12 to 30 months. Glaucoma surgery type 
varied among the studies: four studies used trabeculectomy, three studies used iStent® 
implants,  and two studies used trabecular aspiration. All these studies found greater 
decrease in mean IOP postoperatively in the combined surgery group compared with 
cataract surgery alone. Complications were reported at 12 months (two studies), 12 to 
18 months (one study), and two years (four studies) after surgery. Due to the small 
number of events reported across studies and treatment groups, the difference be-
tween groups was uncertain for all reported adverse events.  Authors graded the over-
all quality of the evidence as low due to observed inconsistency in study results, impre-
cision in effect estimates, and risks of bias in the included studies.  
The aim of Le and colleagues’ systematic review from 2019 (33)was to assess the effec-
tiveness and safety of ab interno trabecular bypass surgery with iStent (or iStent inject) 
for open-angle glaucoma in comparison to conventional medical, laser, or surgical 
treatment. The review included seven RCTs (765 eyes of 764 participants). Four RCTs 
compared iStent in combination with phacoemulsification to phacoemulsification 
alone; summary estimates suggest that participants in the iStent in combination 
with phacoemulsification group were more likely to be topical medicine-free be-
tween 6 and 18 months than those in the phacoemulsification alone group. Data from 
two RCTs also suggested that iStent in combination with phacoemulsification com-
pared to phacoemulsification alone may have offered a small reduction in number of 
IOP-lowering drops. It is uncertain whether there was any difference in terms of mean 
reduction in IOP from baseline (no meta-analysis). Two RCTs compared treatment 
with iStent to medical therapy; one of the two trials used the iStent inject. Both trials 
reported that over 90% of participants in the treatment groups were drop-free com-
pared to no participants in the medical therapy groups at six to 18 months. One RCT 
compared treatment with one versus two versus three iStents. There was no difference 
in terms of participants who were drop-free at 36 months or less; however, at longer 
follow-up (i.e. at 42 months) participants in the one iStent treatment were less likely to 
be drop-free than those in the two iStent or three iStent.  The type and timing of com-
plications reported varied by RCTs. Similar proportions of participants who underwent 
treatment with iStent in combination with phacoemulsification and who underwent 
phacoemulsification alone needed secondary glaucoma surgery. None of RCTs reported 
findings related to quality of life. Authors assessed most trials at unclear or high risk of 
bias due to flaws on methods (i.e. random sequence or concealing allocation; blinding 
and detection bias). Authors graded the certainty of evidence as very low.  
A third Cochrane systematic review, Otarola 2020 (34), evaluated the efficacy and 
safety of ab interno trabecular bypass surgery with the Hydrus microstent in treating 
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people with open angle glaucoma (OAG). They included three international multicenter 
randomised trials with 808 people. Two studies compared the Hydrus microstent com-
bined with cataract surgery to cataract surgery alone, in participants with visually sig-
nificant cataracts and OAG. There was moderate-certainty evidence that adding the Hy-
drus microstent to cataract surgery increased the proportion of participants who were 
medication-free from about half to more than three quarters at 12-months. The Hydrus 
microstent combined with cataract surgery reduced the medium-term mean change in 
unmedicated IOP (after washout) by 2 mmHg more compared to cataract surgery 
alone. Few adverse events were reported in either group. 
The fourth systematic review in the Cochrane Library, King 2018 (32), aimed to evalu-
ate the efficacy and safety of subconjunctival draining minimally-invasive glaucoma de-
vices in treating people with open angle glaucoma and ocular hypertension whose con-
dition is inadequately controlled with drops. The authors searched for trials in July 
2018. However, they found no studies that met their inclusion criteria.  
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Clinical effectiveness and safety 
METHODS 
In this health technology assessment (HTA), we have based the effectiveness and safety 
section of on the HTA by the Canadian Agency for Drugs and Health Technology 
(CADTH) published in January 2019 (5). We have supplemented the CADTH HTA with a 
review of more recent studies that were not included by CADTH. We have based our 
methodology on the methods used by CADTH, with some adaptations which are speci-
fied where they apply.  
 
Further, we used NIPH’s  methods handbook «Slik oppsummerer vi forskning» (35) as 
described in the published protocol (36). Any discrepancies between the protocol and 
the final report are accounted for in Appendix 2. 
 
Inclusion criteria 
We adapted the inclusion and exclusion criteria from  CADTH HTA following a consen-
sus process involving the NIPH technical team, Norwegian clinical experts and patient 
partners (5;28;37). Our adapted inclusion criteria narrowed down the population to 
open-angle glaucoma only, as well as some minor alterations in eligible interventions, 
outcomes and languages (Table 1).   
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Table 1: Inclusion criteria  
 NIPH criteria NIPH adaptations 
to CADTH HTA cri-
teria 
 
Population Adults (i.e., age of ≥ 18 years) with open-angle glaucoma 
(primary and secondary, e.g. pigmentary, pseudoexfolia-
tive)  
Limited to open-an-
gle glaucoma  
Interventions Any of the following MIGS, as stand-alone procedure or 
in conjunction with cataract surgery:  
 
iStent, iStent inject, Hydrus, Trabectome, Kahook Dual 
Blade, GATT (Gonioscopy Assisted Transluminal Tra-
beculotomy), iTrack, Visco360, Trab360, Solx Gold, 
Shunt, iStent Supra, Aquashunt, Xen Gel Stent, InnFocus 
Microshunt, Endoscopic cyclophotocoagulation (ECP) 
• Added: iTrack, 
Visco 360, Trab 
360, Solx Gold 
Shunt, iStent Su-
pra, Aquashunt, 
InnFocus and Mi-
croshunt  
• Removed: CyPass 
Micro-Stent  
Comparators • A different MIGS device or procedure by itself or per-
formed in conjunction with cataract surgery 
• Pharmacotherapy alone 
• Laser therapy (e.g., excimer laser trabeculotomy or se-
lective laser trabeculoplasty) 
• Filtration surgery – trabeculectomy, including non-
penetrating surgery (e.g. viscocanalostomy, deep 
sclerectomy) 
• Filtration surgery – aqueous shunt implantation (e.g. 
Ahmed glaucoma valve, Baerveldt glaucoma implant) 
• Filtration surgery performed in combination with cat-
aract surgery (i.e., phacotrabeculectomy) 
• Cataract surgery (i.e., phacoemulsification) alone 
No adaptations 
Outcomes Primary outcomes: IOP*, IOP fluctuation*  
 
Secondary outcomes: Quality of Life (QoL), number of 
glaucoma medication use*, vision related QoL*, visual 
field loss*, visual impairment, visual acuity, retinal 
Nerve Fibre Layer (RNFL) thickness* 
 
Safety: adverse events and complications (e.g., transient 
IOP fluctuation, infection, hyphema, hypotony, device 
occlusion or malposition, need for additional proce-
dure(s), or cataract formation, suprachoroidal haemor-
rhage, visual loss, endothelial cell loss) 
• Added: RNFL thick-
ness  
• IOP and IOP fluctu-
ation primary out-
comes 
• QoL secondary out-
come 
• Added: Adverse ef-
fects of pharma-
cotherapy  
Study designs • Randomised trials  
• Prospective non-randomised controlled clinical tri-
als such as cohort studies we included only studies 
with a comparator 
No adaptations 
Languages No limitations Limit to English and 
French  
 
IOP: intraocular pressure; MIGS: minimally invasive glaucoma surgery. *These outcomes were identified as being of par-
ticular importance to patients in the input received from patient partners. 
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Exclusion criteria  
• Studies with any of the following populations: 
o Adults with juvenile-onset/congenital glaucoma 
o Adults with closed-angle glaucoma 
o Adults with ocular hypertension but no evidence of optic nerve damage or 
formal diagnosis of glaucoma 
o Animal or ex vivo populations 
• Studies with triple surgery (MIGS + two other non-MIGS procedures) 
• Retrospective studies 
• Case series and case reports  
• Review articles  
• Editorials, letters, and commentaries  
• Studies of any design published as trial registry records only, conference abstracts, 
presentations, or thesis documents 
 
Literature search 
We have adapted and updated CADTH’s search strategy for primary studies to address 
clinical effectiveness and safety of MIGS for adults with open-angle glaucoma. We 
opened the search to other languages in order to capture literature applicable or from 
Scandinavian countries. We carried out the searches on 3rd August 2019, and updated 
the search in November 2020, for studies published in year 2000 or later.  
A research librarian searched the following electronic databases, using a peer-reviewed 
search strategy (Appendix 3):  
• Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed 
Citations and Daily [1946-] 
• OVID EMBASE [1974-] 
• Cochrane Database of Systematic Review (Wileys & Sons) 
• Cochrane Central Register of Controlled Trials (Wileys & Sons) 
• DARE (Centre for Reviews and Dissemination) 
• CINAHL (EBSCO) 
• Clinicaltrials.gov (U.S. National Library of Medicine)  
• International Clinical Trials Registry Platform (World Health Organization) 
 
On 13th November 2020, we carried out a top-up search, re-running the search strate-
gies in MEDLINE, EMBASE, and Cochrane Library for studies published in August 2019 
or later. 
 
Study selection 
We selected studies found in the main (2019) NIPH search in a two-step selection strat-
egy:  
1. Title and abstract screening: two researchers independently screened titles and 
abstracts using Covidence software (38), selecting those that appeared eligible 
for full-text review.  
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2. Full-text screening: two researchers independently screened the full-text 
articles meeting our inclusion criteria. 
Disagreements in either of the two steps were resolved through a consensus meeting, 
and a third researcher was involved when needed. 
 
For the top-up (2020) search, we repeated the two-step selection strategy, but with one 
researcher screening each record. 
 
Assessment of risk of bias in included studies 
Two independent researchers assessed the risk of bias in the included studies using the 
Cochrane Risk of Bias tool v1.0 for randomized control trials and the Risk of Bias in 
non-RCTs (a modified/simplified version of the ROBINS-I tool) (39;40). 
 
Any disagreements were resolved through consensus between the researchers, or by 
consultation with a third party if needed.  
 
Due to time constraints, we did not assess risk of bias in included studies from the 
NIPH 2020 top-up search. 
Data extraction 
We extracted the following data from the studies; Study author/year, country, study de-
sign, inclusion and exclusion criteria, number of participants, age, gender, type of glau-
coma, severity/stage of glaucoma, type of MIGS, control group intervention, follow up 
time, study duration, conflict of interest and funding of study, as well as outcomes of in-
terest to this review.   
 
We entered the data into electronic files created and piloted for this project to facilitate 
independent data extraction. One researcher extracted data and a second one checked 
for accuracy. Any potential disagreements were resolved through consensus, or by con-
sultation with a third researcher.  
 
Due to time contraints, we did not extract data from eligible studies from the 2020 
search, but listed them in Appendix 4. 
 
Data analysis 
If more than one study was included and data was sufficiently homogeneous in clinical, 
methodological and statistical aspects, we pooled the results using random effects 
meta-analysis. We calculated mean differences (MD) and 95% confidence intervals 
(CIs) for all included outcomes. We conducted separate analyses for randomised and 
non-randomised studies. We used the RevMan software (41) to generate forest plots 
for individual effect estimates. 
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We assumed a minimal clinically important difference (MCID) in intraocular pressure 
of 1 mmHg as being clinically relevant, dependent on condition. In the absence of litera-
ture in this area, we based this MCID on expert opinion (28). 
 
Assessment of certainty of the evidence 
We assessed the certainty of evidence for intraocular pressure using the Grading for 
Recommendations Assessment, Development, and Evaluation (GRADE) approach 
(42;43) (Table 2). The assessments were performed by one reviewer and verified by a 
second reviewer, and are presented in GRADE summary of findings tables (Appendix 
5).  
 
Table 2: GRADE classification 
Grade Definition Symbols 
High  We are very confident that the true effect lies close to that of the 
estimate of the effect 
 
Moderate We are moderately confident in the effect estimate: The true effect 
is likely to be close to the estimate of the effect, but there is a possi-
bility that it is substantially different 
 
Low Our confidence in the effect estimate is limited: The true effect may 
be substantially different from the estimate of the effect 
 
Very low We have very little confidence in the effect estimate: The true ef-
fect is likely to be substantially different from the estimate of effect 
 
 
Optimal information size for intraocular pressure 
We calculated the optimal information size for intraocular pressure assuming a mini-
mal clinically important difference of 1 mmHg, a population standard deviation of 2.5, α 
of 0.05 and β of 0.80. The required number of patients in each group was 99.  
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RESULTS 
Search results and selection of studies 
CADTH HTA 
Based on a literature search carried out in November 2017, the authors of CADTH HTA 
identified 2,349 citations. In addition, they retrieved nine potentially relevant reports 
from other sources. Their title and abstract screening identified 87 potentially relevant 
citations, which were retrieved for full-text screening. Of these, 52 publications did not 
meet the eligibility criteria and were excluded. Thirty-two studies in 35 publications 
met the inclusion criteria and were included. Please see the full CADTH HTA report for 
details (5). 
 
NIPH supplementary search 
A total of 1,433 citations were identified in the literature search. After de-duplication 
and screening 1381 titles and abstracts, we obtained and assessed 158 records for eli-
gibility in full text. Of these, 150 were excluded for the following reasons: wrong study 
design (45 records), trial registry record (51 records), wrong comparator (18 records), 
duplicate (19 records), wrong intervention (9 records), wrong publication type (6 rec-
ords), wrong outcomes (1 record), and unable to translate (1 record) (Appendix 6). 
Eight trials met the inclusion criteria (44-51) (Figure 1). 
 
 
Figure 1: Flow chart of study selection process (NIPH search). 
 
1,433  
Records identified through  
database searching  
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8 
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The top-up search identified 520 additional records after de-duplication. Eight were el-
igible, of which three were new trials and five were companion papers to trials already 
identified by the main NIPH search or in CADTH HTA (Appendix 5). Due to time re-
strictions we have not included the new trials in our analyses. 
 
Characteristics of included studies 
Studies and comparisons included in CADTH HTA 
The 32 studies (35 publications) in CADTH HTA examined effectiveness and safety 
across a total of 24 comparisons (Table 3). There was one comparison of a MIGS versus 
another MIGS, six comparisons of a MIGS combined with cataract surgery versus cata-
ract surgery alone, nine comparisons of a MIGS combined with cataract surgery versus 
cataract surgery combined with filtration surgery, six comparisons of a MIGS combined 
with filtration surgery versus filtration surgery alone, two comparisons of a MIGS ver-
sus pharmacotherapy, and one comparison of a MIGS versus laser therapy. 
 
Six of the studies could be pooled in meta-analyses. The authors narratively synthe-
sized findings from all other studies. Please see the full CADTH HTA report for detailed 
study characteristics (5). 
 
Table 3: Studies and comparisons included in CADTH HTA  
Studies  MIGS Comparator 
 Comparison: MIGS vs. another MIGS 
Katz 2018 (52); 2015 (53) iStent 2x iStent vs. 3x iStent 
 Comparison: MIGS + cataract surgery vs. cataract surgery alone 
Fea 2015 (54); Fea 2010 (55); 
Craven 2012 (56); Samuelson 
2011 (57); El Wardani 2015 
(58) iStent + Phaco Phaco alone 
Kang 2017 (59); Perez Bar-
tolome 2017 (60); Sheybani 
2015 (61); Siegel 2015 (62); 
Francis 2014 (63) ECP + Phaco Phaco alone 
El Wardani 2015 (58); Fer-
nandez-Barrientos 2010 (64) 2x iStent + Phaco Phaco alone 
Vold 2016 (65) CyPass Micro-Stent + Phaco Phaco alone 
Pfeiffer 2015 (66); Samuelson 
2018 (67) Hydrus Microstent + Phaco Phaco alone 
 
Comparison: MIGS + cataract surgery vs. filtration surgery + cata-
ract surgery 
Dorairaj 2018 (68) KDB + Phaco iStent + Phaco 
Kurji 2017 (69); Khan 2015 
(70) Trabectome + Phaco 2x iStent + Phaco 
Gonnerman 2017 (71) Trabectome + MICS 2x iStent Inject + MICS 
Vlasov 2017 (72); Belovay 
2012 (73) iStent + Phaco 
2x iStent+Phaco vs. 3x iStent + 
Phaco 
Ferguson 2017 (74) ECP + iStent + Phaco iStent + Phaco 
Moghimi 2018 (75) ECP + Phaco Trabectome + Phaco 
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Studies  MIGS Comparator 
Ting 2018 (76) Trabectome + Phaco Trabeculectomy with MMC + Phaco 
Kinoshita-Nakano 2018 (77) Trabectome + Phaco Trabeculectomy + Phaco 
Marco 2017 (78) ECP + Phaco Trabeculectomy with MMC + Phaco 
 Comparison: MIGS vs. filtration surgery 
Murakami 2017 (79) ECP Second GDD (BGI) 
Lima 2004 (80) ECP AGI 
Pahlitzsch 2017 (81); Jea 
2012 (82) Trabectome  Trabeculectomy with MMC 
Pahlitzsch 2017 (81) 2x iStent Inject Trabeculectomy with MMC 
Pahlitzsch 2017 (81) 
Trabectome or 2x iStent In-
ject (grouped together) Trabeculectomy with MMC 
Schlenker 2017 (83) XEN 45 microstent with MMC Trabeculectomy with MMC 
 Comparison: MIGS vs. pharmacotherapy 
Vold 2016 (65) 2x iStent Travoprost (prostaglandin F analog) 
Fea 2014 (84) 2x iStent Inject 
Combination Latanoprost/timolol 
(prostaglandin F analog and beta-
blocker) 
 Comparison: MIGS vs. laser therapy 
Fea 2017 (85) Hydrus Microstent SLT 
2x = two devices; 3x = three devices; Phaco = phacoemulsification (cataract surgery); ECP = en-
doscopic cyclophotocoagulation; KDB = Kahook Dual Blade; MICS = micro-incision cataract surgery; 
MMC = mitomycin C; BGI = Baerveldt glaucoma implant 250 or 350; AGI = Ahmed glaucoma implant; 
SLT = selective laser trabeculoplasty. 
 
Studies and comparisons included in NIPH supplementary review 
There were seven randomised trials (44;46-51) and one non-randomised trial (45) 
among the eight included studies. Three studies were published in 2019 (47;49;86), 
three in 2018 (45;46;50), one in 2016 (51) and one in 2015 (48). The studies’ first au-
thors were based in Germany (45;46), the USA (47;49), Poland (44) Canada (86), Israel 
(51) and Japan (50), respectively. The COMPARE study (Ahmed 2019) was a mu-
litcenter trial with 12 centers across 9 countries.  
 
The included studies examined effectiveness and safety in a total of seven comparisons 
(Table 4). There was one comparison of a MIGS versus another MIGS, four comparisons 
of a MIGS combined with cataract surgery versus cataract surgery alone, and two com-
parisons of a MIGS combined with cataract surgery versus cataract surgery combined 
with filtration surgery. None of the included studies examined effectiveness and safety 
comparing a MIGS combined with filtration surgery versus filtration surgery alone, 
pharmacotherapy, or laser therapy. 
 
One of the studies, Jones 2019 (47), was a follow-up of Samuelson 2018 (67), which 
was included  in CADTH HTA. Jones 2019 compared Hydrus + phacoemulsification with 
phacoemulsification alone. Only one of the studies examined a comparison that was 
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also examined in studies included in  CADTH HTA: Alnawaiseh 2018 (45) compared 
iStent + phacoemulsification with phacoemulsification alone. Being a non-randomised 
trial, however, results from this study could not be pooled with the randomised trials 
included in CADTH HTA to update the effect estimate. Thus, none of the results from 
any of the studies in the NIPH supplementary review could be pooled with study re-
sults in the CADTH HTA (5). 
 
Table 4: Studies and comparisons included in NIPH supplementary review 
Studies  MIGS Comparator 
 Comparison: MIGS vs. another MIGS 
Ahmed 2019 (86) 2x iStent Hydrus 
 Comparison: MIGS + cataract surgery vs. cataract surgery alone 
Alnawaiseh 2018 (45) iStent + Phaco Phaco alone 
Best 2019 (46); Samuel-
son 2019 (49) iStent Inject + Phaco Phaco alone 
Sato 2018 (50) Trab360 + Phaco Phaco alone 
Jones 2019 (47) Hydrus + Phaco Phaco alone 
 
Comparison: MIGS + cataract surgery vs. filtration surgery + cataract 
surgery 
Rekas 2015 (48) iTrack + Phaco 
Filtration Surgery (NPDS) + 
Phaco 
Skaat 2016 (51) Gold MicroShunt 24um or 48um Ahmed glaucoma valve 
Phaco = phacoemulsification (cataract surgery); 
 
The recipient reservoir for MIGS in all comparisons but one was Schlemm’s canal/tra-
becular meshwork. The exception was the comparison MIGS vs filtration surgery, in 
which the recipient reservoir for MIGS was suprachoroidal space. 
 
Mean patient age ranged from approximately 69 years to 74 years (range 45 to 84 
years) across studies, and men and women were overall equally represented. Most pa-
tients were diagnosed with primary open angle glaucoma (moderate or severe) when 
recruited in the studies. A few studies included patients with other conditions, the most 
common diagnosis being pseudoexfoliation. All studies included intraocular pressure 
(IOP) as outcome, primarily measured by Goldmann applanation tonometry. The num-
ber of medications was an outcome in all studies except for the two in which pharma-
cotherapy was the comparator. The method of measuring number of glaucoma medica-
tions was unclear ornot reported. Other outcomes measured were visual field loss, and 
visual acuity. Safety was reported in most studies as intraoperative or post-operative 
AEs and complications. Safety was measured and reported in a non-systematic way, so 
it is unclear if the information in the studies corresponds to the only AEs in the studies. 
Including in the safety/AEs was also information about the need for a secondary proce-
dure, most often being need for cataract surgery.  
 
For more details on the characteristics of the included studies, please see the Risk of 
bias table 5, the effectiveness section below where we describe the studies under their 
respective comparisons, and also Appendix 7. 
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Risk of bias in included studies 
Randomised trials in CADTH HTA 
Ten of the 32 studies in CADTH HTA were randomised trials. The authors considered 
all of them to be at possible risk of selection bias, while only one trial was considered to 
be at risk of performance bias. One trial was judged to be at risk of detection bias for 
the outcome intraocular pressure. Two trials were at risk of attrition bias, and five tri-
als were at risk of reporting bias. One trial had an additional source of bias. Please see 
the full CADTH HTA report for details (5). 
 
Randomised trials in NIPH supplementary review 
We judged the risk of selection bias as low in four of the randomised trials and unclear 
in three trials, based on available descriptions of sequence generation procedures (Ta-
ble 5). Risk of selection bias was judged as low in two studies, unclear in four studies 
and high in one study, based on study allocation concealment procedures. In our judge-
ment, risk of performance bias was low in one study only, unclear in two studies and 
high in four studies, due to lack of blinding of personnel delivering the interventions. 
We judged risk of detection bias as low in three studies, unclear in four studies and 
high in one study. The risk of attrition bias was judged as low in three studies, unclear 
in one study and high in three studies. We judged the risk of reporting bias as low in 
one study only, unclear in two studies and, due to indications of selective reporting, 
high in four studies.  
 
Table 5: Risk of bias summary, randomised trials 
  Selection 
Bias - Se-
quence 
Generation 
Selection 
Bias  
Allocation 
Conceal-
ment 
Perfor-
mance 
Bias 
Detection 
Bias  
Objective 
Measure 
Detection 
Bias Sub-
jective 
Measure 
Attrition 
Bias 
Reporting 
Bias  
Ahmed 2019 (86) Low Low High Low Unclear Low High 
Best 2019 (46) Unclear Unclear Unclear Unclear Unclear High Unclear 
Jones 2019 (47) Low  Unclear  Low  Low  Unclear  Low  Low   
Rekas 2015 (48) Low High High Unclear Low High Unclear 
Samuelson 2019 (49) Low Unclear High Low Low Unclear High 
Sato 2018 (50) Low Unclear High High High Low High 
Skaat 2016 (51) Unclear Low Unclear Unclear Unclear High High 
  
Non-randomised studies in CADTH HTA 
Twenty-two of the 32 studies in CADTH HTA were non-randomised studies. The au-
thors considered 16 of them to be at serious risk of bias due to confounding, and one 
study was at critical risk. Bias in the selection of participants was considered serious in 
one study and critical in two studies, while bias in the classification of intervention did 
not seem to be a problem in any of the studies. One study was judged to be at critical 
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risk of bias due to deviations from intended interventions, and 13 studies were at seri-
ous risk. Bias due to missing data was serious in ten studies and critical in one study. 
Bias in the measurement of intraocular pressures was considered serious in all but one 
study. Two studies were considered to be at critical risk of bias in selection of the re-
ported result, and six studies were at serious risk. Please see the full CADTH HTA re-
port for details (5). 
 
Non-randomised trial in NIPH supplementary review 
Overall, risk of bias did not seem to be a large concern in the non-randomised trial in-
cluded in the NIPH supplementary review (table 6) (45). 
 
Table 6: Risk of bias summary, non-randomised trial  
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Alnawaiseh 2018 (45) Serious Low Low Low Low Moderate Moderate 
 
 
Effectiveness of MIGS (CADTH HTA) 
CADTH’s primary outcome of interest, quality of life, was only assessed in three of the 
included studies (Figure 2 below), while intraocular pressure and number of medica-
tions used were measured in all studies and comparisons. Visual field and visual acuity 
were measured in four and fifteen comparisons, respectively. 
 
For most comparisons and outcomes, there was no statistically significant difference 
between intervention and comparator, or there was no statistical comparison (Figure 
2). 
 
The authors of the CADTH HTA carried out a total of six meta-analyses across three 
comparisons: iStent + phacoemulsification (phaco) versus phaco alone, Hydrus Mi-
crostent + phaco versus phaco elone, and Trabectome + phaco versus 2x iStents + 
phaco alone. For all these meta-analyses, intraocular pressure and number of medica-
tions used were the outcomes of interest. All other results were reported narratively.  
 
In this section, we present the comparisons with meta-analyses first, followed by sum-
maries of the narrative results. For details, please see the full CADTH HTA report (5).  
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Figure 2: High-level summary of findings by comparison and outcome in CADTH HTA (5) 
Reproduced with kind permission from CADTH. 
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iStent + phacoemulsification vs phacoemulsification alone 
Two randomised trials compared iStent + phacoemulsification (phaco) (n=129 eyes) 
with phaco alone (n=147 eyes).   
 
Intraocular pressure 
At 12 months, the pooled mean difference in intraocular pressure was –0.42 mm Hg 
(95% CI – 1.30 to 0.46; Figure 3x). CADTH HTA authors’ certainty rating of the evidence 
for this outcome was low. 
 
 
Figure 3: Mean difference (95% confidence interval) in intraocular pressure between the 
iStent + phaco and phaco alone groups at 12-month follow-up in CADTH HTA (5). 
Reproduced with kind permission from CADTH. 
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Number of medications used 
At 12 months, the pooled mean difference in number of medications was –0.25 (95% CI 
– 0.52 to 0.01, figure 4).  CADTH’s HTA authors’ certainty rating of the evidence was 
moderate. 
 
 
Figure 4: Mean difference (95% confidence interval) in number of medications used be-
tween the iStent + phaco and phaco alone groups at 12-month follow-up in CADTH HTA 
(5). 
Reproduced with kind permission from CADTH. 
 
Visual field 
There was no statistically significant difference between the groups in visual field 
(mean deviation and pattern standard deviation) at 24 months. This outcome was only 
measured in one of the two randomised trials. 
 
The difference between groups was not tested for the remaining outcome of interest, 
visual acuity. Quality of life was not measured in any of the two randomised trials. 
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Hydrus Microstent + phacoemulsification vs phacoemulsification alone 
Two randomised trials compared Hydrus Microstent + phacoemulsification (phaco) 
(n=419 eyes) with phaco alone (n=237 eyes). 
 
Intraocular pressure 
At 24 months, the pooled mean difference in intraocular pressure was –1.87 mm Hg 
(95% CI - 2.49 to - 1.26; Figure 5). CADTH HTA authors’ certainty rating of the evidence 
was high. 
 
 
Figure 5: Mean difference (95% confidence interval) in intraocular pressure between the 
Hydrus + phaco and phaco alone groups at 24-month follow-up in CADTH HTA (5). 
Reproduced with kind permission from CADTH. 
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Numbers of medications used 
At 24 months, the pooled mean difference in number of medications was –0.41 (95% CI 
– 0.52 to 0.01; Figure 6). The CADTH HTA authors’ certainty rating of the evidence was 
low. 
 
The remaining outcomes of interest, quality of life, visual field and visual acuity, were 
not measured in any of the two randomised trials. 
 
 
Figure 6: Mean difference (95% confidence interval) in number of medications used be-
tween the Hydrus + phaco and phaco alone groups at 24-month follow-up in CADTH HTA 
(5). 
Reproduced with kind permission from CADTH. 
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Trabectome + phacoemulsification vs 2x iStent + phacoemulsification 
Two retrospective cohort studies compared Trabectome + phacoemulsification (phaco) 
(n=88) with 2x iStent + phaco (n=83). 
 
Intraocular pressure 
At six months, the pooled mean difference in intraocular pressure was 2.55 mm Hg 
(95% CI 1.44 to 4.26; Figure 7) in favour of 2x iStent + Phaco. The CADTH HTA authors’ 
certainty rating of the evidence was very low.  
 
 
Figure 7: Mean difference (95% confidence interval) in intraocular pressure between the 
Trabectome + phaco and 2x iStent + phaco alone groups at six-month follow-up in CADTH 
HTA (5). 
Reproduced with kind permission from CADTH. 
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Numbers of medications used 
At 12 months, the pooled mean difference in number of medications was 0.41 (95% CI 
– 0.65 to 1.46, figure 8) in favour of 2x iStent + phaco. The CADTH HTA authors’ cer-
tainty rating of the evidence was very low. 
 
There was no statistically significant difference between groups in visual acuity at 12 
months. The remaining outcomes of interest, quality of life and visual field, were not 
measured. 
 
 
Figure 8: Mean difference (95% confidence interval) in number of medications used be-
tween the Trabectome + phaco and 2x iStent + phaco alone groups at 12-month follow-up 
in CADTH HTA (5). 
Reproduced with kind permission from CADTH. 
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MIGS vs another MIGS 
1x iStent vs 2x iStent vs 3x iStent  
One randomized trial compared one iStent (n=38 eyes) with two (n=41 eyes) or three 
(n=40 eyes) iStents. 
 
At 18 months, intraocular pressure was significantly reduced from baseline in eyes 
with one, two, or three iStents, and the reduction was incrementally greater with in-
creasing numbers of iStents (reductions of approximately 4 mm Hg, 6 mm Hg, and 8 
mm Hg after medication washout for one, two, and three iStents respectively).  
 
There were no statistically significant differences between groups in visual field. Differ-
ences between groups in number of medications and visual acuity were not tested sta-
tistically. 
 
MIGS vs pharmacotherapy 
2x iStent vs travoprost, or 2x iStent Inject vs latanoprost + timolol 
One randomised trial compared two iStent (n=54 eyes) with travoprost (n=47 eyes), 
and one randomised trial compared two iStent Inject (n=94 eyes) with latanoprost and 
timolol (n=98 eyes). 
 
There was no statistically significant difference between groups in number of medica-
tions used. Differences between groups were not tested statistically for the remaining 
outcomes of interest (intraocular pressure, visual field and visual acuity). 
 
MIGS vs laser therapy 
Hydrus Microstent vs selective laser trabeculoplasty 
One prospective cohort study compared Hydrus Microstent (n=31 eyes) with selective 
laser trabeculoplasty (SLT) (n=25 eyes). 
 
There was no statistically significant difference between groups in intraocular pres-
sure. At 12 months, the reduction from baseline in number of medications used was 
greater in the Hydrus group (approximately 1.4 medications) than in the SLT group 
(approximately 0.5 medications). Differences between groups were not tested statisti-
cally for the remaining outcomes of interest (visual field and visual acuity). 
 
MIGS vs filtration surgery 
Endoscopic cyclophotocoagulation vs glaucoma drainage device 
One retrospective cohort study and one non-randomised clinical trial compared Endo-
scopic cyclophotocoagulation (ECP) (n=59 eyes) with Baerveldt glaucoma implant 
(BGI) (n=48 eyes) and Ahmed glaucoma implant (AGI) (n=34 eyes), respectively. 
 
There were no statistically significant differences between groups for any of the out-
comes of interest (intraocular pressure, number of medications used, visual field and 
visual acuity). 
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Trabectome vs trabeculectomy with mitomycin C 
One prospective and one retrospective cohort study compared Trabectome (n=158 
eyes) with trabeculectomy with mitomycin C (MMC) (n=127 eyes). 
 
At 30 months, intraocular pressure was significantly higher in the Trabectome group 
(16.6 mm Hg) than in the trabeculectomy with MMC group (10.0 mm Hg) in the retro-
spective study. At 30 months, the absolute number of medications used was signifi-
cantly greater in the Trabectome group (2.3 medications) than in the trabeculectomy 
with MMC group (0.4), also in the retrospective study. At six months, one out of 12 
quality of life measures was significantly greater (mean difference of approximately 13 
points on a 100-point scale) in the Trabectome than in the trabeculectomy with MMC 
group. The difference between groups was not tested statistically for the remaining 
outcome of interest (visual acuity). 
 
2x iStent Inject vs trabeculectomy with mitomycin C 
One prospective cohort study compared 2x iStent (n=20 eyes) with trabeculectomy 
with mitomycin C (MMC) (n=25 eyes). 
 
There was no statistically significant difference between groups in quality of life. Differ-
ences between groups were not tested statistically for the remaining outcomes of inter-
est (intraocular pressure, number of medications used and visual acuity). 
 
Trabectome or 2x iStent Inject vs trabeculectomy with mitomycin C 
One prospective cohort study compared Trabectome or 2x iStent (grouped together) 
(n=63 eyes) with trabeculectomy with mitomycin C (MMC) (n=25 eyes). 
 
The number of medications used was significantly higher in the Trabectome or 2x 
iStent group than in the trabeculectomy with MMC group at all follow-ups. There were 
no statistically significant differences between groups in intraocular pressure or visual 
acuity. The difference between groups was not tested for the remaining outcome of in-
terest, number of medications used. 
 
Xen45 vs trabeculectomy with mitomycin C 
One retrospective cohort study compared Xen45 (n=185 eyes) with trabeculectomy 
with MMC (n=169 eyes). 
 
There were no statistically significant differences between groups for any of the out-
comes of interest (intraocular pressure, number of medications used, visual field and 
visual acuity). 
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MIGS + cataract surgery vs cataract surgery alone 
Endoscopic cyclophotocoagulation + phacoemulsification vs phacoemulsification 
alone 
One prospective and four restrospective cohort studies compared endoscopic cyclo-
photocoagulation (ECP) and phacoemulsification (phaco) (n=555 eyes) with phaco 
alone (n=282). 
 
Intraocular pressure 
In the prospective cohort study, there was a statistically significant difference in intra-
ocular pressure at 36 months between the ECP+ phaco group and the phaco alone 
group (~15 mm Hg vs. 17 mm Hg). In the retrospective cohort studies, there were no 
statistically significant difference between groups in reduced intraocular pressure.  
 
Number of medications used 
The number of medications used at baseline differed between the intervention and 
comparator groups in four of the five cohort studies, impeding an interpretation of fol-
low-up results. 
 
Visual acuity 
In two retrospective cohort studies, there was no statistically significant difference in 
visual acuity or best-corrected visual acuity at 36 months.  
 
Quality of life and visual field were not measured in any of the studies. 
 
2x iStent + phacoemulsification vs phacoemulsification alone 
One randomised trial compared 2x iStent + phacoemulsification (phaco) (n=17 eyes) 
with phaco alone (n=16 eyes). 
 
At 12 months, the intraocular pressure and the number of medications used were sig-
nificantly lower in the 2x iStent + phaco group than in the phaco alone group. The re-
maining outcomes of interest, quality of life, visual field and visual acuity, were not 
measured. 
 
CyPass Micro-Stent + phacoemulsification vs phacoemulsification alone 
One randomised trial compared CyPass Micro-Stent + phacoemulsification (phaco) 
(n=374 eyes) with phaco alone (n=131 eyes). 
 
At 12 and 24 months, the intraocular pressure and the number of medications used 
were significantly lower in the CyPass Micro-Stent + phaco group than in the phaco 
alone group. The remaining outcomes of interest, quality of life, visual field and visual 
acuity, were not measured. 
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MIGS + cataract surgery vs a different MIGS + cataract surgery 
Goniotomy with Kahook Dual Blade + phacoemulsification vs iStent + phacoemulsi-
fication  
One retrospective cohort study compared goniotomy with Kahook Dual Blade (KDB) + 
phacoemulsification (phaco) (n=237) versus iStent + phaco (n=198). 
 
At 6 months, the reduction from baseline in intraocular pressure and in number of 
medications used was significantly greater in the KDB + phaco group than in the iStent 
+ phaco group. There was no statistically significant difference between the groups in 
visual acuity. The remaining outcomes of interest, quality of life and visual field, were 
not measured.  
 
Trabectome + micro-incision cataract surgery vs 2x iStent + micro-incision cata-
ract surgery 
One retrospective cohort study compared Trabectome + micro-incision cataract sur-
gery (MICS) (n=25) with 2x iStent + MICS (n=25). 
There were no statistically significant differences between groups for any of the meas-
ured outcomes of interest (intraocular pressure, number of medications used and vis-
ual acuity). The remaining outcomes of interest, quality of life and visual field, were not 
measured. 
 
Different numbers of iStent + phacoemulsification 
One non-randomised clinical trial and one retrospective cohort study compared differ-
ent numbers of iStent + phacoemulsification (phaco): 1x iStent + phaco (n=39), 2x 
iStent + phaco (n=58) and 3x iStent + phaco (n=25). 
 
At 12 months, there was no statistically significant difference between any of the 
groups in intraocular pressure. There was no statistically significant difference be-
tween 1x iStent + phaco and 2x iStent + phaco groups in numbers of medications used. 
The number of medications used was higher in the 2x iStent + phaco group than in the 
3x iStent + phaco group. The difference between groups in visual acuity was not statis-
tically tested. The remaining outcomes of interest, quality of life and visual field, were 
not measured. 
 
Endoscopic cyclophotocoagulation + iStent + phacoemulsification vs iStent + 
phacoemulsification 
One retrospective cohort study compared endoscopic cyclophotocoagulation (ECP) + 
iStent + phacoemulsification (phaco) (n=51) with iStent + phaco (n=50). 
 
At 12 months, reductions in intraocular pressure and the number of medications used 
were significantly greater in the ECP + iStent + phaco group than in the iStent + phaco 
group. The remaining outcomes of interest, quality of life, visual field and visual acuity, 
were not measured. 
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Endoscopic cyclophotocoagulation + phacoemulsification vs Trabectome + 
phacoemulsification 
One retrospective cohort study compared endoscopic cyclophotocoagulation (ECP) + 
phacoemulsification (phaco) (n=35) with Trabectome + phaco (n=26). 
 
There were no statistically significant differences between groups for any of the out-
comes of interest (intraocular pressure, number of medications used and visual field). 
The remaining outcomes of interest, quality of life and visual acuity, were not meas-
ured. 
 
MIGS + cataract surgery vs filtration surgery + cataract surgery 
Trabectome + phacoemulsification vs trabeculectomy with mitomycin C + 
phacoemulsification 
One randomized trial compared Trabectome + phacoemulsification (phaco) (n=10) 
with trabeculectomy with mitomycin C (MMC) + phaco (n=9). 
 
There were no statistically significant differences between groups in intraocular pres-
sure or number of medications used. The remaining outcomes of interest, quality of life, 
visual field and visual acuity, were not measured.  
 
Trabectome + phacoemulsification vs trabeculectomy + phacoemulsification 
One prospective and one retrospective cohort study compared Trabectome + 
phacoemulsification (phaco) (n=47) with trabeculectomy + phaco (n=29). 
 
There were no statistically significant differences between groups in intraocular pres-
sure or number of medications used. The remaining outcomes of interest, quality of life, 
visual field and visual acuity, were not measured.  
 
Endoscopic cyclophotocoagulation + phacoemulsification vs trabeculectomy with 
mitomycin C + phacoemulsification 
One retrospective cohort study compared endoscopic cyclophotocoagulation (ECP) + 
phacoemulsification (phaco) (n=24) with trabeculectomy with mitomycin C (MMC) + 
phaco (n=29). 
 
There was no statistically significant difference between groups in inocular pressure or 
visual acuity. At six months, the number of medications used was significantly higher in 
the ECP + phaco group than in the trabulectomy with MMC + phaco group. The remain-
ing outcomes of interest, quality of life and visual field, were not measured.  
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Effectiveness of MIGS (NIPH supplementary review) 
Across studies and comparisons, the intraocular pressure (IOP) measured at 12 to 24 
months’ follow-up was slightly lower in the MIGS arms than in the control arms (Figure 
9). We present effect estimates for each individual comparison below. 
 
  
Figure 9: Intraocular pressure across studies/comparisons 
 
MIGS vs another MIGS 
Hydrus vs 2x iStent  
Ahmed 2019 (44) compared Hydrus with 2x iStent in 152 eyes/patients. This was a 
multicentre study (12 sites and 9 countries), including individuals with open angle, 
pseudoexfoliative, or pigmentary mild to moderate glaucoma. Mean age was 66 years, 
and participants were from European, Latin America, Asian and African American an-
cestry. There were more female participants than men (ratio 84:68). Outcomes of inter-
est in Ahmed 2019 were IOP at 12 months and number of glaucoma medications used. 
The remaining outcomes of interest (ie IOP fluctuation, quality of life, vision related 
quality of life, visual field loss, visual impairment, visual acuity and retinal nerve fibre 
layer thickness) were not evaluated in this study.  
 
IOP 
At 12 months the mean unmedicated IOP was 17.3 mmHg (SD 3.7) in the Hydrus arm 
and 19.2 mmHg (SD 2.4) 2x iStent arm (MD -1.9 mmHg; 95 % CI -2.91 to -0.89) (Com-
parison 1.1.1; Fig 9). The difference was clinically important. Certainty of the evidence: 
low (Appendix 5). 
 
Number of medications used 
At 12 months the mean reduction from baseline in medication use was 1.0 medications 
(SD 1.2) in the Hydrus arm and 1.6 medications (SD 1.2) in the 2x iStent arm (MD 0.6 
medications; 95% CI 0.21, 0.99).  
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MIGS + cataract surgery vs cataract surgery alone 
iStent + phacoemulsification vs phacoemulsification alone 
The non-randomised trial Alnawaiseh 2018 (45) compared iStent + phacoemulsifica-
tion with phacoemulsification alone in 48 eyes (one eye per patient). The study was 
conducted in Germany. Patients’ mean age was 73.5 years in the iStent group and 72.8 
years in the cataract group. Twenty-eight patients (58%) were women. The only out-
come of interest in this study was IOP. 
 
IOP 
At 12 months the mean IOP was 13.2 mmHg (SD 2.3) and 15.1 mmHg (SD 2.7) in the 
iStent + phacoemulsification and the phacoemulsification alone arms, respectively (MD 
-1.90; 95% CI -3.32, -0.48) (Comparison 1.1.2; Fig 9). The difference was clinically im-
portant. Certainty of the evidence: very low (Appendix 5). 
 
iStent inject + phacoemulsification vs phacoemulsification alone 
Best 2019 (46) and Samuelson 2019 (49) investigated the effects of iStent inject 
phacoemulsification versus phacoemulsification alone in two randomized trials con-
ducted in Germany and in 41 US sites, respectively. A total of 570 eyes of 561 patients 
were randomized to one of the treatment arms. Mean patient age was approximately 
66 to 81 years. Patients were described as ‘white’ (73%) in one study; we have no in-
formation about the other. There were more males than females (ratio 289:216; data 
from Samuelson 2019 only). Samuelson 2019 reported IOP and number of medications 
used at 24 months. In Best 2019, patients were followed up with varying time intervals 
up to 38 months, with mean 14 months.  The remaining outcomes of interest (ie IOP 
fluctuation, quality of life, vision related quality of life, visual field loss, visual impair-
ment, visual acuity and retinal nerve fibre layer thickness) were not evaluated in these 
trials. 
 
IOP 
The pooled mean difference in IOP between the iStent inject + phacoemulsification and 
phacoemulsification alone arms was -0.70 mmHg (95% CI -1.27, -0.13) (single study ef-
fect estimates in comparison 1.1.3; Fig 9). The difference was not clinically important. 
Certainty of the evidence: moderate (Appendix 5). 
 
Number of medications used 
The mean reduction of medications used at 24 months in Samuelson 2019 was 1.2 (SD 
1.0) and 0.8 (SD1.0) in the iStent inject + phacoemulsification arm and the phacoemul-
sification alone arm, respectively (MD -0.40; 95% CI -0.61, -0.19). Best 2019 did not re-
port standard deviations, but the mean number of medications used at 4 months was 
1.5 and 2.1 in the iStent inject + phacoemulsification arm and in the phacoemulsifica-
tion alone arm, respectively. 
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Trab360 + phacoemulsification vs phacoemulsification alone 
Sato 2018 compared Trab360 + phacoemulsification with phacoemulsification alone in 
18 eyes/patients in Japan (50). This randomised trial included patients diagnosed with 
coexisting mild to moderate cataract and open angle glaucoma. Patients’ mean age was 
74.2±9.5 years in the Trab360 + phacoemulsification arm and 74.4±3.6 in the 
phacoemulsification alone arm. There were more female participants than male (ratio 
8:10). Sato 2018 reported IOP at 24 months, and number of medications used. The re-
maining outcomes of interest (ie IOP fluctuation, quality of life, vision related quality of 
life, visual field loss, visual impairment, visual acuity and retinal nerve fibre layer thick-
ness) were not evaluated in these trials. 
 
IOP 
At 24 months the mean IOP was 11.8 mmHg (SD 2.3) and 15.1 mmHg (SD 2.7) in the 
Trab360 + phacoemulsification and the phacoemulsification alone arms, respectively 
(MD -2.80; 95% CI -5.49, -0.11) (Comparison 1.1.5; Fig 9). The difference was clinically 
important. Certainty of the evidence: very low (Appendix 5). 
 
Number of medications used 
The mean number of medications used at 24 months was 1.0 (SD 1.7) and 1.2 (SD 1.4) 
in the Trab360 + phacoemulsification and the phacoemulsification alone arms, respec-
tively (MD -0.90; 95% CI -1.46, -0.34).  
 
Hydrus + phacoemulsification vs phacoemulsification alone 
Jones 2019 (47), a 24 month follow-up of Samuelson 2018 (87), which was included in 
the CADTH HTA, compared Hydrus + phacoemulsification with phacoemulsification 
alone. The trial was a multicentre study conducted in the United States including 331 
eyes/patients with mild to moderate open angle glaucoma, pigmentary or pseudoexfo-
liative glaucoma. Patients’ mean age was 70.3 (SD 7.1) and 71.1 years (SD 7.2) in the 
two arms, respectively. There were slightly more female than male patients (ratio 
174:157). Regarding ethnicity, the majority of patients were “white and a small propor-
tion of Asian, black or African American or other origin”.  
 
IOP 
At 24 months the mean unmedicated IOP was 17.5 mmHg (SD 3.9) and 19.3 mmHg (SD 
4.2) in the Hydrus + phacoemulsification and the phacoemulsification alone arms, re-
spectively (MD -1.80; 95% CI -2.73, -0.87) (Comparison 1.1.4; Fig 9). The difference was 
not clinically important. Certainty of the evidence: high (Appendix 5). 
 
Number of medications used 
The mean number of medications used at 24 months was 0.4 (SD 0.8) and 0.8 (SD 0.9) 
in the Hydrus + phacoemulsification and the phacoemulsification alone arms, respec-
tively (MD -0.40; 95% CI -0.60, -0.20). 
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MIGS vs filtration surgery  
Gold MicroShunt (GMS) 24um or 48um vs Ahmed glaucoma valve (AGV) 
Skaat 2016 (51) was conducted in Israel in patients 21 years and older diagnosed with 
open angle, pseudoexfoliative or pigmentary glaucoma in one or both eyes, with at least 
one failed trabeculectomy within the last 60 days. The trial included 29 eyes/patients. 
Patients’ mean age was 71 (SD 4.1), 72.6 (SD 4.5) and 72.1 (SD 4.9) years in the AGV, 
GMS 24um and GMS 48um arms, respectively. Fifteen patients were female and 14 
were male. Ethnicity was not specified. Outcomes of interest included in Skaat 2016 
were IOP and medication use. The remaining outcomes of interest were not evalu-
ated for clinical effectiveness. 
 
IOP 
At 5 years, the mean IOP was 15.6 mmHg (SD 1.4) and 16.3 mmHg (SD 1.8) in the com-
bined GMS (24um + 48um) and AGV arms, respectively (MD -0.70 mmHg; 95% CI -2.71, 
1.31) (Comparison 1.1.6; Fig 9). The difference was not clinically important. Certainty 
of the evidence: very low (Appendix 5). 
 
Number of medications used 
The mean number of medications used at 5 years was 3.0 (SD 0.7) and 3.2 (SD 0.5) in 
the combined GMS (24um + 48um) and AGV arms, respectively (MD 0.20; 95% CI -0.57, 
0.97).  
 
MIGS + cataract surgery vs filtration surgery + cataract surgery 
iTrack + phacoemulsification vs filtration surgery + phacoemulsification 
Rekas 2015 (48) was conducted at the Military Institute in Poland. It included individu-
als diagnosed with open angle glaucoma, pseudoexfoliative and pigmentary glaucoma 
with daily fluctuations in IOP and no-compliance with medication or allergy to topical 
medications. The trial included 59 eyes in patients. Patients’ mean age was 74.6 years 
(SD 8.9) and 73.3 years (SD 5.8) in the two arms, respectively. Thirty-three of the pa-
tients were male and 28 were females (ethnicity not specified). Included outcomes of 
interest were IOP, medication use and visual acuity. No other outcomes of interest were 
measured. 
 
IOP 
At 12 months, the mean IOP was 12.6 mmHg (SD 2.7) and 14.3 mmHg (SD 3.5) in the 
iTrack + phacoemulsification and filtration surgery + phacoemulsification alone arms, 
respectively (MD -1.70 mmHg; 95% CI -3.29, -0.11) (Comparison 1.1.7; Fig 9). The dif-
ference was clinically important. Certainty of the evidence: very low (Appendix 5). 
 
Number of medications used 
The mean number of medications used at 12 months was 0.27 (SD 0.67) and 0.55 (SD 
0.94) in the iTrack + phacoemulsification and the filtration surgery + phacoemulsifica-
tion arms, respectively (MD -0.28; 95% CI -0.70, 0.14).  
 
Visual acuity 
 59  Clinical effectiveness and safety 
There was no difference in mean corrected distance visual acuity measure (CDVA) at 
12 months. The logarithm (base 10) of the minimal angle of resolution (LogMAR) was 
0.11 (SD 0.17) and 0.11 (SD 0.16) in the two arms, respectively (MD 0.00; 95% CI -0.08, 
0.08).  
 
Safety of MIGS (CADTH HTA) 
The CADTH HTA authors characterised the evidence regarding the safety of MIGS as 
“limited”. None of the included studies reported methods of measuring adverse events 
or any restrictions on what was considered an adverse event. Statistical comparisons 
between groups occurred infrequently. Due to these limitations, the CADTH HTA au-
thors rated the evidence regarding safety as “very low” certainty for all comparisons 
and all adverse events. That is, it is uncertain whether there is any difference regarding 
safety between different types of MIGS, between MIGS and other methods, or between 
MIGS in combination with cataract surgery, and other methods. Please see the full 
CADTH HTA report for details (5). 
 
Safety of MIGS (NIPH supplementary review) 
Safety (i.e., adverse events) was measured and reported differently by study authors. 
Some authors included pre-and-post-operative events, others classified the events as 
mild or moderate, others described events by follow up time (i.e., year 1 or 2), and 
some provided a brief description. Aiming not to lose any information, we report in the 
tables below adverse events at any point as reported by authors with number of partic-
ipants and percentages (n, %), and risk ratios with 95% confidence intervals. Our over-
all judgement of the certainty of the evidence was very low. 
 
MIGS vs another MIGS 
Hydrus vs 2x iStent  
Ahmed 2019 (44) recorded the following adverse events and complications associated 
with the comparison Hydrus vs 2x iStent: new cataracts, best-corrected visual acuity 
(BVCA) loss >2 lines, IOP elevation >10 mmHg over baseline, device obstructions, hy-
potony, device migration, dislocation and secondary surgical intervention (Table 7). 
The certainty of the evidence was very low. 
 
Table 7: Adverse events. Comparison: Hydrus vs 2x iStent 
Adverse event Hydrus 
n (%) 
2x iStent 
n (%) 
Risk ratio 
[95% CI] 
 N=74 N=76  
New cataracts 2 (2.7) 1 (1.3) 2.05 [0.19, 22.17] 
BVCA loss >2 lines 3 (4.0) 1 (1.3) 3.08 [0.33, 28.95] 
IOP elevation >10 mmHg 3 (4.0) 4 (5.2) 0.77 [0.18, 3.32] 
Device obstructions 10 (13.5) 9 (11.8) 1.14 [0.49, 2.65] 
Secondary surgical intervention 0 (0) 3 (3.9) 0.15 [0.01, 2.79] 
Hypotony, device migration, dislocation 0 (0) 0 (0) -- 
CI: confidence interval; BVCA: best-corrected visual acuity; IOP: intraocular pressure. 
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MIGS + cataract surgery vs cataract surgery alone 
iStent inject + phacoemulsification vs phacoemulsification alone 
Best 2019 (46) reported one case of bleeding during interventions, which was quickly 
resolved, in the iStent inject + phacoemulsification arm. In the phacoemulsification 
alone arm, there were two cases of very high postoperative IOP and pain.  
 
Samuelson 2019 (49) recorded and reported postoperative ocular adverse events oc-
curring in ≥2% of the study eyes (Table 8). Compared to phacoemulsification alone, the 
combination of iStent inject and phacoemulsification seemed to increase the risk of for-
eign body sensation, IOP increase > 10 mmhg at >1 month, perioperative ocular pain, 
blurred vision/visual disturbance, and secondary surgical intervention. Further, cor-
neal abrasion, corneal opacity, hyperemia, non-proliferative diabetic retinopathy and 
IOP increase requiring medications or surgical intervention where among adverse 
events that seemed to occur more frequently in the phacoemulsification only arm. The 
certainty of the evidence was very low. 
 
Table 8: Adverse events. Comparison: iStent inject + phacoemulsification vs phacoemulsi-
fication alone 
Adverse event 
iStent inject 
+ phaco  
n (%) 
Phaco alone 
n (%) 
Risk ratio  
[95% CI] 
 N=387 N=118  
Foreign body sensation 9 (2.3) 0 (0.0) 5.83 [0.34, 99.38] 
IOP increase > 10mmhg at month >1 8 (2.1) 1 (0.8) 2.44 [0.31, 19.30] 
Perioperative ocular pain 8 (2.1) 1 (0.8) 2.44 [0.31, 19.30] 
Blurred vision/visual disturbance 9 (2.3) 2 (1.7) 1.37 [0.30, 6.26] 
Extraocular inflammation 9 (2.3) 2 (1.7) 1.37 [0.30, 6.26] 
Any intraocular inflammation 22 (5.7) 5 (4.2)  1.34 [0.52, 3.47] 
Secondary surgical intervention 22 (5.4)  6 (5.0) 1.12 [0.46, 2.69] 
Ocular surface disease 62 (16.1) 20 (16.8) 0.95 [0.60, 1.50] 
Epiretinal membrane 9 (2.3) 3 (2.5) 0.91 [0.25, 3.32] 
Ocular allergies 11 (2.8)  4 (3.4) 0.84 [0.27, 2.58] 
Vitreous floaters 8 (2.1) 3 (2.5) 0.81 [0.22, 3.02] 
Loss of BSCVA ≥2 lines 10 (2.6) 5 (4.2)  0.61 [0.21, 1.75] 
Posterior vitreous detachment 10 (2.6) 5 (4.2)  0.61 [0.21, 1.75] 
Corneal abrasion 8 (2.1) 4 (3.4) 0.61 [0.19, 1.99] 
Corneal opacity 4 (1.0) 3 (2.5) 0.41 [0.09, 1.79] 
Non-proliferative diabetic retinopathy  2 (0.5) 3 (2.5) 0.20 [0.03, 1.20] 
Hyperemia 3 (0.8) 7 (5.9) 0.13 [0.03, 0.50] 
IOP increase requiring medications or 
surgical intervention 
1 (0.3) 3 (2.5) 0.10 [0.01, 0.97] 
Stent obstruction  24 (6.2) NA - 
CI: confidence interval; BSVCA: best spectacle-corrected visual acuity; IOP: intraocular pressure 
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Trab360 + phacoemulsification vs phacoemulsification alone 
Sato 2018 (50) recorded and reported adverse events associated with Trab360 + 
phacoemulsification vs phacoemulsification alone (Table 9).  Compared to phacoemul-
sification alone, the combination of Trab360 and phacoemulsification seemed to in-
crease the risk of intraoperative reflux bleeding and hyphema, and decrease the risk of 
additional glaucoma surgery. There appeared to be no difference between the two con-
ditions with regard to IOP elevation and rate of endothelial cell loss. The certainty of 
the evidence was very low. 
 
Table 9: Adverse events. Comparison: Trab360 + phacoemulsification vs phacoemulsifica-
tion alone 
Adverse event Trab360 +  
phaco 
n (%) 
Phaco alone 
n/N 
Risk ratio [95% CI] 
 N=9 N=9  
Intraoperative reflux bleeding  9 (100) 0 (0) 19.00 [1.27, 284.24] 
Hyphema  2 (22) 0 (0) 5.00 [0.27, 91.52] 
IOP elevation 3 (33) 3 (33) 1.00 [0.27, 3.69] 
Additional glaucoma surgery 0 (0) 1 (11) 0.33 [0.02, 7.24] 
Mean rate of endothelial cell loss  5.7% (SD 3.4)  6.1% (SD 5.9)  -0.4%* [-4.85, 4.05] 
CI: confidence interval; IOP: intraocular pressure; *Mean difference 
 
Hydrus + phacoemulsification vs phacoemulsification alone 
Jones 2019 (47) reported cumulative adverse events associated with Hydrus + 
phacoemulsification versus phacoemulsification alone, through 24 months (Table 10). 
Synechiae, uveititis/irititis, hyphema, corneal abrasion, subconjunctival bleeding and 
vitreous complications appeared to occur more frequently in the Hydrus + phacoemul-
sification arm. Conjunctivitis, IOP elevation and secondary surgical interventions ap-
peared to occur more frequently in the phacoemulsification only arm. The certainty of 
the evidence was very low. 
 
Table 10: Cumulative adverse events through 24 months. Comparison: Hydrus + 
phacoemulsification vs phacoemulsification alone 
Adverse event Hydrus+phaco 
n (%) 
Phaco alone 
n (%) 
Risk ratio [95% CI] 
 N=219 N=112  
Synechiae  15 (6.8) 1 (0.9) 7.67 [1.03, 57.33] 
Uveitis/iritis 10 (4.6)  0 (0.0) 10.79 [0.64, 182.41] 
Conjunctivitis 8 (3.7) 10 (8.9) 0.41 [0.17, 1.01] 
Elevated IOP >10mmHg over baseline 2 (0.9) 3 (2.7) 0.34 [0.06, 2.01] 
Hyphema 3 (1.4) 1 (0.9) 1.53 [0.16, 14.58] 
Corneal abrasion 4 (1.8) 0 (0.0) 4.62 [0.25, 85.11] 
Subconjunctival hemorrhage 4 (1.8) 0 (0.0) 4.62 [0.25, 85.11] 
Device obstruction 4 (1.8) -- -- 
Vitreous complications 3 (1.4) 1 (0.9) 1.53 [0.16, 14.58] 
Secondary surgical interventions   1 (0.5) 3 (2.7) 0.17 [0.02, 1.62] 
CI: confidence interval; IOP: intraocular pressure 
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iStent + phacoemulsification vs phacoemulsification alone 
The non-randomised trial Alnawaiseh 2018 (45) did not report any adverse events as-
sociated with the comparison iStent + phacoemulsification vs phacoemulsification 
alone.  
 
MIGS vs filtration surgery  
Gold MicroShunt (GMS) 24um or 48um vs Ahmed glaucoma valve (AGV) 
Skaat 2016 (51) reported that there were no major complications in any of the treat-
ment arms, but did register some minor complications (Table 11). All over, there 
seemed to be more postoperative minor complications in the Ahmed glaucoma valve 
arm, but the study authors noted that all complications resolved within weeks. The cer-
tainty of the evidence was very low. 
 
Table 11: Adverse events. Comparison: Gold MicroShunt 24um/48um vs Ahmed glau-
coma valve  
Adverse event Gold MicroShunt 
24um/48um 
n (%) 
Ahmed glaucoma 
valve 
n (%) 
Risk ratio 
[95% CI] 
 N=20 N=9  
Injection 11 (55) 9 (100) 0.58 [0.38, 0.87] 
Hyphema  3 (15) 2 (22) 0.68 [0.14, 3.37] 
Choroidals 1 (5) 2 (22) 0.23 [0.02, 2.17] 
Shallow anterior chamber 2 (10) 2 (22) 0.45 [0.07, 2.71] 
Hypotony 0 (0)  1 (11)  0.16 [0.01, 3.56] 
CI: confidence interval 
 
MIGS + cataract surgery vs filtration surgery + cataract surgery 
iTrack + phacoemulsification vs filtration surgery + phacoemulsification 
Rekas 2015 (48) recorded and reported a number of perioperative complications (Ta-
ble 12). Adverse events seemed to occur more frequently in the iTrack + phacoemulsifi-
cation arm, except for bleb fibrosis, which occurred more often in the filtration surgery 
+ phacoemulsification arm. There was no difference observed between the two arms in 
intraoperative TDM rupture and iris carceration. The certainty of the evidence was 
very low. 
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Table 12: Adverse events. Comparison: iTrack + phacoemulsification vs filtration surgery 
+ phacoemulsification  
Adverse event iTrack + 
phaco  
 n (%) 
Filtration sur-
gery + phaco  
n (%) 
Risk ratio [95% CI] 
 N=29 N=30  
Intraoperative TDM rupture 1 (3.4) 1 (3.3) 1.03 [0.07, 15.77] 
Hyphema  17 (58.6) 0 (0.0) 36.17 [2.28, 574.84] 
Descemet membrane detachment 1 (3.4) 0 (0.0) 3.10 [0.13, 73.14] 
Choroid detachment 2 (6.9) 0 (0.0) 5.17 [0.26, 103.21] 
Hypotony until 30 days 5 (19.0)  3 (10.0) 1.72 [0.45, 6.57] 
Bleb fibrosis 0 (0.0) 8 (26.7) 0.06 [0.00, 1.01] 
Iris incarceration 1 (3.4) 1 (3.3) 1.03 [0.07, 15.77] 
TDM: trabeculo Descemet’s membrane 
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Organizational aspects 
This chapter about organizational aspects related to using MIGS in Norway is not 
adapted from CADTH. 
 
Background 
MIGS surgery in Norway is generally done at public hospitals with eye units in Norway 
(i.e. Oslo University Hospital, Sørlandet Hospital, Haukeland University Hospital, Sta-
vanger University Hospital , St.Olav Hospial – University Hospital Trondheim, Ålesund 
Hospital, Molde Hospital, Drammen Hospital, Elverum Hospital, probably more) in ad-
dition to a few  private clinics (to our knowledge iFocus and Volvat-Orbita). This chap-
ter is based on input from our clinical experts, representing Oslo University Hospital, 
Hospital of Sothern Norway, Arendal, Haukeland University Hospital, St. Olav’s Univer-
sity Hospital, Trondheim and University of North Norway (28;88).  
 
Method 
In order to evaluate the organizational consequences related to the implementation of 
MIGS and a potential increase in volume of MIGS performed in Norwegian hospitals, we 
asked clinical experts from the five respective state-run hospitals, to answer a ques-
tionnaire regarding their present capacity and procedure used: patient selection, pro-
cedures and ongoing trials. We received answers from all five hospitals. The questions 
used in the questionnaire are listed in Appendix 8. 
 
Patient selection 
There exists one professional guideline within ophthalmology with a specific chapter 
for glaucoma, but there is no national register for glaucoma surgery (28;88). These 
guidelines provide broad advice, they point out that there are many factors that play a 
role in choice of procedure, and that individual considerations are needed. Medical 
knowledge is constantly evolving, and Norwegian ophthalmology follows the European 
Glaucoma Society (EGS) Guidelines (12).   
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Clinicians need to identify which specific patients may or may not benefit from a partic-
ular MIGS procedure. To our knowledge, criteria for patient selection are not specifi-
cally developed in Norway. The patients requiring MIGS treatment are referred by an 
ophthalmologist to a specialised eye unit offering MIGS surgery. What determines 
which MIGS is chosen is one/more of the following: the type of glaucoma, what stage 
the glaucoma is in, what the estimated target pressure is, the patient’s age and compli-
ance regarding treatment (28).  
 
There are three types of recipient reservoars for MIGS procedures: 1.) Subconjunctival 
space, 2.) Suprachoridal space, and 3.) Trabecular meshwork/schlemm canal. Different 
MIGS procedures are used in different settings due to different mechanisms of function. 
Procedures that use subconjunctival space and trabecular meshwork as a recipient res-
ervoir are the most used MIGS procedures in Norway today (28).  
 
The subconjunctival space procedure is usually provided to patients with low target 
pressure. A trabecular meshwork procedure can be chosen when there is a need to 
combine glaucoma with cataract surgery and in cases of mild/moderate glaucoma 
where there the target pressure doesn’t have to be as low. Also, the use of this proce-
dure is relevant amongst others when the patient has intolerance to topic medication 
(28). 
 
To our knowledge iStent inject, ABiC (both trabecular meshwork procedures) and XEN 
Gel Implant (subconjunctival space procedure) dominate the Norwegian marked.  
 
 
Capacity and number of treatments 
MIGS procedures require less follow-up than traditional surgery in early phase after 
surgery, so the benefit may be fewer controls per patient in the hospital. However, bet-
ter treatment options may lead to more patients getting operated, thus resulting in a 
similar overall demand of follow-up consultations. MIGS is suitable for outpatient sur-
gery without hospital admission. This usually requires access to outpatient follow-up 
on day 1, (3) and 7. Ophthalmologists need to be trained and course certification is re-
quired to perform MIGS (28).  
 
The need for glaucoma surgery may increase due to increased population growth in the 
relevant age group, in addition to increased experience with MIGS among clinicians. 
Mainly based on extrapolation of considered needs estimated in 2012 and up to 2030 
as presented in the Konus report (28) conducted by The Norwegian Ophthalmological 
Association, clinical experts predict the number of MIGS procedures will increase annu-
ally to twice as many in 2024 compared to today (2020).  
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Health economic evaluation   
BACKGROUND 
Introduction to Economic Evaluation of Health Care Programmes 
The basic aim of an economic evaluation is to identify, measure and compare costs 
and consequences (effectiveness) of different strategies in an incremental analysis, one 
in which the differences in costs between strategies are compared with differences in 
their consequences (89). Results of an economic evaluation between two strategies can 
be expressed as an incremental cost-effectiveness ratio (ICER), defined by this equa-
tion: 
 
 
 
The health care sector, similarly to society in general, is constrained by scarce re-
sources. Therefore, economic evaluations are useful tools for decision makers facing 
questions of how to prioritize treatments when the objective is to maximize health ben-
efits with scarce resources. For an economic evaluation to be meaningful in a decision 
making process, the ICER is usually compared to a ceiling ratio that reflects the decision 
maker’s maximum willingness to pay (WTP) for a health gain (89). Therefore, the deci-
sion rule for an economic evaluation can be expressed as: 
 
 
where λ equals WTP, and means that if the ICER of a strategy is equal to or below the 
ceiling ratio, introduction of the strategy represents good value for money (89). This 
decision rule does not take uncertainty into account. 
 
Economic evaluations are often based on decision models, such as decision trees and 
Markov models, calculatinge results based on various input parameters. There are al-
ways uncertainties related to the values of these parameters, which is why sensitivity 
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analyses are important features of economic evaluations. In short, sensitivity analyses 
illustrate how robust the results of the model are to variations in model parameters 
(89). 
 
Probabilistic sensitivity analysis (PSA) is a kind of sensitivity analysis where probabil-
ity distributions are assigned to the model parameters. The advantage of PSA is that un-
certainties of many parameters in the model can be considered simultaneously, making 
it very realistic for real world considerations. The basic approach in PSA is to replace 
the deterministic mean value with a distribution (based on published standard errors), 
where values are generated by random draws from the assigned distribution. By doing 
this repeatedly, with a specified number of iterations, the model produces estimates of 
the probabilities of alternative strategies to be cost-effective for a range of ceiling val-
ues of WTP. Results from PSAs are often presented as scatter plots showing point esti-
mates of the ICER for all iterations in a cost-effectiveness plane, and cost-effectiveness 
acceptability curves (CEACs) showing the probabilities of the alternatives being cost-
effective subject to changing values of WTP (89). 
 
In short, making a model probabilistic means that it is possible to estimate the overall 
parameter uncertainty associated with a decision to implement alternative strategies 
(89).  
 
Priority setting criteria  
There are three general criteria for priority setting in the Norwegian health care sector: 
the benefit criterion, the resource criterion, and the severity criterion (6).  
 
The benefit criterion 
The benefit criterion primarily refers to a technology’s expected health gains, i.e. in-
creased longevity and/or improved health-related quality of life. By combining these 
two dimensions of health gains into a single outcome measure, referred to as quality-
adjusted life-year (QALY), it is possible to compare outcomes across different diseases, 
patient groups and types of treatments. According to the benefit criterion, priority in-
creases with the size of the expected health benefit of the strategy (6). 
 
The resource criterion 
The resource criterion focuses on how the healthcare sector allocates its limited re-
sources. Introducing a new technology may create demands for personnel, equipment, 
facilities, etc., that could alternatively be used to provide treatments for other patients. 
This reality is referred to as the “opportunity cost” of a new technology. The larger 
quantity of resources that are allocated to a technology for one patient group, the fewer 
resources are available for treating others. In addition to resource use within the health 
care sector, a technology may also generate costs for other sectors. In Norway, the re-
source criterion is taken into account by weighing resource use (measured as monetary 
costs) against effectiveness (measured as health outcomes) in a cost-effectiveness anal-
ysis of the technology of interest. In addition, a budget impact analysis is expected from 
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the bodies making decisions about health care funding. According to the resource crite-
rion, priority increases the fewer resources that are needed for the strategy if intro-
duced (6).  
 
The severity criterion 
Severity is measured as “absolute shortfall”, defined as the expected loss of future 
health (QALYs) associated with a specified diagnosis. For treatment of a disease, sever-
ity in Norway is calculated as the average expected QALY loss for the relevant patient 
population given the current treatment option. The greater the absolute shortfall asso-
ciated with a disease, the higher costs per QALY-gained would the government be pre-
pared to pay. According to the severity criterion, priority increases with expected fu-
ture health loss resulting from the disease (6;90).  
 
The Norwegian White paper on priority setting 
The Norwegian White paper on priority setting (Meld. St. 34 (2015–2016)) indicates 
that weighting of resource use against utility should be based on the opportunity cost 
principle, and that priority should be further increased according to severity (absolute 
shortfall) (6). The Norheim commission and the Magnussen group suggested that an 
absolute shortfall of less than 2.0 QALYs should indicate diseases with the lowest level 
of severity, while an absolute shortfall above 20 QALYs would indicate diseases in the 
highest severity class. There is no official societal willingness to pay threshold for 
health interventions in Norway. However, the Norheim commission and Magnussen 
group suggested a step-wise weighting scale for societal willingness to pay for different 
severity classes, that ranges from 1 if absolute shortfall were less than two QALYs, up to 
3 if absolute shortfall were 20 or more QALYs (90;91). 
 
Literature review of previous health economic evaluations of MIGS 
A review of the literature was conducted to identify published health economic evalua-
tions on patients with glaucoma treated with MIGS that may be applicable to a Norwe-
gian setting. The review identified no study that had been conducted in a Norwegian 
setting, and there is generally limited evidence available regarding cost-effectiveness of 
MIGS for glaucoma. Most of the identified economic evaluations of glaucoma treatment 
focused on non-MIGS comparisons, such as pharmacotherapy, laser therapy, and surgi-
cal treatments, like filtration surgery (92-95). We identified some studies that consid-
ered separately either the costs or HRQoL associated with MIGS, but these did not in-
corporate the efficacy of treatments with costs together and, as such, did not assess the 
cost-effectiveness of MIGS (81;96). While HRQoL studies have some value, given com-
parable quality of the procedures between countries, the value of costs analyses from 
other countries do not reflect Norwegian costs levels.  
 
Further, the identified studies were either retrospective case studies or industry - 
sponsored RCTs with short follow-up times. The reported results were associated with 
high levels of uncertainty (5;31) 
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CADTHs health economic evaluation 
The report from the CADTH examined the cost-effectiveness of MIGS, with or without 
cataract surgery, compared with alternative strategies (i.e., pharmacotherapy, laser 
therapy, filtration surgery, cataract surgery, or filtration surgery combined with cata-
ract surgery) over a patient’s lifetime from a Canadian health care perspective. The pri-
mary outcome was ICER, i.e., incremental cost per QALYs gained in 2018 Canadian dol-
lars (CAD). Their findings suggest that there are some cases where MIGS may be cost-
effective, and in other cases, MIGS is unlikely to be economically beneficial. We have 
presented the results from CADTHs base case economic models in table 13. The incre-
mental difference in QALYs and costs were relatively small (i.e., incremental QALYs 
ranged from –0.07 to 0.039, and incremental costs ranged from CAD –3,267 (NOK -20 
484) to CAD 1,726 (NOK 10 822)), among all models, suggesting that the alternative 
procedures were not dramatically different from each other neither in terms of costs or 
benefits. Incremental costs between comparators occurred early of the time horizon in 
the model and were mostly driven by initial surgery-related costs. Except for the com-
parison of MIGS (Hydrus Microstent) combined with cataract surgery compared with 
cataract surgery alone, which was based on “high” quality evidence, the rest of the com-
parisons were informed by clinical studies with evidence of lower quality. CADTH con-
cluded that adequately powered studies using clinically important outcome measures 
with longer follow-up periods would be useful to confirm and validate the findings of 
their health economic assessment (5).  
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Table 13: CADTHs* results of the probabilistic base case cost-utility analysis (lifetime 
horizon, discounted).  
Strategy Total costs 
(CAD) 
Effects 
(QALYs) 
Incremen-
tal Costs 
(CAD) 
Incremental Ef-
fect (QALYs) 
ICER 
(CAD/QALY) 
Model 1: 
Pharmacotherapy 
2 x iStent Inject (MIGS) 
 
11,900 
12,641 
 
12.85 
12.89 
 
 
741 
 
 
0.039 
 
 
18,808 
Model 2: 
Laser therapy 
Hydrus Microstent 
(MIGS)  
 
9,013 
10,739 
 
10.36 
10.34 
 
 
1,726 
 
 
-0.023 
MIGS 
dominated 
(highest cost, 
less 
effective) 
Model 3A: 
Filtration surgery 
Trabectome (MIGS)  
 
13,375 
12,672 
 
12.49 
12.42 
 
 
-703 
 
 
-0.070 
 
 
10,093 
Model 3B: 
Filtration surgery 
ECP (MIGS)  
 
14,621 
11,354 
 
10.85 
10.83 
 
 
-3,267 
 
 
-0.027 
 
 
121,959 
Model 4: 
Cataract surgery alone 
 
Hydrus Microstent 
(MIGS)  
+ cataract surgery 
 
8,431 
 
10,072 
 
9.04 
 
9.06 
 
 
 
 
1,641 
 
 
 
0.026 
 
 
 
63,626 
 
Model 5: 
Filtration surgery  
+ cataract surgery 
 
Trabectome (MIGS)  
+ cataract surgery 
 
11,309 
 
 
10,836 
 
 
7.92 
 
 
7.89 
 
 
 
 
-473 
 
 
 
 
 
-0.032 
 
 
 
 
14,968 
ICER = incremental cost-effectiveness ratio; MIGS = minimally invasive glaucoma surgery; ECP = Endoscopic Cyclophotcoag-
ulation; QALYs = quality adjusted life-years; $ = Canadian dollars. *Reference: CADTH (5). 
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METHOD 
General 
Our overall objective was to examine the cost-effectiveness of MIGS, as stand-alone 
procedure and in combination with cataract surgery, compared with current treatment 
options, for the treatment of glaucoma. 
   
This health economic evaluation was conducted according to a protocol developed a 
priori (36). The choice of sets of interventions and comparators was based on the com-
missioning from The National System for Managed Introduction of New Health Tech-
nologies within the Specialist Health Service in Norway, and refined in cooperation 
with a panel of Norwegian clinical experts and patient partners (3;28;37). We based 
our health economic analysis on a previous HTA carried out by CADTH, which corre-
sponded well to the views reflected by our Norwegian clinical experts and patient part-
ners. Our analytical approach is therefore based on an adaptation of the decision ana-
lytical model underlying their HTA, and on considerations of data identified in the clini-
cal review documented previously in this report (5;28;37). 
 
We developed six different decision analytic cost-effectiveness models in TreeAge Pro 
® 2020, to estimate ICER, which is appropriate in the context of a Norwegian health 
care priority setting. The approach is also able to capture benefits related to morbidity 
consequence related to the progression of glaucoma on visual field. The clinical condi-
tion and its potential treatments have no mortality effects. The models provide insight 
into costs, health effects, survival, and disease stage. Relevant costs were expressed in 
2019 Norwegian kroner (NOK), and unit costs collected from previous years were ad-
justed in accordance with the consumer price index (98). In accordance with the Gov-
ernment White Paper about priority setting, (Meld. St. 34 (2015-2016)) the analysis 
was carried out from a modified Norwegian health care perspective (direct medical 
costs plus travel costs for patients) and both costs and effects were discounted using an 
annual discount rate of 4% (6;99).  The health care perspective is relevant for prioriti-
sation of interventions within a fixed budget (no expansion of the budget is assumed). 
As glaucoma and its treatment have long-term consequences, the analysis is carried out 
using a lifetime horizon. 
 
Following the recommendations from the Norwegian White paper on priority setting 
and the severity criterion, we have estimated absolute shortfall for patients with glau-
coma (6). The cost-effectiveness can be considered for each of the six models for the 
complete range of willingness to pay (WTP) threshold suggested by the Norheim and 
Magnussen commissions, i.e., from 275 000 (reflecting severity weight = 1) up to  
825 000 NOK (severity weight = 3) per QALY (90;91). 
 
We handled uncertainties in model parameters by assigning probability distributions 
to the parameters and performing PSA, designed as a Monte Carlo simulation, with 10 
000 iterations. Results from PSAs are presented as scatter plots in a cost-effectiveness 
plane, and as CEACs. We also performed one-way sensitivity analyses for each of the six 
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models to explore potential impact of uncertainty in single parameters. For each of the 
six models, we present the results of the one-way sensitivity analyses as tornado dia-
grams. 
 
In addition, we estimated the budget impact of introducing MIGS as a routine treatment 
option in Norway for patients with glaucoma. 
 
Model structure 
We made several adaptations to the model which the HTA from CADTH was based on, 
including both adaptations of model structure and input data. The adaptations were in 
agreement with a panel of Norwegian clinical experts and representatives of Norwe-
gian patient organizations (28;37). All six models were based on a Markov model struc-
ture. Each model was designed to compare one intervention and one comparator for 
the six different treatment scenarios. 
 
As mentioned above, we chose to incorporate clinical efficacy and safety data from the 
HTA carried out by CADTH. All the included clinical comparisons and pathways mod-
elled in this previous HTA were assumed to be of value in a Norwegian context. The Ca-
nadian clinical review concluded that it was not possible to determine significant differ-
ences in effectiveness and safety between alternative MIGS devices. The clinical review 
reported 24 unique comparisons but found great clinical heterogeneity between stud-
ies. Indirect treatment comparison to determine relative effectiveness between MIGS 
devices was therefore considered inappropriate (e.g., network meta-analysis). As such, 
only pairwise comparisons were done in the economic evaluation (5).  
 
Each model incorporated four live Markov health states, in addition to an absorbing 
health state “death”. The health states are mutually exclusive, meaning that patients can 
be in only one of them at any time, and complete, meaning that they cover all possible 
health situations of the patient group. Each health state is associated with state-specific 
utility weights and costs, and costs- and utilities are aggregated depending on the time 
spent in different health states. In the base-case analysis, we followed a hypothetical 
cohort of glaucoma patients up to 100 years, and patients can move between health 
states between each annual cycle, depending on transition probabilities. The live Mar-
kov health states in the model were defined according to the Hodapp-Parrish-Anderson 
grading scale for disease stage, where visual field (VF) is measured by mean deviation 
(MD) in decibels (dB), based on a previous model by NICE (100); 
 
-  Mild stage (VF MD of 0 to -6 dB); 
-  Moderate stage (VF MD of -6.01 to -12 dB); 
-  Advanced stage (VF MD of -12.01 to -20 dB); and 
-  Severe visual impairment/blindness (VF MD of < -20 dB). 
 
This grading scale was used to trace the progression of patients between the model 
health states and allowed consideration of patients entering the model at different se-
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verities of the disease. Furthermore, as the clinical management and treatment of glau-
coma depend on the extent of glaucomatous damage, these categories allowed model-
ling of potential changes in the clinical care pathway of glaucoma over time with re-
spect to health related quality of life years and associated resource use. Glaucoma is a 
progressive disease and it is important to note that these health states are irreversible, 
meaning that the VF can only stay the same or worsen over time. Therefore, once pa-
tients progress to the next disease stage, they can not reverse to a better glaucoma 
health state. The possible transitions between the states and the model structure are 
illustrated in figure 10. Death was included as an absorbing health state, and does not 
dependent of glaucoma as a disease, only background mortality. No further costs or 
health outcomes are included in the absorbing health state, death. 
 
Initial Markov state (in this case, disease progression from start) varied between the 
six models, as well as baseline visual field and start age. All patients were propagated 
through the model based on transition probabilities estimated from epidemiological 
and clinical data.  
 
 
Figure 10: Outline of model structure with Markov health states with possible transitions, 
reproduced from CADTH (5). MIGS device used in the models: Model 1: two iStent Inject devices, 
Model 2: Hydrus Microstent, Model 3: Trabectome, Model 4: ECP, Model 5: Hydrus Microstent, 
Model 6: Trabectome. 
 
Patient populations and interventions 
The health economic findings primarily reflect patients with open-angle glaucoma. 
Baseline patient characteristics (start age, baseline visual field and baseline disease 
stage) are listed in table 13b and were identified from the Clinical Review carried out 
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by CADTH (5). Our clinical experts considered model 1, 2 and 5 to be most relevant in 
Norwegian conditions. Although, the baseline age in model 1 might be somewhat low. 
The patient populations were adults diagnosed with glaucoma (models 1 - 4) and glau-
coma + cataract combined (models 5 - 6). The starting age was calculated based on 
weighted average from included clinical studies, ranged from 64 to 72 years old. As 
described in the background chapter, the patient population with glaucoma consists of 
elderly, and the prevalence increases with age. It is estimated that more than 10% 
among people above 80 years have the disease (101). The Hodapp-Parrish-Anderson 
grading scale was used to assume the initial progression stage in each model (table 14). 
As the potential use of MIGS within the treatment pathway for glaucoma is unclear, it is 
important to define disease stage at baseline to allow modelling patients’ disease pro-
gression within each model (5).  
 
Table 13b: Baseline characteristics of patients in each model based on CADTH (5). 
Model and  
Strategies 
Population Baseline Age Baseline VF (dB) Glaucoma Stage* 
Model 1:  
2x iStent Inject 
(MIGS) vs. 
pharmacotherapy 
 
 
Glaucoma 
 
 
64 
 
Average used for 
both strategies:  
-6.65 dB 
 
 
Moderate 
Model 2: 
Hydrus 
Microstent 
(MIGS) vs. laser 
therapy 
 
 
Glaucoma 
 
 
70 
 
 
 -8.43 dB*  
 
 
 
Moderate 
Model 3: 
Trabectome 
(MIGS) vs. filtra-
tion surgery 
 
 
Glaucoma 
 
 
65 
 
Average used for 
both strategies:  
-6.45 dB 
 
 
Moderate 
Model 4: 
ECP (MIGS) vs. fil-
tration surgery 
 
Glaucoma 
 
65 
 
-13.94 dB* 
 
Advanced 
Model 5: 
Hydrus Mi-
crostent (MIGS) + 
cataract surgery 
vs. cataract sur-
gery alone  
 
 
Glaucoma + 
cataract 
 
 
 
72 
 
Average used for 
both strategies: 
-3.61 dB 
 
 
 
Mild 
Model 6: 
Trabectome 
(MIGS) + cataract 
surgery vs. filtra-
tion surgery + 
cataract surgery 
 
 
Glaucoma + 
cataract 
 
 
 
71 
 
 
-11.6 dB* 
 
 
 
 
Advanced 
CADTH = Canadian Agency for Drugs and Technologies in Health; VF = visual field; dB = decibels; 2x = two devices; MIGS = 
Minimally Invasive Glaucoma Surgery; vs = versus; ECP = Endoscopic Cyclophotcoagulation; *According to the Hodapp-Par-
ish-Anderson grading scale; *MIGS Baseline VF assumed. Reference: CADTH (5). 
 
As described in the chapter about model structure, different MIGS devices are not com-
pared with each other, only with non-MIGS procedures. It is important to note that the 
clinical evidence used in the model is based on various types of MIGS devices, and that 
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the underlying MIGS device may vary between the different models. Efficacy, safety and 
costs may vary between various MIGS devices. This is in accordance with the fact men-
tioned above that it was not possible to make indirect pairwise comparisons between 
MIGS devices, and the implicit assumption that MIGS procedures therefore are compa-
rable in terms of efficacy and safety. Detailed information about which MIGS is used in 
which model is listed in table 14, based on the individual efficacy and safety studies (5). 
We have listed interventions and comparators, used in the models, to treat patients 
with glaucoma only and patients with both glaucoma and cataract. Type of MIGS is in-
cluded without accounting for status on CE-mark. Medication use and reduction for 
managing IOP was included in both arms of the models, except from model 1 (5). 
 
Table 14: Interventions, comparators and studies in the health economic evaluation based 
in CADTH (5). 
Model Type of MIGS Supplier of MIGS Type of com-
parator 
Studies used 
in CADTH 
(5) 
Model 1:  
MIGS vs. 
pharmacotherapy 
 
2x iStent Inject 
Glaukos  
Corporation / 
Pharmerit 
 
Latanoprost + 
Timolol 
 
Fea et al. 
2014 (84) 
Model 2: 
MIGS vs. Laser 
therapy 
 
Hydrus  
Microstent 
 
 
Ivantis Inc 
Selective laser 
trabeculoplasty 
(SLT) 
 
Fea et al. 
2017 (85) 
Model 3: 
MIGS vs. filtration 
surgery 
 
Trabectome 
 
NeoMedix Inc 
Trabeculectomy 
with Mitomycin 
C (MMC)  
 
Jea et al. 2012 
(82) 
Model 4: 
 
MIGS vs. filtration 
surgery 
 
 
Endoscopic  
Cyclophotcoag-
ulation (ECP) 
 
 
 
BVI / Endo Optiks  
Glaucoma  
Drainage Device 
(Baeveldt Glau-
coma Implant 
(BGI) or Ahmed 
Glaucoma  
Implant (AGI)) 
 
Murakami et 
al. 2017 (79);  
Lima et al. 
2004 (80) 
Model 5: 
MIGS + cataract 
surgery vs. cataract 
surgery alone 
 
Hydrus  
Microstent 
 
 
Ivantis Inc 
 
Phacoemulsifica-
tion 
Pfeiffer et al. 
2015 (66); 
Samuelson et 
al. 2018 (67) 
Model 6: 
MIGS + cataract 
surgery vs.  
filtration surgery + 
cataract surgery 
 
 
Trabectome 
 
 
NeoMedix Inc 
 
Trabeculotomy + 
Phacoemulsifica-
tion 
 
Kinoshita-
Nakano et al. 
2018 (102) 
CADTH = Canadian Agency for Drugs and Technologies in Health; 2x = two devices; MIGS = Minimally Invasive Glaucoma 
Surgery; vs = versus. 
 
In the model, patients who experience worsening of the visual field (VF) from “moder-
ate” to “advanced” stage are assumed to receive subsequent lines of treatments. Specifi-
cally, when patients reached advanced-stage glaucoma (<-12dB), trabeculectomy was 
performed. The rate of moving through the health states after such secondary treat-
ments were based on reduction in IOP when receiving this secondary intervention.  
 
Model validation 
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The model structure and data inputs were presented to the clinical experts and patient 
partners to ensure that the model, its parameters, and its assumption reflect clinical 
practice in Norway as well as the available body of literature (i.e., face validity). Inter-
nal validity was assessed through a peer review process to ensure the mathematical 
calculations were performed correctly and were consistent with the model specifica-
tion. 
 
Model parameters 
Below we have described what values we have used as data inputs for our model 
parameters. 
 
Epidemiology  
Treatment effect was measured as reduction in IOP. The speed of deterioration (VF re-
duction) was based on the natural rate of glaucoma progression (dB) in untreated pa-
tients and how effectively the alternative treatments reduce IOP. We assumed that the 
relative efficacy of treatment would be similar regardless of disease stage (defined by 
VF). Differences in QALYs between strategies reflect differences in disease progression 
and side-effects between treatment strategies.  
 
Transition Probabilities 
We adopted the strategy used by CADTH to estimate the rate of glaucoma progression 
defined by visual field (VF) from change in IOP (5). Here, modelling was used to derive 
the relationship between rate of glaucoma progression (db) and change in IOP. IOP is 
easy to observe, but an indirect health measure, while dB is a direct but less observable 
health measure that expresses visual field. For natural history of disease, we assumed 
that untreated patients progressed (natural progression; NP) annually at a rate of -0.6 
dB, in accordance with the Early Manifest Glaucoma Trial (103). NP was assumed to be 
constant and applied to all patients in each treatment arm, regardless of glaucoma stage. 
In the Early Manifest Glaucoma Trial treatment with laser therapy and medication re-
sulted in an IOP reduction of 5.1 mm Hg and was associated with a reduction in the rate 
of VF progression from -0.05 dB at baseline to -0.03 dB per month. This change in IOP 
corresponded to a reduction factor of 0.6 dB for VF progression (i.e., -0.03 dB and -0.05 
dB). The standardized reduction (SR) per unit of IOP reduction was then calculated as: 
 
SR = Reduction factor (1/IOP reduction) = 0.6 dB (1/5.1 mmHg) = 0.905 dB 
 
By using this equation, the IOP reduction of alternative treatments reported from clinical 
studies was used to estimate changes in disease progression.  
 
The CADTH report provides an example where MIGS (two iStent Injects, 2nd generation) 
yielded an annual IOP reduction of 12.2 mm Hg, while pharmacotherapy (i.e., Latano-
prost + Timolol) gave an annual IOP reduction of 11.6 mm Hg (used in Model 1) (5;84). 
The annual rate of disease progression with treatment (PT) can then be calculated as: 
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Annual baseline progression in untreated patients (NP) * standardized reduction (SR) 
(annual IOP reduction)  
= - 0.6 dB * 0.905 dB 12.2mmHg = - 0.177 dB (MIGS, Two iStent Injects) 
= - 0.6 dB * 0.905 dB 11.6mmHg = - 0.188 dB (Pharmacotherapy) 
 
While the CADTH report use this information to estimate annual probabilities of transi-
tioning between health states (mild – moderate – advanced – severe/blind), we use log-
ical expressions to more directly model when patients deteriorate from one health state 
to another. For example, when the dB fall below - 6 dB the patients deteriorate from mild 
to moderate stage of glaucoma, while they further deteriorate to advanced when the es-
timated dB falls below – 12 dB. In the model, treatments slow down the process of dete-
rioration so that patients remain in the better health states for longer. 
 
We assume that there is no condition- or treatment-related mortality. However, to 
capture background mortality we used age-adjusted life tables from Statistics Norway 
(104). 
 
Clinical Efficacy 
Relative treatment efficacy in the economic model was based on the most commonly 
reported outcomes from the identified studies of the clinical review: IOP reduction. Ac-
cording to CADTH, the selection of clinical studies to be used as the base case was 
based on the following criteria: 1) when meta-analysis was available, the pooled clinical 
measure was used (model 5); 2) when a statistically significant difference (least con-
servative estimate) was observed in IOP reduction (Model 3) or 3) when 12-month 
data were reported (models 4 and 6). For Model 1, Fea et al. 2014 was selected as the 
base case with the medication strategy assumed to entail two medication (i.e., average 
costs of one and three medication therapy) (84). Only one study was available for 
Model 2 (85). Treatment effects, in terms of reduced IOP, were measured at 12 months 
rates to inform the model inputs. We assumed a 10% decline per year in the IOP reduc-
tion after the trial follow-up period for all interventions (5). For subsequent treatment 
IOP reduction was assumed constant over time, and independent of the primary inter-
vention. Note that non-adherence to drugs was not considered, and we assumed it to be 
100% in all models (table 16). 
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Table 16: Efficacy in base-case models. 
Model: compar-
ison 
IOP Reduc-
tion with 
MIGS at 12 
Months 
(p-value) 
IOP Reduc-
tion with 
comparator 
at 12 Months 
(p-value) 
Medication 
Reduction 
at 12 
Months 
Probability 
Distribu-
tion 
Reference (Type of 
study) 
Model 1:  
MIGS (2x iStent 
Inject) vs Phar-
macotherapy 
12.2 mm Hg  
(p = NR) 
11.6 mm Hg 
(p = NR) 
NA Normal Fea et al., 2014 (RCT) 
(84) 
Model 2:  
MIGS (Hydrus 
Microstent) vs 
Laser Therapy 
6.6 mm Hg 
(p = 0.57) 
7.3 mm Hg 
(p = 0.57) 
1.4 vs 0.5 
(p<0.01) 
Normal Fea et al., 2017 (pros-
pective corhort) (85) 
Model 3A: 
MIGS (Tra-
bectome) vs Fil-
tration surgery 
 
10.7 mm Hg 
(p < 0.01) 
14.1 mm Hg 
(p < 0.01) 
1.5 vs. 2.7 
(p=NR) 
6months: 
0.28 vs 1.82 
 
Normal Jea et al., 2012 (retros-
pective cohort) (82); 
Pahlitzsch et al., 2017 
(prospective corhort) 
(105) 
Model 3B: 
MIGS (ECP) vs 
Filtration sur-
gery 
 7.8 mm Hg 
(p < NR) 
9.3 mm Hg 
(p < NR) 
1.6 vs 1.5 
(p=0.74) 
 
24months: 
1 vs 1 
(p=NR) 
Normal 
Murakami et al., 2017 
(retrospective cohort) 
(79); Lima et al., 2004 
(non-randomized con-
trolled trial) (80) 
Model 4: 
MIGS (Hydrus 
Microstent) + 
cataract sur-
gery vs. cataract 
surgery alone 9.1 mm Hg 
7.75 mm Hg Meta-analy-
sis 
Normal 
Pfeiffer et al., 2015 
(RCT) (66); Samuel-
son et al., 2018 (RCT) 
(67) 
Model 5: 
MIGS (Trabec-
tome) + cata-
ract surgery vs. 
filtration sur-
gery + cataract 
surgery 
5.4 mm Hg 
(p = 0.53) 
7.7 mm Hg 
(p = 0.53) 
1.0 vs 1.6 
(p=0.027) 
 
1.3 vs 0.65 
(p=0.41) 
Normal 
Kinoshita-Nakano et 
al., 2018 (retrospec-
tive cohort) (102); 
Ting et al., 2018 (RCT) 
(76) 
ECP = Endoscopic Cyclophotcoagulation; 2x = two devices; IOP = Intraocular Pressure; MIGS = Minimally Invasive Glaucoma 
Surgery; NR = Not reported; NA = Not applicable; RCT = Randomized Controlled Trial; vs = versus. 
 
  
 79  Health economic evaluation 
Health-related Quality of Life 
CADTH reported quality of life outcomes measured with the preference-based instru-
ment, EQ-5D, considered appropriate for cost-utility analyses (5). The utility values 
were taken from a Dutch study with 531 patients with ocular hypertension or POAG 
(106). In order to ensure that we had the best available utility data compatible with 
Norwegian guidelines, we searched for published articles with HRQoL values. We found 
one British study which was also based on EQ-5D (107). The British utility data did not 
deviate much from the Dutch utility data reported by CADTH. Therefore, we considered 
it reasonable to use the utilities presented in CADTH. For patients with glaucoma, util-
ity values were derived from the discrete event simulation model developed by Van 
Gestel et al. (106): 
 
Health Related Quality of Life weight = 0.88 – 0.101 * pharmacotherapy + 0.011 * VF – 
0.065 * Cataract 
 
For each health state defined by a range of VF, we used the midpoint VF in this calcula-
tion (mild: - 3 dB, moderate: - 9 dB, advanced: - 16 dB, and severe/blind: - 26 dB). For 
patients with cataract in addition to glaucoma, we subtracted a constant of  - 0.065 
from the utility values in patients with glaucoma only (5) (table 17). 
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Table 17: State utilities in the health economic model based on EQ-5D* Utilities associ-
ated with health states, side effects and surgery. 
Variable 
Descrip-
tion/state of 
health 
 
Health related quality of life weight 
Source/ comment 
Patients with glaucoma only 
Mild stage 0.847  Van Gestel 2012* (106) 
Moderate stage 0.781  CADTH 2019 (5) 
Advanced stage 0.704   
Severe/blindness 
Death 
0.594 
0.000 
 
 
Patients with glaucoma and cataract 
Mild stage 
0.782   
Van Gestel 2012* (106) 
Moderate stage 0.716  CADTH 2019 (5) 
Advanced stage 0.639   
Severe/blindness 
Death 
0.529 
0.000 
 
 
Disutilities (per event) 
Filtration or ma-
jor complica-
tions requiring 
surgeries 
 
 
0.008 
 
 Van Gestel 2012* (106) 
CADTH 2019 (5) 
Minor complica-
tions 
0.000  
 
*The state utilities presented in this table are derived from EQ-5D utilities in Van Gestel 2012 (106) and reported by CADTH 
(5). 
 
We used safety data from CADTHs HTA. As mentioned, we pooled possible complica-
tions into three categories: minor complications, major complications and secondary 
surgery complications based on incidence probabilities in Table 18. All the possible 
complications would appear in the “acute phase” after treatment, and were assumed to 
be one-time events at the time of the surgical procedure. We applied a disutility of -
0.008 to filtration and major complications requiring secondary surgery, while we as-
sumed the disutility associated with minor complications to be negligible. 
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Table 18: Incidence probabilities for adverse events in the base-case model  
 
Intervention 
No compli-
cations 
Minor com-
plications 
Major com-
plications 
Secondary 
Surgical In-
terven-
tions 
Reference 
Model 1 
iStent Inject 
(MIGS)* 
# 22% 0% NA Vold et al. 2016 (65) 
Pharmacotherapy # 17% 0% NA 
Model 2 
Hydrus Microstent 
(MIGS) # 16% 
 
10% 
 
NA 
Fea et al. 2017 (85)  Laser therapy # 40% 0% NA 
Model 3 
Trabectome 
(MIGS) # 4% 
 
0% 
NA 
Jea et al. 2012 (82) Filtration Surgery # 36% 13% NA 
Model 4 
ECP (MIGS) # 32% 12% NA 
Lima et al. 2004 (80) 
 
Filtration Surgery # 76% 
26% NA 
Model 5 
Hydrus Microstent 
(MIGS) + cataract 
surgery # 18% - 35 % 
 
        19% 
 
2% Pfeiffer et al. 2015, 
Samuelson et al. 
2018 (66;67) Cataract sugery # 18% 2% 5% 
Model 6 
Trabectome 
(MIGS) # 100% 
NA 0% 
Ting et al. 2018, 
Marco et al. 2017 
(76;78) 
Filtration surgery + 
cataract surgery # 99% 
44% 7% 
ECP = Endoscopic Cyclophotocoagulation; MIGS = Minimally Invasive Glaucoma Surgery; NA = not applicable; # = we have 
assumed that the proportion that was not reported with any complications had no complications in the model; HRQoL = 
Health Related Quality of Life. *Assumed rate of complications for iStent Inject would be similar to iStent (5). 
 
Costs 
For costing, we apply the perspective of the public health services. We captured all 
medical costs associated with the alternative treatments, including device or drug 
costs, procedure costs, complication and rehabilitation costs, as well as the cost of stay-
ing in a specific health state (ophthalmologists visits/consultations, and tests) (Table 
19). All costs are reported as 2021 Norwegian Kroner (NOK), and cost information 
originated from other years were inflated to 2021 costs using the Consumer Price In-
dex for all items in Norway (98). 
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Cost of procedures 
We obtained information about procedure costs associated with treatment of glaucoma 
and cataract from the Norwegian Directorate of Health, Norwegian diagnosis related 
groups (DRGs) prices from 2021 (108). The estimates were based on average costs per 
patient for the entire hospital stay including surgery, medicines, materials, stay at the 
intensive care-unit and regular ward. The cost did not include the value added tax 
(109). In general, a DRG payment covers all charges associated with an inpatient stay 
from the time of admission to discharge. Based on DRG information, we estimated a 
unit cost per-patient for the different treatments. We calculated this by multiplying the 
weight associated with each DRG with NOK 46 719, which is the 2021 unit price per 
DRG (108).  
 
For MIGS we added the cost of the devices in addition to the cost of the procedure. As 
there is no DRG available for MIGS yet, often the case for new interventions, we utilized 
the DRG of cataract surgery (phacoemulisification). More specifically, we assumed that 
the DRG for MIGS is equal to half the DRG for cataract surgery, based on estimates of 
time required to perform the MIGS procedure relative to the time required to perform 
cataract surgery. According to CADTH a MIGS procedure lasts for about 10 minutes 
(range from 4 – 18 minutes), while a cataract procedure lasts for about 20 minutes, 
which subsequently affects also personal costs (5). Personal costs are often a great part 
of procedure costs and therefore DRG costs. For comparators, we assumed that devices 
used in the procedure was included in the DRG cost (108). Therefore, it may be double 
counting for MIGS intervention if we add the whole DRG cost, as we already accounted 
for device cost here.  
 
Norwegian clinical experts and representatives from the relevant companies provided 
cost-information about the MIGS-devices that are currently used in Norwegian hospi-
tals. As far as we know there are no national tender or agreements on MIGS device 
prices today, and there are therefore some differences in devices and prices between 
hospitals and regional health authorities (RHAs) (28).  
  
According to the panel of experts the main difference in costs between MIGS devices 
and the comparators would be the implant itself. Further, start-up or investment cost 
associated with MIGS treatment are generally minimal or are covered by manufactures 
(i.e., possible costs of training staff performing MIGS treatment). We assumed start-up 
costs to be negligible and did not account for this (28).  
 
For pharmacotherapy (medication) costs in model 1, no DRGs were included as pa-
tients do not need to receive this treatment option at the hospital. We obtained prices 
on pharmacotherapy from the Norwegian prescription database (18). Patients’ were 
assumed to be on two medications at baseline until secondary treatment occurred (49). 
We calculated per-bottle cost of each medication, and a wastage adjustment factor was 
added to the cost: 
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1 medication = NOK 1 860 per year 
2 medication = NOK 3 719 per year 
3 medication = NOK 5 579 per year 
 
Annual cost for medication was used as unit cost to calculate cost of relative medication 
reduction for model two to six. We based relative medication reduction on numbers re-
ported in CADTH (5). The difference in medication use after 12-month follow-up was 
assumed to decline 10% per year. For example, in model 2, where the relative medica-
tion reduction at 12 months for Hydrus Microstent versus laser therapy was reported 
to be 1.4 versus 0.5 (i.e., 0.9 less for laser therapy), an incremental medication cost of 
0.9 units was added to the laser therapy group (85). 
 
Table 19: Device, drug, and procedure (DRGs) costs used in the analyses (gamma distri-
bution used for PSA). 
Strategy  Device / drug   
cost (NOK) 
DRG cost 
(NOK) 
DRG code and 
weight 
Reference 
Model 1 
 
MIGS (2x iStent 
Inject)  
 
 
---- 
 
7 195 
 
DRG 42O 
(50%),  
weight 0.308 
Expert opinion & The 
Norwegian Direc-
torate of Health 
(28;108) 
 
Pharmaco- 
therapy  
 
 
3 719 
 
 
NA 
 
 
NA 
The Norwegian pre-
scription database &  
The Norwegian Direc-
torate of Health 
(18;108) 
Model 2 
MIGS (Hydrus 
Microstent)  
---- 7 195 DRG 42O 
(50%), 
weight 0.308 
Assumption & The 
Norwegian Direc-
torate of Health (108) 
Laser therapy  NA 1 682 DRG 36R, 
weight 0.036 
The Norwegian Direc-
torate of Health (108) 
Model 3 
MIGS  
(Trabectome)  
 
---- 
 
7 195 
DRG 42O 
(50%),  
weight 0.308 
Assumption & The 
Norwegian Direc-
torate of Health (108) 
Filtration  
Surgery 
NA 16 912 DRG36S, 
weight 0.362 
The Norwegian Direc-
torate of Health (108) 
Model 4 
 
MIGS (ECP)  
 
---- 
 
7 195 
DRG 42O 
(50%),  
weight 0.308 
Assumption & The 
Norwegian Direc-
torate of Health (108) 
Filtration  
Surgery 
NA 16 912 DRG 36S, 
weight 0.362 
The Norwegian Direc-
torate of Health (108) 
Model 5 
 
MIGS (Hydrus 
Microstent) + 
cataract surgery 
 
---- 
 
7 195 +  
14 389 
DRG 42O 
(50%),  
 
Assumption & The 
Norwegian Direc-
torate of Health (108) 
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the same x 1,25. **MIGS devices we did not retrieve any prices on, we used  ----NOK  :----NOK  Assumed same as 2x iStent:*
cost associated with 2x iStent;. MIGS = Minimally Invasive Glaucoma Surgery; ECP = 
Endoscopic Cyclophotocoagulation; NA = not applicable; NOK = Norwegian kroner; DRG = Diagnose Related Groups; 
2x = two devices.  
 
Cost of complications 
The costs of treating complications were based on prevalence rates of adverse events, 
reported in the clinical studies used by CADTH (table 20) (5). In terms of complications, 
it was assumed that complications relating to surgery would be a one-time event that 
happened at the time of the original procedure. Thus, complications from treatment 
were included in the model as a one-time cost. 
 
We divided complications into three categories, minor complication, major complication 
and secondary surgical intervention, and allocated cost on weighted averages according 
to frequencies of occurence. In addition, we accounted for no complication in the model. 
 
We assumed that a patient with a complication requires some additional resource use. 
 
Patients with minor and major complication would require two additional ophthalmol-
ogist consultations, but 10% of those with major complications would in addition require 
minor eye interventions. Also, patients undergoing secondary surgical interventions 
were assumed to require two additional ophthalmologist consultations after minor eye 
intervention. A minor eye intervention was assumed to be trabeculectomy surgery and 
therefore the same cost.  
 
  
 weight 0.308 + 
DRG 42O, 
weight 0.308 
Cataract surgery NA 14 389 DRG 42O, 
weight 0.308 
The Norwegian Direc-
torate of Health (108) 
Model 6 
 
MIGS  
(Trabectome) + 
cataract surgery  
 
---- 
 
7 195 +  
14 389 
DRG 42O 
(50%),  
weight 0.308 + 
DRG 42O, 
weight 0.308 
 
Assumption & The 
Norwegian Direc-
torate of Health (108) 
 
Filtration  
surgery +  
cataract surgery 
 
NA 
 
8 456 + 
7 195   
 
Average of DRG 
36S, weight 
0.362, and DRG 
42O, weight 
0.308 
 
The Norwegian Direc-
torate of Health (108) 
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Table 20: Annual Cost of complications used in the analysis (Gamma distribution). 
NOK = Norwegian kroner; DRG = Diagnosis related groups. 
 
Cost health states 
Health state costs and associated resource utilization in Norway was determined by 
quantity of ophthalmologist consultations and set of tests including vision field defect 
test, optic disc imaging, and IOP measurement required in a specific health state. Oph-
thalmologists consultations are recommended at least every four to 12 months, depend-
ing on the stage of glaucoma (table 21). We used European guidelines, Norwegian 
sources, and consulted our clinical experts for this (12;28;108;110). We used the follow-
ing unit costs for consultations and test (the unit costs were found in the unit cost data-
base published by the Norwegian Medicines Agency (12;28;108;110)): 
 
Consultation = NOK 725 
VF defect test = NOK 179 
Optic disc imaging = NOK 179 
 
We considered transport cost to be the same in all of the different strategies, and there-
fore it would most likely not affect the results.  
 
  
Complication  Unit cost in 
NOK 
Description Reference 
No complication 0 No cost CADTH (5) 
Minor complication 2 336 2 consultations 
(follow-up visits) 
Cost based on 2x  
DRG 902O 
CADTH (5), assumption 
& The Norwegian Di-
rectorate of Health 
(108) 
Major complication 4 027 All major complica-
tions lead to 2 con-
sultations (follow-up 
visits, 2x DRG 902O), 
and 10% would re-
quire surgical inter-
vention 
CADTH (5), assumption 
& The Norwegian Di-
rectorate of Health 
(108) 
Secondary Surgical in-
tervention 
16 912 Cost based on DRG 
36S (same as tra-
beculectomy) 
CADTH (5) & The Nor-
wegian Directorate of 
Health (108) 
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Table 21: Annual Health State Cost estimates used in the analyses (Gamma distribution) 
VF = visual field; NOK = Norwegian kroner. 
 
Probabilistic sensitivity analysis 
The reference case reflects the probabilistic results based on 10 000 Monte Carlo simu-
lations. The probabilistic results characterize the extent to which uncertainty in many 
parameter values combined affects the cost-effectiveness estimates in the model. 
Standard distributional forms were taken to describe the probability distribution func-
tions relating to input parameters: relative efficacy (relative IOP reduction and relative 
medication reduction) were characterized by normal distributions, utility and compli-
cation rates were characterized by beta distribution, and costs were characterized by 
gamma distributions. The inference information for each distribution were based on 
the reference case or meta-analysis (5). Cost-effectiveness acceptability curves demon-
strating the probability that a modality would be considered optimal for a range of 
WTP threshold were also presented.  
 
The uncertainty surrounding cost parameters were assessed by using gamma distribu-
tion in the health economic model. Beta distributions were used for utility values. 
 
Health state Unit cost in NOK Description Reference 
 
Mild Health State 
 
1 949 
2 consultations, 
1.4 VF test, 
1.4 optic disc imaging 
Expert opinion 
(28) & unit cost 
database pub-
lished by the 
Norwegien Medi-
cines Agency 
(110) 
 
Moderate Health 
State 
 
2 709 
3 consultations, 
1.5 VF test, 
1.5 optic disc imaging 
Expert opinion 
(28) & unit cost 
database pub-
lished by the 
Norwegien Medi-
cines Agency 
(110) 
 
Advanced Health 
State 
 
2 780 
3 consultations, 
1.7 VF test, 
1.7 optic disc imaging 
Expert opinion 
(28) & unit cost 
database pub-
lished by the 
Norwegien Medi-
cines Agency 
(110) 
 
Severe/Blind Health 
State 
 
1 189 
1 consultations, 
1.3 VF test, 
1.3 optic disc imaging 
Expert opinion 
(28) & unit cost 
database pub-
lished by the 
Norwegien Medi-
cines Agency 
(110) 
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Sensitivity analyses 
In addition to performing probabilistic sensitivity analysis, we carried out a series of 
one-way sensitivity analyses in order to investigate how uncertainty around single 
parameters could affect our cost-effectiveness results. We present results of this 
analysis as a tornado diagram in the results chapter.  
 
Confidence ranges (value interval) for sensitivity analyses were calculated as base 
case value +/- 25%, while the standard errors for estimation of gamma distributions 
were based on the formula: (Value interval/2) * 1,96. 
 
Budget impact analysis 
Budget impact analysis can be defined as an assessment of the financial consequences 
of adopting a new intervention at a population level. In other words, budget impact is 
the total incremental cost (additional costs) of introduction of an intervention versus 
non-introduction (i.e., the total expenditure of inserting the new method minus the to-
tal costs of not doing so) (109).  
 
The allocation of number of patients receiving different treatment options related to in-
troduction of MIGS in Norway are unknown, and we have therefore not estimated the 
total budget impact for the specialist health services of the intervention in a national 
perspective. Further, due to these uncertainties we have not extracted total costs calcu-
lated by the Markov model. However, we have made a simplified calculation of MIGS 
device cost and procedure cost only (both as a stand-alone procedure and in combina-
tion with cataract surgery). We did not include cost inputs as health state costs and cost 
of treating procedure-related complications that we used in the cost-effectiveness 
model. We have not calculated total cost of treatment comparators. We used undis-
counted costs, in line with recommendations from the International Society for Phar-
macoeconomics and Outcomes Research (ISPOR) for budget impact analyses, and five 
years time horizon (111). 
 
To NIPH’s knowledge, in 2018, there were about 200 MIGS procedures performed in 
Norway. Based on expert opinions we have assumed that there are 255 patients that 
will receive MIGS in Norway in 2019, 50% as stand-alone procedure and 50% in combi-
nation with cataract surgery. According to our clinical experts, there will be a doubling 
of the current number MIGS procedures five years ahead by implementing MIGS as a 
public funded treatment in Norway (28). By taking our clinical experts opinions into 
consideration, we conservatively assume that this growth will be a doubling in five 
years by introducing MIGS to Norwegian hospitals. Based on the above assumptions we 
calculated the numbers of patients eligible for MIGS as prognosis for the next four 
years. 
 
Tables 22 and 23 shows unit cost input used in our calculations. We have used average 
cost of MIGS devices used in our models. For treating glaucoma costs for iStent inject 
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x2, Hydrus Microstent, Trabectome, and ECP are included. Our estimates for MIGS com-
bined with cataract surgery includes costs for Hydrus Microstent and Trabectome. 
 
Table 22: Input data to budget impact analysis for MIGS procedures (no cataract) 
MIGS device Unit cost device* 
(NOK)  
DRG cost MIGS 
(NOK) 
Unit cost device 
+ DRG cost 
(NOK) 
Reference 
iStent Inject 
(x2) 
----  7 195 ---- Expert opinion 
(28) and as-
sumption 
Hydrus 
microstent 
----  7 195 ---- Expert opinion 
(28) and as-
sumption 
Trabectome ----  7 195 ---- Expert opinion 
(28) and as-
sumption 
ECP ----  7 195 ---- Expert opinion 
(28) and as-
sumption 
Average cost ----  7 195  ---- Expert opinion 
(28) and as-
sumption 
*Unit cost device is included WAT (25%). x2 = 2 devices; NOK = Norwegian kroner. 
 
 
 
Table 23: Input data to budget impact analysis for MIGS with cataract procedures 
MIGS device Unit cost 
device  
(NOK) 
DRG cost MIGS 
(NOK) 
DRG cost 
cataract 
surgery 
(NOK) 
Unit cost de-
vice + DRG 
cost MIGS + 
DRG cost cata-
ract surgery 
(NOK) 
Reference 
Hydrus 
microstent 
---- 7 195 14 389 ---- Expert opinion 
(28) and as-
sumption 
Trabectome ---- 7 195 14 389 ---- Expert opinion 
(28) and as-
sumption 
Average cost ---- 7 195 14 389 ---- Expert opinion 
(28) and as-
sumption  
NOK = Norwegian kroner. 
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Severity considerations – absolute shortfall (AS) 
We calculated absolute shortfall (AS) based on projections about life expectancies from 
the health economic model. Calculation of AS has been described in more detail in the 
submission guideline for pharmaceutical reimbursements of the Norwegian Medicines 
Agency, which is based on the white paper on priority setting, and a Norwegian life ta-
ble and age adjusted health related quality of life information from a general Swedish 
population (6;104;109;112). Absolute shortfall is defined as the difference in quality 
adjusted life expectancies at age (A) without the disease (QALYsA), and prognosis with 
the disease with current standard of care (PA):  
 
AS = QALYsA – PA  
 
In the calculations, undiscounted numbers for QALYsA and PA are used.  
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RESULTS 
Severity considerations – absolute shortfall 
In accordance with the economic models, we have listed patients age when entering the 
model in table 24. Further, the table describes the expected quality adjusted life expec-
tancy at this age, and what the prognosis with disease is expected to be in QALYs for 
standard treatment, based on simulations from the health economic model with life-
time (up to 100 years) horizon. The absolute shortfall in each model with these as-
sumptions is: 
 
Table 24:  Absolute shortfall in each sub-model 
Model Age QALYs at age with-
outh disease (QAL-
YsA) 
Prognosis with 
disease (PA) 
Absolute shortfall 
(AS)* 
Model 1 64 17.0 16.7 0.3 
Model 2 70 12.9 12.6 0.3 
Model 3 65 16.3 16.1 0.2 
Model 4 65 16.3 14.1 2.2 
Model 5 72 11.6 11.4 0.2 
Model 6 71 12.3 10.4 1.9 
QALY: quality-adjusted life year; *AS = QALYs at age withouth the disease – Prognosis with the disease. 
 
This puts patients with glaucoma in the least severe of the six severity classes sug-
gested by the Magnussen group, irrespective of model. These classes range from: AS < 4 
QALYs lost (severity class 1), 4-7,9; 8-11,9; 12- 15,9; 16-19,9, and AS ≥ 20 QALYs (se-
verity class 6) (90). Accordingly, severity is not an argument for giving extra priority to 
glaucoma patients. 
 
Incremental cost–effectiveness estimates in the analysis 
The baseline cost-effectiveness results of all models are based on the probabilistic anal-
yses and presented in table 25; demonstrating lifetime expected costs and QALYs, in-
cremental costs and QALYs, as well as the ICER. Each model considered a different set 
of comparators, and therefore represent different patient populations. It is therefore 
inappropriate to calculate incremental values across the different models, but still 
highly relevant to compare the ICERs if a stepwise scale up of the procedure to different 
population group is considered. The lifetime total cost per patient for glaucoma treat-
ment ranged between NOK 52 000 and NOK 84 000 depending on the treatment strat-
egy and patient’s baseline disease stage. For all models, strategies involving MIGS were 
between 3 and 21 thousand more costly over the lifetime. The absolute effects (dis-
counted quality adjusted life expectancies) varied between 14 and 17 QALYs in the 
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models, with average age when receiving treatment as the most important factor. In-
cremental QALYs between MIGS and comparators ranged between -0.080 and 0.052. 
The detailed results are subsequently presented.  
 
Table 25: Results of the base-case cost-effectiveness analyses (lifetime horizon, dis-
counted). 
Intervention Total costs 
(NOK) 
Effects  
(QALYs) 
Incremental 
Costs (NOK) 
Incremental 
Effect (QALYs) 
ICER 
(NOK/QALY) 
Model 1: 
 
Pharma-
cotherapy 
 
2 x iStent In-
ject (MIGS) 
 
 
64 269 
 
 
---- 
 
 
16.695 
 
 
16.711 
 
 
 
 
 
---- 
 
 
 
 
 
0.016 
 
 
 
 
 
--- 
Model 2: 
 
Laser therapy 
 
Hydrus Mi-
crostent 
(MIGS)  
 
 
29 799 
 
 
---- 
 
 
12.648 
 
 
12. 567 
 
 
 
 
 
---- 
 
 
 
 
 
-0.080 
 
 
 
 
 
 
Dominated 
Model 3: 
 
Filtration 
surgery 
 
Trabectome 
(MIGS)  
 
 
75 834 
 
---- 
 
 
16.043 
 
16.068 
 
 
 
 
---- 
 
 
 
 
0.024 
 
 
 
 
--- 
Model 4: 
 
Filtration 
surgery 
 
ECP (MIGS)  
 
 
72 253 
 
---- 
 
 
14.108  
 
14.141 
 
 
 
 
---- 
 
 
 
 
 
0.033 
 
 
 
 
--- 
Model 5: 
 
Cataract sur-
gery 
 
Hydrus Mi-
crostent 
(MIGS) + cat-
aract surgery 
 
 
51 568 
 
 
---- 
 
 
11.399 
 
 
11.438 
 
 
 
 
 
---- 
 
 
 
 
 
0.038 
 
 
 
 
 
--- 
Model 6: 
 
Filtration 
surgery + cat-
aract surgery 
 
Trabectome 
(MIGS) + cat-
aract surgery 
 
 
62 722 
 
 
 
---- 
 
 
10.483 
 
 
 
10.540 
 
 
 
 
 
 
---- 
 
 
 
 
 
 
0.057 
 
 
 
 
 
 
--- 
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Incremental cost-effectiveness estimates in model 1 
As the clinical review only found clinical studies comparing iStent Inject (2nd genera-
tion) to pharmacotherapy, the findings below specifically address the cost-effectiveness 
of iStent compared with pharmacotherapy. The potential cost-effectiveness of other 
MIGS devices to a pharmacotherapy strategy remains unclear and could not be ex-
plored in this economic evaluation. 
 
The results of the probabilistic sensitivity analysis with a lifetime horizon are illus-
trated in figure 11. The blue dots in the scatterplot represent results for patients fol-
lowing MIGS (iStent Inject) and the red ones represent pharmacological treatment. The 
blue “cloud” is, on average, situated to the right and higher than the red “cloud”, indi-
cating that MIGS is likely to be more costly, and a bit more effective than pharmacologi-
cal treatment for patients at a moderate glaucoma stage. The truncated right side of the 
scatter plot expresses the maximum achievable benefit in the model.  
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Figure 11: Cost-effectiveness scatterplot for model 1. 
 
The expected results of the Monte Carlo simulation in base-case analysis are presented 
in Table 25, and show that the total expected intervention-related costs per patient (in 
moderate glaucoma stage) in a lifetime horizon are about 64 0000 NOK for patients 
who are treated with pharmacotherapy and ---- NOK for patients who undergo MIGS (2 
x iStent Inject). These costs include procedures, complication, rehabilitation and health 
state costs. The incremental cost for MIGS patients is thus about ---- NOK. During a life-
time perspective MIGS patients accumulate slightly more QALYs, with a different of 
0.016 QALYs. The modest difference in health effect is the main driver of the result that 
MIGS costs ---- per QALY (ICER).  
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The cost-effectiveness acceptability curves in figure 12 demonstrate that pharma-
cotherapy has a higher probability of being cost-effective than MIGS for the entire 
range of willingness-to-pay (WTP) thresholds. suggested by the Norheim commission 
and Magnussen group (90;91). When simultaneously taking into account all parameter 
uncertainties, the probability of MIGS being cost-effective does not exceed about 1/3. 
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Figure 12: Cost-effectiveness acceptability curves indicating the probability that either 
intervention is cost-effective for a WTP range from zero to 1 000 000 NOK per QALY. 
 
Incremental cost-effectiveness estimates in model 2 
The systematic review only identified clinical studies that compared Hydrus Microstent 
to laser therapy, and thus these are the alternatives compared. The potential cost-effec-
tiveness of other MIGS devices to a laser therapy strategy remains unclear. 
 
The results of the probabilistic sensitivity analysis with a lifetime horizon are illus-
trated in figure 13. The blue dots in the scatterplot represent results for patients that 
received laser therapy and the red ones MIGS (Hydrus Microstent). The red “cloud” is, 
on average, situated less to the right than the blue “cloud” and above the blue “cloud”, 
indicating that MIGS is likely to be more costly, and less effective than laser therapy for 
patients at a mild glaucoma stage. The truncated right side of the scatter plot expresses 
the maximum achievable benefit in the model. 
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Figure 13: Cost-effectiveness scatterplot for model 2. 
 
The expected results of the Monte Carlo simulation in base-case analysis are presented 
in Table 25, and show that the total expected intervention-related costs per patient (in 
moderate glaucoma stage) in a lifetime horizon are about 30 000 NOK for patients who 
are treated with laser therapy and ---- NOK for patients who undergo MIGS (Hydrus Mi-
crostent). These costs include procedures, complication, rehabilitation, and health state 
costs. The incremental cost for MIGS patients is thus about ---- NOK. During a lifetime 
perspective MIGS patients accumulate less health, with a difference of – 0.080 QALYs. 
Consequently, MIGS is dominated by laser therapy for this patient population. 
 
The cost-effectiveness acceptability curves (figure 14) show that MIGS’s propability of 
being the cost-effective alternative will not exceed about 1/3 irrespective of willingness 
to pay for health. 
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Figure 14: Cost-effectiveness acceptability curves indicating the probability that either 
intervention is cost-effective for a WTP range from zero to 1 000 000 NOK per QALY. 
 
Incremental cost-effectiveness estimates in model 3 
As the clinical review only found clinical studies that have compared Trabectome to fil-
tration surgery, the findings below specifically address the cost-effectiveness of Tra-
bectome compated with filtration surgery. The potential cost-effectiveness of other 
MIGS devices to a laser therapy strategy remains unclear and could not be explored in 
this Economic Evaluation. 
 
The results of the probabilistic sensitivity analysis with a lifetime horizon are illus-
trated in figure 15. The blue dots in the scatterplot represent results for patients that 
received filtration surgery and the red ones MIGS (Trabectome). The red “cloud” is, on 
average, situated more to the right than the blue “cloud” and above the blue “cloud”, in-
dicating that MIGS is likely to be more costly, and slightly more effective than filtration 
surgery for patients at a moderate glaucoma stage. The truncated right side of the scat-
ter plot expresses the maximum achievable benefit in the model. 
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Figure 15: Cost-effectiveness scatterplot for model 3. 
ICER 
The expected results of the Monte Carlo simulation in base-case analysis are presented 
in Table 25, and show that the total expected intervention-related costs per patient (in 
moderate glaucoma stage) in a lifetime horizon are about 76 000 NOK for patients who 
are treated with filtration surgery and about ---- NOK for patients who undergo MIGS 
(Trombectome). These costs include procedures, complication, rehabilitation and 
health state costs. The incremental cost for MIGS patients is thus about ---- NOK. Over a 
lifetime perspective MIGS patients accumulate slightly more QALYs, with a different of 
0.024 QALYs. ICER is estimated to be about ---- NOK. 
 
Below, we present cost-effectiveness acceptability curves at willingness-to-pay (WTP) 
thresholds for one additional QALY between zero and 1 000 000 NOK (figure 16). The 
figure demonstrates that filtration surgery has a higher probability of being cost-effec-
tive up to a WTP threshold of about 282 000 NOK.  The observed non-linearities are ar-
tefacts of the assumed average baseline visual field (Table 14), the assumed IOP reduc-
tions with both treatments (Table 16) and subsequent duration before transitioning a 
milder to a more severe glaucoma stage (Figure 10). 
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Figure 16: Cost-effectiveness acceptability curves indicating the probability that either 
intervention is cost-effective for a WTP range from zero to 1 000 000 NOK  
per QALY.   
 
Incremental cost-effectiveness estimates in model 4 
As the clinical review only found clinical studies comparing ECP to filtration surgery, 
the findings below specifically address the cost-effectiveness of ECP compated with fil-
tration surgery. The potential cost-effectiveness of other MIGS devices to a laser ther-
apy strategy remains unclear and could not be explored in this economic evaluation. 
 
The results of the probabilistic sensitivity analysis with a lifetime horizon are illus-
trated in figure 17. The blue dots in the scatterplot represent results for patients that 
received filtration surgery and the red ones MIGS (ECP). The colored dots are mixed, 
which indicates that it is not obvious which strategy that is more cost effective. The 
truncated right side of the scatter plot expresses the maximum achievable benefit in 
the model. 
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Figure 17: Cost-effectiveness scatterplot for model 4. 
ICER 
 
The expected results of the Monte Carlo simulation in base-case analysis are presented 
in Table 25, and show that the total expected intervention-related costs per patient (in 
advanced glaucoma stage) in a lifetime horizon are about 72 000 NOK for patients who 
are treated with filtration surgery and about ---- NOK for patients who undergo MIGS 
(ECP). These costs include procedures, complication, rehabilitation, and health state 
costs. The incremental cost for MIGS patients is thus about ---- NOK. During a lifetime 
perspective MIGS patients accumulate more QALYs, with a different of 0.033 QALYs. 
MIGS costs about ---- NOK per QALY (ICER). 
 
Below, we present cost-effectiveness acceptability curves at willingness-to-pay (WTP) 
thresholds for one additional QALY between zero and 1 000 000 NOK (figure 18). The 
figure demonstrates that filtration surgery has a higher probability of being cost-effec-
tive than MIGS up to a WTP threshold of about 94 000 NOK, when simultaneously con-
sidering all parameter uncertainties. 
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Figure 18: Cost-effectiveness acceptability curves indicating the probability that either 
intervention is cost-effective for a WTP range from zero to 1 000 000 NOK per QALY. 
 
Incremental cost-effectiveness estimates in model 5 
As the clinical review only found clinical studies that have compared Hydrus Microstent 
+ cataract surgery to cataract surgery, the findings below specifically address the cost-
effectiveness of Hydrus Microstent + cataract surgery compated with cataract surgery. 
The potential cost-effectiveness of other MIGS devices to a laser therapy strategy re-
mains unclear and could not be explored in this Economic Evaluation. 
 
The results of the probabilistic sensitivity analysis with a lifetime horizon are illus-
trated in figure 19. The blue dots in the scatterplot represent results for patients that 
received cataract surgery alone and the red ones MIGS (Hydrus Microstent) combined 
with cataract surgery. The red “cloud” is, on average, situated slightly more to the right 
than the blue “cloud” and above the blue “cloud”, indicating that MIGS is likely to be 
more costly, and a bit more effective than cataract surgery for patients at a mild glau-
coma stage. The truncated right side of the scatter plot expresses the maximum achiev-
able benefit in the model. 
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Figure 19: Cost-effectiveness scatterplot for model 5. 
ICER 
 
The expected results of the Monte Carlo simulation in base-case analysis are presented 
in Table 25, and show that the total expected intervention-related costs per patient (in 
mild glaucoma stage) in a lifetime horizon are about  51 000 NOK for patients who are 
treated with cataract surgery alone and about ---- NOK for patients who undergo MIGS 
(Hydrus Microstent) in combination with cataract surgery. These costs include proce-
dures, complication, rehabilitation, and health state costs. The incremental cost for 
MIGS in combination with cataract surgery patients is thus about ---- NOK. During a 
lifetime perspective, patients who receive MIGS in combination with cataract surgery 
accumulate more QALYs, with a different of 0.038 QALYs. MIGS combined with cataract 
surgery costs about ---- NOK per QALY (ICER). 
 
Below, we present cost-effectiveness acceptability curves at willingness-to-pay (WTP) 
thresholds for one additional QALY between zero and 1 000 000 NOK (figure 20). The 
figure demonstrates that cataract surgery alone has a higher probability of being cost-
effective than MIGS combined with cataract surgery, when simultaneously taking into 
account all parameter uncertainties. 
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Figure 20: Cost-effectiveness acceptability curves indicating the probability that either 
intervention is cost-effective for a WTP range from zero to 1 000 000 NOK per QALY. 
 
Incremental cost-effectiveness estimates in model 6 
As the clinical review only found clinical studies that have compared Trabectome + cat-
aract surgery to filtration surgery + cataract surgery, the findings below specifically ad-
dress the cost-effectiveness of Trabectome + cataract surgery compated with filtration 
surgery + cataract surgery. The potential cost-effectiveness of other MIGS devices to a 
laser therapy strategy remains unclear and could not be explored in this Economic 
Evaluation. 
 
The results of the probabilistic sensitivity analysis with a lifetime horizon are illus-
trated in figure 21. The blue dots in the scatterplot represent results for patients that 
received filtration surgery combined with cataract surgery and the red ones MIGS 
(Trombectome) combined with cataract surgery. The red “cloud” is, on average, situ-
ated more to the right than the blue “cloud” and slightly above the blue “cloud”, indicat-
ing that MIGS is likely to be more costly, and more effective than filtration surgery com-
bined with cataract surgery for patients at an advanced glaucoma stage. The truncated 
right side of the scatter plot expresses the maximum achievable benefit in the model. 
 
  
 102  Health economic evaluation 
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------- 
Figure 21: Cost-effectiveness scatterplot for analysis in model 6. 
ICER 
 
The expected results of the Monte Carlo simulation in base-case analysis are presented 
in Table 25, and show that the total expected intervention-related costs per patient (in 
advanced glaucoma stage) in a lifetime horizon are about 63 000 NOK for patients who 
are treated with filtration surgery + cataract surgery and ---- NOK for patients who un-
dergo MIGS (Trombectome) in combination with cataract surgery. These costs include 
procedures, complication, rehabilitation, and health state costs. The incremental cost 
for MIGS in combination with cataract surgery patients is thus about ---- NOK. During a 
lifetime perspective, patients who receive MIGS in combination with cataract surgery 
accumulate more QALYs, with a different of 0.057 QALYs. MIGS combined with cataract 
surgery costs about ---- NOK per QALY (ICER). 
 
Below, we present cost-effectiveness acceptability curves at willingness-to-pay (WTP) 
thresholds for one additional QALY between zero and 1 000 000 NOK (figure 22). The 
figure demonstrates that filtration surgery combined with cataract surgery has a higher 
probability of being cost-effective than MIGS combined with cataract surgery up to a 
WTP threshold of 360 000 NOK, when simultaneously taking into account all parame-
ter uncertainties.  
 
  
 103  Health economic evaluation 
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------- 
Figure 22: Cost-effectiveness acceptability curves indicating the probability that either 
intervention is cost-effective for a WTP range from zero to 1 000 000 NOK per QALY. 
 
Sensitivity analyses 
We have presented our sensitivity analyses in tornado diagrams for each model. A 
tornado diagram is a graphical method for presenting a series of one-way sensitivity 
analyses and shows how cost-utility results (ICER) are influenced by variation in 
individual model parameters.The blue bar represents low parameter estimate and the 
red one represents high values of the parameter. 
 
Sensitivity analyses in model 1 
Figure 23 presents parameters with greatest impact on results in model 1. We can 
observe that the results are most affected by variation in baseline visual field, cost 
intervention MIGS and progression visual field natural data. We can see that the if we 
had another value for baseline visual field within the interval it would not have been 
below our WTP threshold anyhow. On the other hand, natural progression visual field 
for untreated patients may be below this threshold if the rate changes to slower rate of 
progression than -0.6 per year. CADTH used -0.92 dB rater than -0.6 dB per year in a 
scenario analysis, based on the reported decline in VF in untreated patients in some 
studies. However, this is the reverse of what could lead to an ICER below our threshold. 
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Figure 23: Tornado diagram revealing possible impact of reasonable variation in main 
parameters on the ICER of MIGS compared to pharmacotherapy. The blue bar represents 
low parameter estimate and the red one represents high values of the parameter. 
 
 
Sensitivity analyses in model 2 
Figure 24 presents parameters with greatest impact on results. We can observe that the 
results are most affected by variation in progression visual field natural data. However, 
the greater the utility increases the more is the ICER decreased, which indicate that 
MIGS will be even more dominated than in the base-case model (laser therapy is more 
effective and less costly in the basecase model). 
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Figure 24: Tornado diagram revealing possible impact of reasonable variation in main 
parameters on the ICER of MIGS compared to laser therapy. The blue bar represents low 
parameter estimate and the red one represents high values of the parameter. 
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Sensitivity analyses in model 3 
Figure 25 presents parameters with greatest impact on results. We can observe that the 
results are most affected by variation in cost intervention MIGS, followed by cost 
intervention filtration data. Here, the description about undertainty around the cost 
intervention parameters for model 1 is applicable.  
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Figure 25: Tornado diagram revealing possible impact of reasonable variation in main 
parameters on the ICER of MIGS compared to filtration surgery. The blue bar represents 
low parameter estimate and the red one represents high values of the parameter. 
 
Sensitivity analyses in model 4  
Figure 26 presents parameters with greatest impact on results. We can observe that the 
results are most affected by variation in intervention costs.  
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Figure 26: Tornado diagram revealing possible impact of reasonable variation in main 
parameters on the ICER of MIGS compared to filtration surgery. The blue bar represents 
low parameter estimate and the red one represents high values of the parameter. 
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Sensitivity analyses in model 5 
Figure 27 presents parameters with greatest impact on results. We can observe that the 
results are most affected by variation in cost intervention MIGS combined with cataract 
surgery followed by baseline visual field and cost intervention cataract surgery data. 
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Figure 27: Tornado diagram revealing possible impact of reasonable variation in main 
parameters on the ICER of MIGS combined with cataract surgery compared to cataract 
surgery alone. The blue bar represents low parameter estimate and the red one 
represents high values of the parameter. 
 
 
Sensitivity analyses in model 6 
Figure 28 presents parameters with greatest impact on results. We can observe that the 
results are most affected by variation in costs related to the interventions, followed by 
the annual IOP reduction for the comparator strategy, filtration + cataract. 
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Figure 28: Tornado diagram revealing possible impact of reasonable variation in main 
parameters on the ICER of MIGS combined with cataract surgery compared to filtration 
surgery combined with cataract surgery. The blue bar represents low parameter estimate 
and the red one represents high values of the parameter. 
 
Budget impact analysis  
We calculated the budgetary impact of introducing MIGS to Norwegian patients with 
glaucoma and patients with glaucoma and cataract. In the budget impact analysis, we 
tried to explore how the potential expansion of MIGS would influence the total number 
of MIGS performed in the next five years. The costs used in the next tables are pre-
sented in table 19, 22 and 23 (Cost section). The costs are not discounted. 
 
The prediction depends on several factors, including any change in clinical practice 
from current practice, the relative changes in procedure costs and the number of pa-
tients eligible for different treatment alternatives. The results of the predicted cost im-
pact of MIGS as a stand-alone procedure and MIGS in combination with cataract sur-
gery are shown in Table 26.  
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Table 26 Predicted impact of MIGS on the number of patients and results of the budget 
impact; estimated costs based on future practice compared to estimated costs based on 
current practice   
Year 2020 2021 2022 2023 2024 
Number of MIGS 
procedures (50% as 
stand-alone 
procedure and 50% 
in combination with 
cataract surgery) 
255 319 383 446 510 
Cost of MIGS alone 2 479 236 3 099 047 3 718 856 4 338 666 4 958 475 
Cost of MIGS in com-
bination with cata-
ract surgery  
4 823 835 6 029 794 7 235 753 8 441 711 9 647 670 
Sum 7 303 073 9 128 841 10 954 609 12 780 377 14 606 145 
Costs are in Norwegian kroner. 
 
Further, we tried to examine the budgetary consequences of introducing MIGS as a 
stand alone procedure compared with pharmaeuticals alone, laser therapy alone and 
filtration surgery alone, and budgetary consequences of introducing MIGS in combina-
tion with cataract surgery compared to cataract surgery alone and filtration in combi-
nation with cataract surgery. 
 
The potential additional costs are presented in the tables 27 to 31 below.  
 
Table 27 presenting the costs associated to MIGS as a stand-alone procedure compared 
with costs related to pharmaceuticals, and the potential additional costs of introducing 
MIGS alone for glaucoma patients receiving pharamaceuticals today. 
 
 
Table 27: Predicted budget impact of MIGS alone compared with pharmaceuticals alone 
Year 2020 2021 2022 2023 2024 
Cost of MIGS alone 2 479 238 3 099 047 3 718 856 4 338 666 4 958 475 
Cost of pharma 474 173 592 716 711 259 829 802 948 345 
Sum  2 005 065 2 506 331 3 007 598 3 508 864 4 010 130 
Costs are in Norwegian kroner. 
 
 
Table 28 presenting the costs associated with MIGS alone compared with costs related 
to laser therapy, and the potential additional costs of introducing MIGS alone for glau-
coma patients receiving laser therapy today. 
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Table 28: Predicted budget impact of MIGS alone compared with laser therapy 
Year 2020 2021 2022 2023 2024 
Cost of MIGS alone 2 479 238 3 099 047 3 718 856 4 338 666 4 958 475 
Cost of laser therapy 214 455 268 068 321 683 375 297 428 910 
Sum  2 264 783 2 830 978 3 397 174 3 963 369 4 429 565 
Costs are in Norwegian kroner. 
 
 
Table 29 presenting the costs associated with MIGS alone compared with costs related 
to filtration surgery, and the potential additional costs of introducing MIGS alone for 
glaucoma patients receiving filtration surgery today.  
 
 
 
Table 29: Predicted budget impact of MIGS alone compared with filtration surgery 
Year 2020 2021 2022 2023 2024 
Cost of MIGS alone 2 479 238 3 099 047 3 718 856 4 338 666 4 958 475 
Cost of filtration sur-
gery 
2 156 280 2 695 350 3 234 420 3 773 490 4 312 560 
Sum  322 958 403 697 484 436 3565 176 645 915 
Costs are in Norwegian kroner. 
 
 
Table 30 presenting the costs associated with MIGS in combination with cataract sur-
gery compared with costs related to cataract surgery alone, and the potential additional 
costs of introducing MIGS in combination o cataract with surgery for glaucoma patients 
receiving cataract surgery as a stand-alone procedure today.  
 
 
 
Table 30: Predicted budget impact of MIGS in combination with cataract surgery com-
pared with cataract surgery alone 
Year 2020 2021 2022 2023 2024 
Cost of MIGS in com-
bination with cata-
ract surgery 
4 823 835 6 029 794 7 235 753 8 441 711 9 647 670 
Cost of cataract sur-
gery 
1 834 598 2 293 247 2 751 896 3 219 545 3 669 195 
Sum  2 989 238 3 736 547 4 483 856 5 231 166 5 978 475 
Costs are in Norwegian kroner. 
 
 
Table 31 presenting the costs associated with MIGS in combination with cataract sur-
gery compared with costs related to filtration surgery in combination with cataract sur-
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gery, and the potential additional costs of introducing MIGS in combination with cata-
ract surgery for glaucoma patients receiving filtration surgery in combination with cat-
aract surgery today.  
 
 
Table 31: Predicted budget impact of MIGS in combination with cataract surgery com-
pared with filtration surgery in combination with cataract surgery  
Year 2020 2021 2022 2023 2024 
Cost of MIGS in com-
bination with cata-
ract surgery 
4 823 835 6 029 794 7 235 753 8 441 711 9 647 670 
Cost of filtration sur-
gery in combination 
with cataract surgery 
1 995 503 2 494 378 2 993 254 3 492 129 3 991 005 
Sum  2 828 333 3 535 416 4 242 498 4 949 582 5 656 665 
Costs are in Norwegian kroner. 
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Ethics 
This chapter about ethical aspects of using MIGS in Norway is not adapted from CADTH. 
 
Method 
In this section we have analysed central ethical implications of MIGS implementation. 
The purpose was to identify key ethical concerns raised by MIGS, to assess the main 
challenges, and offer recommendations on how to deal with these challenges. The anal-
ysis proceeded in three major steps: 
1. Brief description of the situation, alternative actions and solutions, and the involved 
stakeholders 
2. Analysis of the ethical challenges and possible consequences in terms of the four 
principles: benefit, harm, autonomy and justice  
3. Summary of the analysis 
These steps were chosen to fit the central ethical issues raised by using MIGS devices 
and procedures, based on the methodologies used or discussed in relevant HTA ethics 
guidelines and reports (113-115). 
 
Brief description of the situation, alternatives and stakeholders 
MIGS comprise of several surgical procedures and devices that present an alternative 
to or complement current treatment of glaucoma. The potential advantages of MIGS are 
shorter procedure times, earlier treatment, shorter recovery times, and probably 
higher success rates both as a standalone treatment and for subsequent surgical treat-
ments.  
MIGS have been developed and used since the turn of the millennium. MIGS procedures 
are already offered at Norwegian hospitals, and there is a growing demand. As MIGS 
represent a group of relatively new treatment options, our knowledge of optimal use 
and long-term effects is still incomplete. 
Current alternatives to MIGS are IOP lowering eye drops, laser treatment, and tradi-
tional surgical procedures. The compliance rates for eye drops is low, and laser therapy 
is not recommended for all patients. Traditional surgical procedures are often post-
poned in patient treatment, because of the risk of complications, demanding follow-up 
procedures, and potential lifelong discomfort for the patient.  
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MIGS have the potential to offer better alternatives for glaucoma patients. The use of 
MIGS procedures may, however, lower the development of and competence in tradi-
tional surgical procedures. This might reduce the quality of treatment for some pa-
tients, especially patients that cannot benefit from the available MIGS procedures. 
Involved stakeholders are glaucoma patients and their relatives, medical doctors and 
other health personnel, health authorities, public hospitals, private medical centres, 
and therapy developers including pharmaceutical industry. 
 
Analysis of the ethical challenges 
We structure the ethical analysis in terms of the four principles: benefit, harm, auton-
omy and justice (116). 
 
Benefit 
The principle of benefit denotes the production of benefits for others, and the positive 
balance of good minus bad effects for individuals and society.  
Glaucoma is a chronic disease often leading to blindness. As there is currently no cura-
tive treatment for glaucoma, and the progressive vision loss experienced by glaucoma 
patients is irreversible, current treatment options focus on reduction of IOP, nerve 
damage, and further loss of vision. Being a chronic disease, a comprehensive life-cycle 
perspective on benefit is the most suitable.  
In a life-cycle perspective, the potential benefits of MIGS compared to alternative treat-
ment options are significant, both for individual patients and society at large. Avoiding 
the potential loss of life quality for patients in adhering to, and often failure of adhering 
to, a strict pharmaco-therapeutical regime, is such a significant benefit. The possibility 
of earlier surgical intervention and resulting prevention of deteriorating eyesight is an-
other.   
Because of the reduced risk of complications, MIGS treatments can be offered to the pa-
tient at an earlier stage of treatment. This might reduce irreversible damage from pro-
longed non-treatment. Compared to traditional surgical options, MIGS might reduce 
risks of serious post-surgical medical complications, patient discomfort, and reduced 
quality of life.  
 
Harm 
The principle of harm denotes not inflicting avoidable harmful effects on others. Imple-
mentation of MIGS procedures without a sound knowledge base of short- and long-
term risks and benefits might induce harm to patients (117). To avoid such harm, MIGS 
implementation and development should follow standard approval procedures and in-
ternational guidelines (12).  
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Autonomy 
The principle of autonomy denotes the opportunity for genuine self-determination and 
freedom of choice for individuals. 
Patients must be thoroughly informed about risks of and alternatives to the MIGS pro-
cedure in question, as well as the knowledge status of the information provided.  
 
Justice 
The principle of justice denotes the equal distribution of risks and benefits between in-
dividuals and groups. 
From the principle perspective of justice, health authorities should be careful not to in-
troduce incentive structures that could lead hospitals to prefer/avoid the use of certain 
MIGS procedures for economical rather than medical reasons, as this might result in 
unjust treatment choices between patient groups. Outsourcing MIGS to private medical 
centres should also be set up to avoid incentive structures producing injustice between 
patient groups, especially if centres have close ties with pharmaceutical industry.  
Access to MIGS treatment should not depend on the ethnic or cultural background, geo-
graphical location, or personal economic resources of the patient. 
 
Summary of the analysis 
The are potential benefits of MIGS, but the potential harms must be avoided or mini-
mized. The challenges for patient autonomy seem manageable, if patients can be thor-
oughly informed about risks of and alternatives to a given MIGS procedure. In terms of 
justice, it is important to guarantee patients equal access to treatment, regardless of 
ability to pay, place of residence, social status, or cultural background. 
 
 –  
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Discussion 
Key findings summary 
Key findings on effectiveness and safety  
CADTH HTA 
CADTH HTA included 32 studies from 35 publications; 10 randomized trials and 22 
non-randomised studies. The evidence included 24 specific comparisons: one compari-
son of a MIGS versus another MIGS, six comparisons of a MIGS combined with cataract 
surgery versus cataract surgery alone, nine comparisons of a MIGS combined with cata-
ract surgery versus cataract surgery combined with filtration surgery, six comparisons 
of a MIGS combined with filtration surgery versus filtration surgery aone, two compari-
sons of a MIGS versus pharmacotherapy, and one comparison of a MIGS versus laser 
therapy. The CADTH authors considered all the included studies to be at risk of bias. 
 
To summarise, the findings showed that there were essentially no statistically signifi-
cant differences between interventions and comparators, or it was not statistical 
tested.  
 
NIPH  review 
We identified and included eight studies (seven randomised trials and one non-ran-
domised study) that compared a MIGS procedure alone or in combination with cataract 
surgery, with another MIGS procedure or non-MIGS procedures. None of the results 
from any of these studies could be pooled with study results in the CADTH HTA. 
There was moderate-certainty evidence of lower unmedicated intraocular pressure 
(IOP) at 24 months with the iStent inject combination with cataract surgery than with 
cataract surgery alone, and high-certainty evidence of lower IOP at 24 months with Hy-
drus in combination with cataract surgery than with cataract surgery alone. Otherwise, 
there was no or little difference between the MIGS and interventions in control groups, 
or the certainty of the evidence was too low to make a judgement.  
 
The evidence for the safety of MIGS was inconclusive across the comparisons. 
 
Key findings of health economic evaluation 
The results of the clinical review, based on the HTA from CADTH, impacted the ap-
proach taken in our health economic evaluation. The clinical evidence was generally of 
poor quality as noted in the clinical review. There was substantial heterogeneity be-
tween studies comparing MIGS with other treatment strategies, and it was considered 
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clinically inappropriate to conduct a network meta-analysis to pool all possible com-
parisons. The MIGS group as a whole is so broad that it encompasses therapies that ad-
dress different parts of the glaucoma treatment pathway, and have different control 
comparators. As such, the health economic analysis consisted of six models with pair-
wise comparisons, and each model considered MIGS with a different set of compara-
tors, patients with varying glaucoma stages, and different types of MIGS devices. Com-
parisons of results between models are therefore not appropriate. 
 
The health economic models demonstrated lifetime expected costs and QALYs, incre-
mental costs and QALYs, and ICERs. Our probabilistic analysis suggested that the cost-
effectiveness of MIGS varied depending on the patient population’s baseline disease 
stage and the comparator. A lifetime total cost per patient for glaucoma treatment 
ranged between 30 000 NOK and 83 000 NOK. The incremental differences in costs 
ranged between 3 000 NOK and 24 000 NOK per patient. The incremental QALYs for 
MIGS between comparators ranged between – 0.080 and 0.057 QALYs. 
 
MIGS (2x iStent inject) seemed to gain more QALYs at a higher cost when compared 
with pharmacotherapy in moderate glaucoma stage (model 1), or when MIGS (ECP) 
was compared with filtration surgery in advanced glaucoma stage (model 4). The same 
result applied when MIGS (Hydrus Microstent) was performed in combination with cat-
aract surgery compared with cataract surgery alone in mild glaucoma stage (model 5). 
Results were sensitive to various parameters in the different models. The incremental 
differences in costs and QALYs over a lifetime horizon were relatively small. Unlike 
QALYs, the incremental costs tended to occur relatively early, largely due to the initial 
costs of the device and procedure that occur within the first year. The attractiveness of 
MIGS may differ depending on the cost of the device, and the procedure, from a cost 
perspective. From a health care perspective, these findings illustrate that MIGS may be 
cost-effective in specific situations, but if used indiscriminately, MIGS may not always 
be the cost-effective treatment strategy for certain glaucoma patients. Results on the 
cost-effectiveness of MIGS should be interpreted with caution given the uncertainty in 
relative efficacy and costs. Scenarios where there may be multiple treatment options 
for a MIGS patient, may require further evidence prior to recommendations for the op-
timal use of treatments in patients with glaucoma. 
 
Our budget impact analysis estimated a cost of about 17 million after five years if intro-
ducing MIGS in the Norwegian specialist health care. The patient volume in need of 
MIGS is assumed to increase from 255 patients to 510 patients in five years. 
 
Evidence quality 
Certainty of the evidence of effectiveness and safety 
CADTH HTA 
The CADTH HTA authors judged the certainty of the evidence as very low to low across 
the 24 comparisons and outcomes. Very low certainty-evidence cannot be interpreted, 
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and it is highly likely that future research findings may be very different from the cur-
rent evidence. Low certainty-evidence gives a weak indication of effectiveness and 
safety, and it is likely that future research findings may differ from the current evi-
dence. 
 
NIPH supplementary review 
We assessed the certainty of the evidence for the primary outcome, intraocular pres-
sure, as high for one comparison (Hydrus + cataract surgery vs cataract surgery alone), 
moderate for one comparison (Hydrus vs 2x iStent) , low for one comparison (iStent in-
ject + cataract surgery vs cataract surgery alone) and very low for the four remaining 
comparisons. A major reason for downgrading the certainty of the evidence was seri-
ous to very serious concerns for risk of bias in the included studies. Another important 
reason for downgrading the certainty was that the evidence largely consisted of results 
from small single studies that could only be pooled in two cases. Further, imprecision 
was a concern for two of the comparisons.  
 
The quality of the economic model used  
We made several assumptions to conduct the six health economic models leading to un-
certainty around our economic results. For example, we chose to use a lifetime horizon. 
Most clinical studies, however, considered outcomes at only one year, and the long-
term relative effects of various treatment strategies are unknown. We extrapolated the 
incremental QALYs over a lifetime, and thus estimated differences in QALYs should be 
interpreted with caution. Health states in the models were defined according to the 
Hodapp-Parrish-Anderson grading scale. Further, there is uncertainty in the relation-
ship between IOP changes and its direct impact on VF status and vision related QoL in a 
lifetime perspective. Treatment efficacy were commonly described as a change in IOP 
in the clinical studies and in the economic models we chose to utilize a predictive equa-
tion to describe the relationship between changes in IOP and its impact on visual field. 
We do not know the predictive ability of this equation that was used in the models. 
Finally, MIGS is a heterogeneous group of devices with potentially different costs and 
different relative treatment effects, which can have an impact on our result. There re-
mains uncertainty with respect to decision making on what patients are suited to what 
type of treatment strategy, for example, there may be subgroups of patients with more 
aggressive glaucoma who may not be appropriate for all treatment strategies.  
 
Strengths and weaknesses 
Strengths and weaknesses of the systematic reviews of effectiveness and safety 
The strengths of CADTH’s and our systematic reviews of the evidence for effectiveness 
and safety include updated systematic searches in electronic databases, pre-specified 
inclusion and exclusion criteria, independent screening of identified records, independ-
ent assessments of risk of bias in included studies, systematic data extraction and re-
porting, and assessments of the certainty of the evidence. 
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Due to time constraints, the NIPH supplementary review did not include retrospective 
non-randomised studies, ongoing studies and unpublished studies. Including these 
study categories would probably not add anything to the evidence, but still be informa-
tive.    
 
Strengths and weaknesses of health economic evaluation  
Firstly, we replicated the model from CADTH with respect to model structure and effi-
cacy data, and we do not know if we have missed some important variables. The input 
is adjusted according to Norwegian conditions. 
 
A second limitation concerns how the clinical review transferred over to the health eco-
nomic evaluation. The comparative cost-effectiveness of different MIGS devices could 
not be addressed.  
 
Another limitation was the area with impact on our health economic modelling was the 
natural history of glaucoma. To model the lifetime economic consequences of treatment 
strategies, the model had to incorporate the expected natural history of the disease. We 
used the Hodapp-Parrish-Anderson grading scale to examine this, and incorporated 
visual field changes over time in patients with glaucoma, based on the CADTH report 
(5;103). According to CADTH several studies evaluating the natural history of glaucoma 
are expected in the coming years, and face validity of the health economic model should 
be reassessed when such studies become available (5). Further, we had to do extrapola-
tions to model a lifetime horizon, with long-term costs and consequences, as the clinical 
studies used report on surrogate outcomes over short time periods. 
 
Furthermore, costs were challenging to assess because of limited availability of data on 
all MIGS devices. We used DRGs in our cost estimates which may influence the uncer-
tainty in our results. DRG costs are based on various ranges in costs and represent av-
erage estimates on different procedures. This approach may double count some cost 
items, for example, costs of MIGS devices. There is no DRG for MIGS, which is often the 
case for new strategies. Further, assessment of actuel costs may be valuable and allow 
greater certainty in the incremental- and total cost estimates, like detailed Norwegian 
micro-costing studies of MIGS and comparator strategies (i.e., real world evidence). 
Sensitivity analyses strengthen this economic evaluation and highlights that the cost of 
MIGS plays an important role in determining its cost-effectiveness. 
 
In addition, we included costs that are not incorporated in the DRG costs, i.e., costs in-
fluenced by glaucoma stage in patients, inpatients or outpatients, stand-alone treat-
ment or combination treatment etc. As glaucoma stage has been identified as a predic-
tor of higher health state costs, devices aimed at advanced or high IOP glaucoma pa-
tients may have higher cost-savings potential (118;119). 
 
We included extra time used on combining MIGS procedure with cataract surgery com-
pared to cataract surgery alone. On the other hand, according to our clinical experts, 
the difference in costs in this case are only the price of MIGS. We received prices on 
MIGS-devices from our clinical experts. As such, we only got prices on the MIGS-devices 
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that are in use in Norwegian hospitals today. Device prices vary between hospitals to-
day because of no national tender (28). We used the average of the prices we retrieved. 
As a conservative assumption, on MIGS-devices that are not in use in Norway, we esti-
mated prices as the average cost of the price on the devices we received prices on. In 
addition, we did not account for possible discounts on prices. 
First, one strength in our economic analysis is that we developed decision analytic 
models for POAG, which commonly has been approached with Markov state-transition 
models using different glaucoma staging systems. This approach has been justified 
from a clinical point of view as it correctly represents the stepwise changes in costs and 
utilities as the disease progresses.  
 
We did the health economic analysis from a broad health care perspective, and there-
fore, we did not include societal costs. In the glaucoma disease area, societal costs may 
be important aspects as this is a progressive disease. For example, in our analysis it is 
less costly with a blind patient than with a patient with moderate glaucoma, as there 
are no costs occurring for the specialist health care sector in the blind stage. However, 
there may be high societal costs to take care of a blind patient, as well as costs occur-
ring when patients are absent from work etc. Our clinical experts and patient partners 
mentioned these aspects as especially important to include in an evaluation in the area 
of glaucoma (28;37). However, a societal perspective was omitted in the final report 
given it being outside the scope of our commission. 
 
Other aspects that may have an impact on the conclusion of cost-effectiveness is medi-
cation adherence on relative effectiveness and disease progression and medication-
specific disutilities. Our analysis assumed no adherence rates for medication and no 
medication-specific disutilities. However, CADTH reported that, if other assumptions 
were selected for the pharmacotherapy strategy (e.g., lower drug adherence or 
disutility for medication use), MIGS may be a beneficial treatment strategy in 
populations where adherence to medication is expected to be low or if there are side 
effects experienced on medication. 
 
In the case of MIGS combined with cataract surgery, which is included in model 5 and 6, 
and applies to Trabectome and Hydrus Microstent (types of MIGS). According to our 
clinical experts, in principle all MIGS could be combined with cataract surgery. How-
ever, it is most applicable to combine iStent with cataract surgery. In some cases, XEN is 
also combined with cataract surgery, but mainly used as a stand-alone procedure. Usu-
ally, when patients also have cataract it will be combined with that kind of procedure. 
We assume that in the models where cataract surgery is included, patients have both 
glaucoma and cataract. According to our clinical experts, this relates to 10 to 15 % of 
the cases. There are several weaknesses to compare MIGS combined with cataract sur-
gery with other treatment strategies to glaucoma treatment. According to our clinical 
experts MIGS combined with cataract surgery is most relevant to compare with cata-
ract surgery combined with other type of MIGS device (but we do not compare MIGS 
with MIGS), cataract surgery combined with other type of glaucoma surgery, or cata-
ract surgery alone. According to our clinical experts 70% of patients above 70 years de-
velop cataract (some with limited cataract that do not need surgery). Most patients 
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with glaucoma are above 70 years, and therefore there is a strong coexistence of these 
eye disorders (28).  
 
Further, there may be some uncertainty in our calculation of absolute shortfall (AS). 
This applies for example to uncertainty in the estimates of age or prognosis. 
 
According to our clinical experts there are also some differences with respect to what 
MIGS is used or not. We are unsure if all MIGS and procedures are comparable with all 
treatment options and comparators in terms of when to use them. In addition, the pro-
cedure group (subconjunctival space) of XEN and Innfocus, the last one more invasive, 
are by many considered not to be a MIGS. The subconjunctival approach is difficult 
when a patient has received several operations and often a MIGS using another ap-
proach has been used. According to our clinical experts there has been a viewpoint of 
dividing MIGS into groups: MIGS and MIGS+. The clinical experts categorised iStent in-
ject as a MIGS and XEN as a MIGS+. In most cases, they have used MIGS as an alternative 
to eyedrops or laser and MIGS+ as an alternative to trabeculectomy. I.e., these are dif-
ferent patient groups which are not directly comparable (28).  
 
With respect to MIGS as first-line treatment, there is a risk of complications with all 
surgery and therefore few will choose MIGS before eye drops. Most clinicians will also 
choose laser treatment before MIGS, but laser can be poorly suited for some patients, 
(eg, unable to sit at the slit-lamp mounted laser, past history of uveitis, inadequate view 
of trabecular meshwork or symptomatic cataract) (27). In terms of mild, moderate and 
advanced health states, these might not mean the same for first, second line treatment 
and so on (i.e., you may not only receive first line treatment in mild, second line treat-
ment in moderate and so on. i.e., you can have second line treatment in mild).  
 
Also, we have assumed that every patient only receives MIGS once in a lifetime horizon. 
We do not know if this is realistic in “real life”, and if a patient may receive MIGS sev-
eral times.  
 
We have no information on earlier treatment of the patients included in the studies 
(and assume that patients included are in their first treatment scheme. Also, we do not 
know how the efficacy of treatment is in different disease stages. One example here is, 
efficacy of filtration surgery in moderate glaucoma health state (model 3) versus effi-
cacy of filtration surgery on advanced health state (model 4) (different MIGS in the dif-
ferent models). 
 
Complications can have an impact on time and outpatient resources/costs. There may 
be different complications for different treatment strategies, for example, surgery ver-
sus pharmacotherapy. We chose to replicate CADTH and pool our complications into 
groups as minor and major, as well as secondary surgical interventions, and thereby 
utilising an identical model structure in the different models, but here, different vari-
bles are put into the three complication groups. We have not accounted for if a MIGS in-
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tervention can fail, and if this is a complication or not. Does the patient need a re-inter-
vention? If yes, how often is this happening? Does the patient get any disutility? Accord-
ing to our clinical experts this could be difficult to categorise, as the same complication 
could be less severe or more severe dependent on the severity of the glaucoma. Infec-
tion could be a lot of things, for example, if it is an intraocular infection, also called en-
dophthalmitis, blebitis, this is a major complication. On the other hand, minor compli-
cations are other extraocular infections. Further, there are some of the minor complica-
tions that could be considered major, for example, endothelial cell loss could be both 
minor and major, dependent on the extent of cell loss.  
 
A patient can start different treatments with respect to which disease stage they are in. 
They also have a different baseline. It is important to define glaucoma stage at baseline 
to allow modelling the patients disease progression within each model. As such, we 
have compared MIGS with different comparators depending on glaucoma stage and di-
vided stages dependent on decibels. Number of visits and follow up were not included 
in health economic evaluation. 
 
Finally, many of the assumptions in the health economic evaluation rely on clinical 
expert opinions, and would benefit from real world evidence. 
 
Generalisability of findings 
Overall completeness and applicability of evidence from systematic review  
We have summarised the CADTH HTA evidence ansupplemented it with more recent 
evidence. The evidence largely consists of several small, single studies with results that 
cannot be pooled with each other due to differences in comparisons. So, for the vast 
majority of comparisons, the evidence is not conclusive. Further, our pre-specified sec-
ondary outcomes were rarely reported in the included studies. 
 
We assume that applicability of the evidence is acceptable to a Norwegian setting with 
regard to populations and interventions. However not all interventions or comapari-
sons we have reported are relevant to clinical practice in Norway.  
 
Generalizability of findings from health economic evaluation 
The health economic findings primarily reflects patients with open-angle glaucoma, 
which is in accordance with what our clinical experts suggested, as MIGS is mainly 
meant for this patient population (28). The economic evaluation therefore has limita-
tions regarding possibilities to address whether cost-effectiveness of MIGS would differ 
by other types of glaucoma. However, it may be important to not exclude other glau-
coma patients in receiving MIGS-treatment from a patient partner perspective (37). 
The main findings from the health economic evaluation reflect the potential cost-effec-
tiveness of MIGS in patients who are receiving treatment at an early stage of glaucoma. 
However, as disease stage can impact costs, utilities, and options for subsequent treat-
ment, the economic analysis was divided into baseline stage when clinical data existed. 
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The results from this set of comparisons highlight the fact that the cost-effectiveness of 
MIGS may depend on the stage of glaucoma. Therefore, population characteristics may 
influence the cost-effectiveness of MIGS.  
 
As mentioned above, to inform relative treatment effects and thereby incorporate natu-
ral history of glaucoma for our economic evaluation, we included clinical studies used 
in the CADTH report, taken from a large Canadian study (5;103). We assume those pa-
tient populations reflect characteristics of a Norwegian population. Furthermore, costs 
and resource utilisation were from Norwegian sources and the findings are expected to 
be generalisable to the Norwegian context. 
 
Although MIGS are categorised as a particular class of strategies, each MIGS may have 
different clinical effectiveness and safety profiles. There exist some various definitions 
and opinions on what MIGS is and is not. 
 
In Norway, the infrastructure results in long distances to hospital for many patients 
within geographical areas and the distance to specialised glaucoma centres may be 
long. Therefore, a question may be if all hospitals should offer MIGS. According to our 
project group, consisting of clinical experts and patient partners many hospitals offer 
MIGS today, but the treatment availability might differ between patients in the country.  
 
Consistency with other reviews 
Consistency of systematic review with other reviews  
Our review is consistent with the CADTH HTA and four Cochrane reviews in that we 
identified small, single studies with different comparisons. Overall, in our and others’ 
reviews, it is unclear whether MIGS reduces intraocular pressures, compared to other 
interventions, in patients with open-angle glaucoma. Adverse events seemed infre-
quent in all interventions.  
 
None of the results in the included studies in our supplementary review could have 
been pooled with any of the results from studies in the CADTH HTA because of different 
comparisons. While all evidence in the CADTH HTA was graded as low or very low cer-
tainty, we assessed the certainty as high and moderate, respectively, in two cases. Our 
assessment of the certainty of the evidence was in line with four recent Cochrane re-
views (15;32-34).  
 
Consistency of health economic evaluation with other studies 
Our health economic evaluation is consistent with other evaluations on health econom-
ics, among others the CADTH report, with regards to uncertainty around estimates due 
to lack of data. Cost components may be different in different countries. 
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Implication of results on practice 
With respect to implication of results on practice one of the greatest challenges to the 
organization of MIGS in Norway may be access at system and patient level. At a system 
level, access varies for patients living in different geographical regions, and Norway’s 
considerable geographical size can create difficulties in caring for patients with glau-
coma that live rurally or remotely. Today, however, many hospitals offer MIGS treat-
ment. There might be that difficulty can be present due to long distances, fewer special-
ised ophthalmologists, problems attracting trained and experienced ophthalmologists 
to the area etc. Therefore, patients may receive MIGS treatment later in the glaucoma 
pathway, and at that stage, ophthalmologists may opt to refer patients for more inva-
sive procedures. Our patient partners’ and clinical experts described the systemic bur-
dens of having to travel to access MIGS and follow-ups as important aspects in this as-
sessment (28;37).  
 
Today, there may be some issues at a patient level, as access to MIGS can vary due to 
the surgery itself being offered by a few private clinics, necessitating the procedure or 
device to be paid for by the patient. As the specialist health care has a restricted budget 
that is often shared with other specialties, this can be a barrier to implementing MIGS. 
In facilities that provide MIGS, these facilities may only fund some potential types of 
MIGS devices or procedures available for patients. Today different hospitals use differ-
ent types of MIGS, and there is no national agreement on what to use and in which 
cases. According to some experts Xen is mostly used for advanced glaucoma and iStent 
or ABiC for light/moderate glaucoma. Additionally, as the number of MIGS surgeries in-
creases, the time in the OR required for these surgeries also increases, which may 
lengthen waiting lists for patients who require the intervention. In such instances, pa-
tients may choose to get it done privately, but to our knowledge this is not a big issue at 
the moment. For patients who lack the financial means to pay privately for a MIGS de-
vice, or for those whose glaucoma could in principle be treated through medication but 
are unable to use eye drops as prescribed, the unclear status of MIGS as an “optional 
upgrade” versus a “medical need” may itself be a barrier to access. One specialist might 
consider a patient’s circumstances to clearly present medical need for MIGS treatment, 
whilst another would not. Clearer guidelines on when and for whom MIGS should be 
considered a medical need will reduce barriers currently created by the discretionary 
interpretation of these concepts by professionals and health systems (5). 
 
Although these are relevant considerations that may impact access to MIGS, this HTA 
focused on the evidence that would be useful and specifically relevant to decision mak-
ers in Norway’s publicly funded specialist health care system. For example, costs in-
cluded in the analysis were specific to those paid by RHAs and may not reflect indirect 
costs from a broader societal perspective (e.g., costs borne by patients and relatives).  
 
According to our clinical experts and patient partners there are different use of MIGS in 
hospitals in Norway today. Implementation of a technology is often dependent on the 
diffusion of the technology into the professional community. Many physicians are 
“early adopters” of newer technology, including MIGS devices and procedures, although 
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many physicians take a more cautious approach before integrating newer interventions 
into practice. As MIGS are relatively new technologies, this diffusion may not yet be 
complete. Nonetheless, new graduates of ophthalmology are frequently trained in MIGS 
devices and procedures, and often expect this training. MIGS have been noted to have a 
fairly short learning compared to other surgery for glaucoma.  
 
Additionally, MIGS are not included in many clinical practice guidelines for ophtalmol-
ogy and this lack of guidance can create difficulties for ophtalmologists when deciding 
on patient selection, type of MIGS and funding. Further, there is a lack of formalised in-
dications for the use of MIGS, that might lead to differences in clinical practice. As such, 
it is possible that providers’ perceptions of patients’ “compliance” may influence pa-
tient selection for MIGS. This could have the effect rewarding “compliant” patients with 
access to MIGS, while those struggling with other treatment regimens are overlooked 
as “noncompliant” (5).  
 
Moreover, it is probable that clinical discretion is influenced by the available evidence 
regarding effectiveness and safety, the state of which is in its infancy. Authors of the 
majority of the studies in the clinical review reported several disclosures, including fi-
nancial or non-financial support from industry, other involvement with industry (e.g., 
consulting for, or employee of, industry), or having other interests in manufacturer 
companies (e.g., shareholder, stock holder or patent holders). Therefore, MIGS devices 
and procedures with greater manufacturer support are likely to be better represented 
in the literature and therefore have more available evidence regarding clinical effec-
tiveness and safety and subsequently greater uptake. In the current landscape of MIGS 
use in Norway, the potential for conflict of interest arises from incentives that institu-
tions and professionals may have to recommend the use of specific MIGS devices to pa-
tients for reasons extraneous to patients’ individual circumstances and needs. Reme-
dies to prevent and mitigate conflicts include transparency by surgeons and institu-
tions in acknowledging all potential conflicts, institutional oversight in granting privi-
leges for innovative surgeries, and candid discussion with patients. In order to advance 
more personalised selection of MIGS for patients, it may be essential for health systems, 
facilities, and professionals to assign and carry out the responsibility of tracking and re-
porting outcomes of MIGS usage. 
 
As MIGS is a quickly evolving research area, implementation issues involving MIGS may 
also change rapidly; some implementation issues that were described may no longer be 
of relevance or there may be novel issues that were not captured. 
 
However, the direct and indirect costs of MIGS can be considerable. Therefore, there is 
need to clarify current policy on access and reimbursement related to MIGS devices and 
procedures (120). 
 
The evidence should be interpreted with caution, given the uncertainty in data about 
clinical efficacy, safety and cost. Glaucoma management is a rapidly changing field and 
as substantial new evidence of MIGS devices and procedures emerge, reassessment 
may be needed. Both patient groups and clinicians have raised positive attitudes and 
expectations to offer more use of MIGS to patients with claucoma, although also being 
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aware of the limitations in the evidence on effect and safety clearly shown in this re-
port.  
 
 
Considerations of the prioritisation criteria in light of available evidence 
Lack of high-certainty evidence of MIGS comparisons in the CADTH HTA restrict the 
possibilities to consider the established prioritisation criteria in Norway; i.e., benefit, 
resources and severity in the following way: 
 
- Benefit: The clinical evidence on MIGS is limited. The main reason for this is the 
lack of comparative studies of MIGS. 
- Resources: Definitive conclusions on the cost-effectiveness of MIGS is uncertain, 
given the uncertainty in the analysis. Our health economic evaluation shows 
some scenarios where MIGS may be cost-effective, depending on comparator 
and disease stage. 
- Severity: Our analysis puts patients with glaucoma in severity class 1 irrespective 
of model. 
 
Need for further research 
To obtain high-certainty evidence for the myriad of possible MIGS comparisons, there 
is a need for more well-designed randomised trials. Relevant comparisons should also 
be considered (e.g. XEN should be compared to trab, whilst trabecular bypass surgeries 
might more reasonably be compared to laser). It is worth noting that the comparator 
here is often cataract surgery alone, which is not really broadly implemented as a glau-
coma therapy in Norway. Further, detailed micro-costing of MIGS procedures may al-
low for greater certainty in the true absolute and incremental costs of MIGS to better 
inform the potential economic value of MIGS.  
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Conclusion  
 
Efficacy and safety 
MIGS with Hydrus Microstents combined with cataract surgery reduces intraocular 
pressure (IOP) at 24 months, compared to cataract surgery alone. MIGS with Hydrus 
Microstents probably reduces IOP at 12 months, compared to MIGS with 2x iStents. For 
other comparisons and outcomes, it is uncertain whether there is a difference in IOP re-
duction.  
 
Neither MIGS procedures nor alternative surgical strategies appear to be at high risk of 
adverse events, and it is uncertain whether complications occur more or less frequently 
in either category. 
 
Organisational aspects 
MIGS is suitable as a outpatient surgery without hospital admission. Ophthalmologists 
need to be trained to perform MIGS. Experts predict that the number of annual MIGS 
procedures might increase annually to twice as many in 2024 than today. 
 
Health economics 
Cost-effectiveness analysis of MIGS are uncertain, given the uncertainty in available 
data. The economic evaluation provided some scenarios where MIGS may be cost-effec-
tive, depending on comparator and disease stage. 
 
Ethical aspects 
The are potential benefits of MIGS, but the potential harms must be avoided or mini-
mized. The challenges for patient autonomy seem manageable, if patients can be thor-
oughly informed about risks of and alternatives to a given MIGS procedure. It is im-
portant to guarantee patients equal access to treatment, regardless of ability to pay, 
place of residence, social status, or cultural background. 
Consideration of the priority criteria 
Lack of high-certainty evidence of MIGS comparisons in the CADTH HTA restrict the 
possibilities to consider the established prioritisation criteria in Norway. 
Regarding benefit the clinical evidence on MIGS is limited. The main reason for this is 
the lack of comparative studies of MIGS. Regarding resources definitive conclusions on 
the cost-effectiveness of MIGS is uncertain, given the uncertainty in the analysis. Our 
health economic evaluation shows some scenarios where MIGS may be cost-effective, 
depending on comparator and disease stage. Finally, on the aspect of severity: Our anal-
ysis puts patients with glaucoma in severity class 1 irrespective of model. 
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Appendices  
Appendix 1: Progress log 
Date Correspondence 
24.06.2018 
 
Proposal for HTA submitted to New Methods by manufacturer Glau-
kos Corpeation 
24.09.2018 
 
- The RHA Forum commissioned NIPH a single HTA on MIGS 
(iStent Inject) 
- Several manufacturers of MIGS contacted NIPH regarding the 
conduct of an HTA 
22.10.2018 
 
The RHA Forum revised the commission, from a single HTA to a mul-
tiple HTA because of several manufacturers of MIGS 
October/December 2018 NIPH was in contact with Pharmerit (Glaukos Corperation) and Aller-
gan about questions regarding the HTA 
09.01.2019 NIPH start-up meeting for health economists 
February 2019 
 
- NIPH contacted clinical experts first time 
- NIPH contacted patient partners first time 
- NIPH contacted Sykehusinnkjøp HF first time 
- NIPH sent tuestionnaire on organizational consequences to 
RHF coordinators 
- NIPH received documentation on MIGS-device and glaucoma 
from Allergan and Phaemerit (Glaukos Corperation) 
- NIPH in contact with consulting firm working for 
manufacturer Santen 
- Internship student started working on the project 
04.03.2019 Uncertainty about clinical experts, NIPH sent another request about 
this to the secretariat of Nye Metoder 
07.03.2019 - Internal project participants on the efficacy and safety parts 
on board in the project 
- NIPH first internal status meeting 
18.03.2019 
 
Meeting with project participant on the HTA conducted by CADTH, 
with focus on patient involvement  
27.03.2019 
 
- First meeting with research librarian  
- All internal project participants in place in the project 
01.04.2019 Contacted the secretariat for another request on clinical experts 
30.04.2019 Internal project meeting regarding re-use of the HTA from CADTH, 
and contacted CADTH about search strategy 
02.05.2019 All clinical experts in place on the HTA 
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16.05.2019 Patient partner from Norwegian Glaucoma Association in place on 
the HTA 
20.05.2019 Patient partners from Norwegian Association of the Blind and Par-
tially Sighted in place on the HTA 
14.06.2019 – official start 
up date 
Start-up meeting with internal project team, clinical experts and pa-
tient partner at NIPH 
August 2019 Search done 
18.09.2019 First meeting with ethicist 
October 2019 Protocol prepared 
06.02.2020 Meeting with Sykehusinnkjøp HF  
20.11.2020 Report sent to external project group, internal and external reviewers 
06.02.2021 Report sent to internal reviewer and co-authors 
18.03.2021 Sent to final external reviewer 
06.04.2021 Final approval with director Kåre Birger Hagen 
14.04.2021 Sent to secretariat Nye metoder 
21.04.2021 Published 
*Note that there have been delays due to internal and external priorities, and availability in the 
time of Covid-19. HTA = Health Technology Assessment; RHA Forum = Commissioning Forum for 
the Regional Health Authorities; NIPH = Norwegian Institute of Public Health; MIGS = Minimally 
invasive glaucoma surgery; CADTH = Canadian Agency for Drugs and Technologies in Health 
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Appendix 2: Inconsistencies between the protocol and the final report 
Inclusion and exclusion criteria 
Due to the lack of studies comparing the effects of MIGS with pharmacotherapies, we 
did not include adverse effects of pharmacotherapy. 
 
As we already had identified the CADTH HTA, which addressed research questions that 
were identical to ours, was up-to-date, and methodologically sound, we did not include 
systematic reviews in our update. Also, we narrowed down the inclusion criteria to 
study designs that provide the best evidence of effectiveness, i.e. randomised trials and 
prospective non-randomised, controlled studies. 
 
Search 
We chose not to carry out literature searches in other sources than electronic data-
bases. The database searches provided several relevant studies, and we did not con-
sider it worthwhile to spend additional time hand searching for potentially supple-
menting literature.  
 
We did not review regular alerts to update the database searches. Instead we updated 
our literature search, running the search strategy again on 13th November 2020, limited 
to studies published in August 2019 or later. 
 
Missing data 
We did not contact authors due to time constraints, except for one case, where we con-
tacted a study author for a confirmation that the NCT registry number was wrong.  
 
Data analysis 
As there were no dichotomous data reported in the included studies, we did not calcu-
late relative risks. For the same reason, we did not use adjusted effects measures in the 
analyses. 
 
Due to study heterogeneity, the planned assessment of statistical heterogeneity was not 
possible to carry out. 
 
Due to the small number of included studies for each comparison, assessment of publi-
cation bias was not possible to carry out as planned. For the same reason we could not 
conduct any subgroup, sensititvity or meta-regression analyses. 
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Appendix 3: Search strategy 
 Før dublett: 1422 
 
 
Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-In-
dexed Citations and Daily 1946 to August 02, 2019  
Date: 03.08.2019 
Hits: 553 
 
# Searches Results 
1 exp Glaucoma, Open-Angle/ 13430 
2 exp Glaucoma Drainage Implants/ 1618 
3 Filtering Surgery/ 1191 
4 Sclerostomy/ 870 
5 Trabeculectomy/ 5263 
6 Filtering Surgery/ 1191 
7 ((glaucoma* adj2 (open angle or wide angle or simple*)) or antiglaucoma* or anti-
glaucoma*).ti,ab,kf. 14560 
8 (open adj5 angle* adj5 (eye or eyes or ocular*)).ti,ab,kf. 2935 
9 (glaucoma* or opthalmol*).jw. 13782 
10 or/1-9 35976 
11 exp Microsurgery/ 32526 
12 exp Minimally Invasive Surgical Procedures/ 490285 
13 exp Stents/ 73273 
14 ((Minimal* or minimiz* or minimis* or micro*) adj5 (incision* or invasive* or 
penetrat* or surgery or surgeries)).ti,ab,kf. 92082 
15 (Microinvasive or microincision* or microbypass* or small incision* or micro-
surg* or MicroPulse or micro pulse or non penetrat* or nonpenetrat* or less in-
vasive or mini device* or minidevice*).ti,ab,kf. 48567 
16 MIGS.ti,ab,kf. 235 
17 (stent* or microstent* or shunt* or microshunt* or dual blade or dualblade or duo 
blade or duoblade or micro blade or microblade or scaffold* or microscaf-
fold*).ti,ab,kf. 242805 
18 (Trabectome or Ab interno or XGEN or Xen* or Hydrus or Aquashunt or STARflo 
or Esnoper-Clip or Innfocus or SOLX or Kahook or iStent or iTrack or VISCO360 
or TRAB360).ti,ab,kf. 151698 
19 (Gonioscopy adj5 Trabeculotomy).ti,ab,kf. 21 
20 (excimer adj5 laser adj5 trabeculo*).ti,ab,kf. 20 
21 (Endocyclophotocoagulation* or (Cyclophotocoagulation adj5 en-
doscop*)).ti,ab,kf. 128 
22 or/11-21 948850 
23 10 and 22 2171 
24 exp animals/ not humans.sh. 4605113 
25 (news or editorial or comment).pt. 1320221 
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26 23 not (24 or 25) 2019 
27 limit 26 to yr="2000-current" 1693 
28 remove duplicates from 27 1689 
29 exp Glaucoma/ or exp Glaucoma Drainage Implants/ or exp Sclerostomy/ or exp 
Trabeculectomy/ 51636 
30 (glaucoma* or antiglaucoma*).ti,ab,kf. 58582 
31 ((open or close or closed or OAG or CAG or POAG or COAG) adj5 angle* adj5 (eye 
or eyes or ocular*)).ti,ab,kf. 3083 
32 (glaucoma* or opthalmol*).jw. 13782 
33 or/29-32 78102 
34 exp Microsurgery/ or exp Minimally Invasive Surgical Procedures/ or stents/
 548146 
35 ((Minimal* or Minimiz* or minimis* or micro*) adj5 (incision* or invasive* or 
penetrat* or surgery or surgeries)).ti,ab,kf. 92082 
36 (Microinvasive or micro-invasive or microincision* or micro-incision* or micro 
bypass* or microbypass* or small incision* or micro-surg* or microsurg* or Mi-
croPulse or micro pulse or non penetrat* or nonpenetrat* or less invasive or 
mini device* or minidevice*).ti,ab,kf. 49191 
37 (stent* or microstent* or microshunt* or shunt* or dual blade or dualblade or duo 
blade or duoblade or micro blade or microblade or scaffold* or microscaf-
fold*).ti,ab,kf. 242805 
38 MIGS.ti,ab,kf. 235 
39 (Trabectome or Ab interno or XGEN or Xen* or iStent or I stent or hydrus or Aq-
uashunt or STARflo or Esnoper-Clip or Cypass or infocus or SOLX or gel stent* 
or gelatin stent* or canalicular scaffolding or Kahook).ti,ab,kf. 151726 
40 ((Gonioscopy adj5 Trabeculotomy) or GATT).ti,ab,kf. 151 
41 (Excimer adj5 laser adj5 trabeculotom*).ti,ab,kf. 18 
42 (Endocyclophotocoagulation* or (Cyclophotocoagulation adj5 en-
doscop*)).ti,ab,kf. 128 
43 Endoscope-assisted goniosynechialysis.ti,ab,kf. 2 
44 or/34-43 948679 
45 33 and 44 3195 
46 (english or french).lg. 26027738 
47 45 and 46 2789 
48 limit 47 to yr="2000-2017" 1745 
49 28 not 48 489 
50 47 and 2017 dec.dp. 13 
51 28 and (201712* or 2018* or 2019*).ed,ez,ep,dt. 418 
52 49 or 50 or 51 553 
53 52 not (24 or 25) 553 
54 remove duplicates from 53 553 
 
 
Database: Embase 1974 to 2019 August 02  
Date: 03.08.2019 
Hits: 556 
 
 
 
138  
 
# Searches Results 
1 open angle glaucoma/ 16531 
2 exp glaucoma surgery/ 14223 
3 exp glaucoma drainage implant/ 2419 
4 exp glaucoma device/ 2428 
5 sclerostomy/ 65 
6 trabeculectomy/ 7965 
7 filtering operation/ 2430 
8 ((glaucoma* adj2 (open angle or wide angle or simple*)) or antiglaucoma* or anti-
glaucoma*).ti,ab,kw. 17579 
9 (open adj5 angle* adj5 (eye or eyes or ocular*)).ti,ab,kw. 3556 
10 (glaucoma* or opthalmol*).jw. 4269 
11 or/1-10 34806 
12 exp microsurgery/ 35703 
13 minimally invasive surgery/ 39064 
14 minimally invasive procedure/ 14392 
15 exp stent/ 165772 
16 ((Minimal* or minimiz* or minimis* or micro*) adj5 (incision* or invasive* or 
penetrat* or surgery or surgeries)).ti,ab,kw. 136113 
17 (Microinvasive or microincision* or microbypass* or small incision* or micro-
surg* or MicroPulse or micro pulse or non penetrat* or nonpenetrat* or less in-
vasive or mini device* or minidevice*).ti,ab,kw. 65805 
18 MIGS.ti,ab,kw,dv. 418 
19 (stent* or microstent* or shunt* or microshunt* or dual blade or dualblade or duo 
blade or duoblade or micro blade or microblade or scaffold* or microscaf-
fold*).ti,ab,kw,dv. 345622 
20 (Trabectome or Ab interno or XGEN or Xen* or Hydrus or Aquashunt or STARflo 
or Esnoper-Clip or Innfocus or SOLX or Kahook or iStent or iTrack or VISCO360 
or TRAB360).ti,ab,kw,dv. 200902 
21 (Gonioscopy adj5 Trabeculotomy).ti,ab,kw,dv. 24 
22 (excimer adj5 laser adj5 trabeculo*).ti,ab,kw,dv. 25 
23 (Endocyclophotocoagulation* or (Cyclophotocoagulation adj5 en-
doscop*)).ti,ab,kw,dv. 174 
24 or/12-23 785403 
25 11 and 24 2686 
26 (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or 
animal tissue/ or animal cell/ or nonhuman/) not (human/ or normal human/ 
or human cell/) 6269946 
27 (news or editorial or comment or conference abstract).pt. 4134335 
28 25 not (26 or 27) 2162 
29 limit 28 to embase 1858 
30 limit 29 to yr="2000-current" 1642 
31 remove duplicates from 30 1599 
32 exp glaucoma drainage implant/ or exp glaucoma/ or exp glaucoma surgery/ or 
exp sclerostomy/ or exp trabeculectomy/ 81997 
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33 (glaucoma* or antiglaucoma*).ti,ab,kw. 68673 
34 ((open or close or closed or OAG or CAG or POAG or COAG) adj5 angle* adj5 (eye 
or eyes or ocular*)).ti,ab,kw. 3767 
35 (glaucoma* or opthalmol*).jw. 4269 
36 or/32-35 92417 
37 exp microsurgery/ or exp minimally invasive surgery/ or exp minimally invasive 
procedure/ or exp stent/ 251008 
38 ((Minimal* or Minimiz* or minimis* or micro*) adj5 (incision* or invasive* or 
penetrat* or surgery or surgeries)).ti,ab,kw. 136113 
39 (Microinvasive or micro-invasive or microincision* or micro-incision* or micro 
bypass* or microbypass* or small incision* or micro-surg* or microsurg* or Mi-
croPulse or micro pulse or non penetrat* or nonpenetrat* or less invasive or 
mini device* or minidevice*).ti,ab,kw. 66816 
40 (stent* or microstent* or microshunt* or shunt* or dual blade or dualblade or duo 
blade or duoblade or micro blade or microblade or scaffold* or microscaf-
fold*).ti,ab,kw,dv. 345622 
41 MIGS.ti,ab,kw,dv. 418 
42 (Trabectome or Ab interno or XGEN or Xen* or iStent or I stent or hydrus or Aq-
uashunt or STARflo or Esnoper-Clip or Cypass or infocus or SOLX or gel stent* 
or gelatin stent* or canalicular scaffolding or Kahook).ti,ab,kw,dv. 200948 
43 ((Gonioscopy adj5 Trabeculotomy) or GATT).ti,ab,kw,dv. 188 
44 (Excimer adj5 laser adj5 trabeculotom*).ti,ab,kw,dv. 20 
45 (Endocyclophotocoagulation* or (Cyclophotocoagulation adj5 en-
doscop*)).ti,ab,kw,dv. 174 
46 Endoscope-assisted goniosynechialysis.ti,ab,kw,dv. 1 
47 or/37-46 785677 
48 36 and 47 3829 
49 (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or 
animal tissue/ or animal cell/ or nonhuman/) not (human/ or normal human/ 
or human cell/) 6269946 
50 (news or editorial or comment or conference abstract).pt. 4134335 
51 48 not (49 or 50) 3056 
52 (english or french).lg. 28714796 
53 51 and 52 2515 
54 limit 53 to yr=2000-2017 1692 
55 31 not 54 521 
56 53 and ("0* dec 2017" or "1* dec 2017" or "2* dec 2017" or "3* dec 2017").dp. 15 
57 31 and (201712* or 2018* or 2019*).dd,dc. 379 
58 55 or 56 or 57 558 
59 limit 58 to embase 558 
60 59 not (26 or 27) 558 
61 remove duplicates from 60 556 
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Database: Cochrane Library [CDSR & CENTRAL] (Wiley) 
Date: 03.08.2019 
Hits: 220 
 
 
ID Search Hits 
#1 [mh "Glaucoma, Open-Angle"] 1716 
#2 [mh "Glaucoma Drainage Implants"] 83 
#3 [mh ^Sclerostomy] 53 
#4 [mh ^Trabeculectomy] 556 
#5 [mh ^"Filtering Surgery"] 45 
#6 ((glaucoma* NEAR/2 (open-angle or wide-angle or simple*)) or antiglaucoma* or 
anti-glaucoma*):ti,ab,kw 3703 
#7 (open NEAR/5 angle* NEAR/5 (eye or eyes or ocular*)):ti,ab,kw 1446 
#8 (121-#7) 3964 
#9 [mh Microsurgery] 624 
#10 [mh "Minimally Invasive Surgical Procedures"] 26499 
#11 [mh Stents] 3975 
#12 ((Minimal* or minimiz* or minimis* or micro*) NEAR/5 (incision* or invasive* or 
penetrat* or surgery or surgeries)):ti,ab,kw 8598 
#13 (Microinvasive or microincision* or microbypass* or small-incision* or micro-
surg* or MicroPulse or micro-pulse or non-penetrat* or nonpenetrat* or less-
invasive or mini-device* or minidevice*):ti,ab,kw 3038 
#14 MIGS:ti,ab,kw 16 
#15 (stent* or microstent* or shunt* or microshunt* or dual-blade or dualblade or 
duo-blade or duoblade or micro-blade or microblade or scaffold* or microscaf-
fold*):ti,ab,kw 17641 
#16 (Trabectome or Ab interno or XGEN or Xen* or Hydrus or Aquashunt or STARflo 
or Esnoper-Clip or Innfocus or SOLX or Kahook or iStent or iTrack or VISCO360 
or TRAB360):ti,ab,kw 2027 
#17 (Gonioscopy NEAR/5 Trabeculotomy):ti,ab,kw 1 
#18 (excimer NEAR/5 laser NEAR/5 trabeculo*):ti,ab,kw 8 
#19 (Endocyclophotocoagulation* or (Cyclophotocoagulation NEAR/5 en-
doscop*)):ti,ab,kw 15 
#20 (8-#19) 51714 
#21 #8 and #20 with Cochrane Library publication date Between Jan 2000 and Aug 
2019, in Cochrane Reviews 10 
#22 #8 and #20 with Publication Year from 2000 to 2019, in Trials 210 
#23 #21 or #22 220 
 
 
Database: CINAHL (EBSCO) 
Date: 03.08.2019 
Hits: 93 
 
# Query Results 
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S1 (MH "Glaucoma+") 7,089 
S2 (MH "Filtering Surgery") 53 
S3 (MH "Sclerostomy") 29 
S4 (MH "Trabeculectomy") 270 
S5 TI ( (glaucoma* N1 (open-angle or wide-angle or simple*)) or antiglaucoma* or 
anti-glaucoma*) ) OR AB ( (glaucoma* N1 (open-angle or wide-angle or sim-
ple*)) or antiglaucoma* or anti-glaucoma*) ) OR SU ( (glaucoma* N1 (open-an-
gle or wide-angle or simple*)) or antiglaucoma* or anti-glaucoma*) ) 1,239 
S6 TI ( (open N4 angle* N4 (eye or eyes or ocular*)) ) OR AB ( (open N4 angle* N4 
(eye or eyes or ocular*)) ) OR SU ( (open N4 angle* N4 (eye or eyes or ocular*)) 
) 265 
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6 7,388 
S8 (MH "Microsurgery+") 2,791 
S9 (MH "Minimally Invasive Procedures+") 11,192 
S10 (MH "Stents+") 18,949 
S11 TI ( ((Minimal* or minimiz* or minimis* or micro*) N4 (incision* or invasive* or 
penetrat* or surgery or surgeries)) ) OR AB ( ((Minimal* or minimiz* or mini-
mis* or micro*) N4 (incision* or invasive* or penetrat* or surgery or surger-
ies)) ) OR SU ( ((Minimal* or minimiz* or minimis* or micro*) N4 (incision* or 
invasive* or penetrat* or surgery or surgeries)) ) 22,130 
S12 TI ( (Microinvasive or microincision* or microbypass* or small-incision* or mi-
crosurg* or MicroPulse or micro-pulse or non-penetrat* or nonpenetrat* or 
less-invasive or mini-device* or minidevice*) ) OR AB ( (Microinvasive or mi-
croincision* or microbypass* or small-incision* or microsurg* or MicroPulse or 
micro-pulse or non-penetrat* or nonpenetrat* or less-invasive or mini-device* 
or minidevice*) ) OR SU ( (Microinvasive or microincision* or microbypass* or 
small-incision* or microsurg* or MicroPulse or micro-pulse or non-penetrat* or 
nonpenetrat* or less-invasive or mini-device* or minidevice*) ) 11,793 
S13 TI MIGS OR AB MIGS OR SU MIGS 222 
S14 TI ( (stent* or microstent* or shunt* or microshunt* or dual-blade or dualblade or 
duo-blade or duoblade or micro-blade or microblade or scaffold* or microscaf-
fold*) ) OR AB ( (stent* or microstent* or shunt* or microshunt* or dual-blade 
or dualblade or duo-blade or duoblade or micro-blade or microblade or scaf-
fold* or microscaffold*) ) OR SU ( (stent* or microstent* or shunt* or microsh-
unt* or dual-blade or dualblade or duo-blade or duoblade or micro-blade or mi-
croblade or scaffold* or microscaffold*) ) 37,900 
S15 TI ( (Trabectome or Ab-interno or XGEN or Xen* or Hydrus or Aquashunt or 
STARflo or Esnoper-Clip or Innfocus or SOLX or Kahook or iStent or iTrack or 
VISCO360 or TRAB360) ) OR AB ( (Trabectome or Ab-interno or XGEN or Xen* 
or Hydrus or Aquashunt or STARflo or Esnoper-Clip or Innfocus or SOLX or Ka-
hook or iStent or iTrack or VISCO360 or TRAB360) ) OR SU ( (Trabectome or 
Ab-interno or XGEN or Xen* or Hydrus or Aquashunt or STARflo or Esnoper-
Clip or Innfocus or SOLX or Kahook or iStent or iTrack or VISCO360 or 
TRAB360) ) 7,940 
S16 TI (Gonioscopy N4 Trabeculotomy) OR AB (Gonioscopy N4 Trabeculotomy) OR 
SU (Gonioscopy N4 Trabeculotomy) 8 
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S17 TI (excimer N4 laser N4 trabeculo*) OR AB (excimer N4 laser N4 trabeculo*) OR 
SU (excimer N4 laser N4 trabeculo*) 5 
S18 TI ( (Endocyclophotocoagulation* or (Cyclophotocoagulation N4 endoscop*)) ) 
OR AB ( (Endocyclophotocoagulation* or (Cyclophotocoagulation N4 en-
doscop*)) ) OR SU ( (Endocyclophotocoagulation* or (Cyclophotocoagulation 
N4 endoscop*)) ) 34 
S19 S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18
 78,022 
S20 S7 AND S19 592 
S21 S7 AND S19 [Limiters - Exclude MEDLINE records; Published Date: 20000101-
20190831] 
 424 
S22 S7 AND S19 [Limiters - Exclude MEDLINE records; Published Date: 20000101-
20190831; Limiters – Journals] 
 93 
 
Database: ClinicalTrials.gov (U.S National Library of Medicine) 
Date: 11.09.2019 
Hits: 93 
 
Search 1 
[Condition or disease:] Glaucoma, Open-Angle 
[Other terms:] glaucoma 
[Study type:] Interventional Studies (Clinical Trials) 
[Study results:] All studies 
[Intervention/treatment:] micro OR minimal OR minimally OR minimise OR minimize 
OR minimising OR minimizing OR migs OR microinvasive OR microincision OR microin-
cisions OR microbypass OR microbypasses OR microsurgy OR microsurgeries OR Mi-
croPulse OR “micro pulse”  
 
Search 2 
[Condition or disease:] Glaucoma, Open-Angle 
[Other terms:] glaucoma 
[Study type:] Interventional Studies (Clinical Trials) 
[Study results:] All studies 
[Intervention/treatment:] non-penetrating OR non-penetration OR non-penetrations 
OR nonpenetrating OR nonpenetration OR nonpenetrations OR “less invasive” OR “mini 
device” OR “mini devices” OR minidevice OR minidevices OR stent OR stents OR mi-
crostent OR microstents OR shunt  
 
 
Search 3 
[Condition or disease:] Glaucoma, Open-Angle 
[Other terms:] glaucoma 
[Study type:] Interventional Studies (Clinical Trials) 
[Study results:] All studies 
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[Intervention/treatment:] shunts OR microshunt OR microshunts OR “dual blade” OR 
dualblade OR “duo blade” OR duoblade OR “micro blade” OR microblade OR scaffold OR 
scaffolding OR microscaffold OR microscaffolding OR Trabectome OR “Ab interno” OR 
XGEN OR Xen* OR Hydrus  
 
Search 4 
[Condition or disease:] Glaucoma, Open-Angle 
[Other terms:] glaucoma 
[Study type:] Interventional Studies (Clinical Trials) 
[Study results:] All studies 
[Intervention/treatment:] Aquashunt OR STARflo OR Esnoper-Clip OR Innfocus OR 
SOLX OR Kahook OR iStent OR iTrack OR VISCO360 OR TRAB360 
 
 
 
Database: International Clinical Trials Registry Platform (WHO) 
Date: 11.09.2019 
Hits: 172 
micro OR minimal OR minimally OR minimise OR minimize OR minimising OR minimiz-
ing OR migs OR microinvasive OR microincision OR microincisions OR microbypass OR 
microbypasses OR microsurgy OR microsurgeries OR MicroPulse OR “micro pulse” OR 
non-penetrating OR non-penetration OR non-penetrations OR nonpenetrating OR non-
penetration OR nonpenetrations OR “less invasive” OR “mini device” OR “mini devices” 
OR minidevice OR minidevices OR stent OR stents OR microstent OR microstents OR 
shunt OR shunts OR microshunt OR microshunts OR “dual blade” OR dualblade OR “duo 
blade” OR duoblade OR “micro blade” OR microblade OR scaffold OR scaffolding OR mi-
croscaffold OR microscaffolding OR Trabectome OR “Ab interno” OR XGEN OR Xen* OR 
Hydrus OR Aquashunt OR STARflo OR Esnoper-Clip OR Innfocus OR SOLX OR Kahook 
OR iStent OR iTrack OR VISCO360 OR TRAB360 
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Appendix 4: Eligible studies from top-up search 
1. Ahmed IIK, Fea A, Au L, Ang RE, Harasymowycz P, Jampel HD, et al. A Prospective Randomized 
Trial Comparing Hydrus and iStent Microinvasive Glaucoma Surgery Implants for Standalone 
Treatment of Open-Angle Glaucoma: The COMPARE Study. Ophthalmology 2020;127(1):52-61.  
2. Ahmed IIK, Rhee DJ, Jones J, Singh IP, Radcliffe N, Gazzard G, et al. Three-year findings of the 
HORIZON trial: a Schlemm canal microstent for pressure reduction in primary open angle 
glaucoma and cataract. Ophthalmology 2020;06:06.  
3. Falkenberry S, Singh IP, Crane CJ, Haider MA, Morgan MG, Grenier CP, et al. Excisional goniotomy 
vs trabecular microbypass stent implantation: a prospective randomized clinical trial in eyes 
with mild to moderate open-angle glaucoma. J Cataract Refract Surg 2020;46(8):1165-71.  
4. Fechtner RD, Voskanyan L, Vold SD, Tetz M, Auffarth G, Masood I, et al. Five-Year, Prospective, 
Randomized, Multi-Surgeon Trial of Two Trabecular Bypass Stents versus Prostaglandin for 
Newly Diagnosed Open-Angle Glaucoma. Ophthalmology glaucoma 2019;2(3):156-66.  
5. Kozera M, Konopinska J, Mariak Z, Rekas M. Effectiveness of iStent trabecular micro-bypass sys-
tem combined with phacoemulsification vs. phacoemulsification alone in patients with glau-
coma and cataract depending on the initial intraocular pressure. Ophthalmic Res 2020;09:09.  
6. Laspas P, Garcia-Feijoo J, Martinez-de-la-Casa JM, Larrosa JM, Fea A, Lemij H, et al. Three-Year 
Results of Hydrus Microstent with Phacoemulsification. Ophthalmol Glaucoma 2019;2(6):440-
2.  
7. Lenzhofer M, Strohmaier C, Hohensinn M, Hitzl W, Steiner V, Baca B, et al. Change in visual acuity 
12 and 24 months after transscleral ab interno glaucoma gel stent implantation with adjunc-
tive Mitomycin C. Graefes Arch Clin Exp Ophthalmol 2019;257(12):2707-15.  
8. Zebardast N, Zheng C, Jampel HD. Effect of a Schlemm's Canal Microstent on Early Postoperative 
Intraocular Pressure after Cataract Surgery: An Analysis of the HORIZON Randomized Con-
trolled Trial. Ophthalmology 2020;127(10):1303-10.  
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Appendix 5: GRADE evidence profile 
Certainty assessment № of patients Effect 
Certainty № of 
stu-
dies 
Study 
design 
Risk of 
bias 
Incon-
sis-
tency 
In-
directness 
Impre-
cision 
Other 
con-
side-
ra-
tions 
Effecti-
veness 
of 
MIGS 
pla-
cebo 
 
Absolute 
(95% CI) 
IOP - Hydrus vs 2x iStent 
1  randomi-
sed trial  
serious 
a 
not se-
rious  
not serious  serious 
b  
none  73  75  MD 1.9 lower 
(2.91 lower to 0.89 
lower)  
⨁⨁◯◯ 
LOW  
IOP - iStent+phaco vs phaco alone 
1  observa-
tional 
study  
serious 
c 
serious  not serious  serious 
b  
none  24  24  MD 1.9 lower 
(3.32 lower to 0.48 
lower)  
⨁◯◯◯ 
VERY LOW  
IOP - iStent inject+phaco vs phaco alone 
2  randomi-
sed trials  
very 
serious 
a 
not se-
rious  
not serious  not se-
rious  
none  418  152  MD 0.7 lower 
(1.27 lower to 0.13 
lower)  
⨁⨁⨁◯ 
MODERATE  
IOP - Hydrus+phaco vs phaco alone 
1  randomi-
sed trial  
not se-
rious  
not se-
rious  
not serious  serious none  219  112  MD 1.8 lower 
(2.73 lower to 0.87 
lower)  
⨁⨁⨁⨁ 
HIGH  
IOP - Trab360+phaco vs phaco alone 
1  random-
ised trial  
very 
serious 
d 
serious not serious  very 
serious 
b  
none  9  9  MD 2.8 lower 
(5.49 lower to 0.11 
lower)  
⨁◯◯◯ 
VERY LOW  
IOP - Gold MicroShunt vs Ahmed glaucoma valve 
1  randomi-
sed trial  
very 
serious 
g 
serious 
d 
not serious  very 
serious 
b 
none  8  4  MD 0.7 lower 
(2.71 lower to 1.31 
higher)  
⨁◯◯◯ 
VERY LOW  
IOP - iTrack+phaco vs flitration surgery+phaco 
1  randomi-
sed trial  
very 
serious 
f 
serious not serious  serious 
b  
none  29  30  MD 1.7 lower 
(3.29 lower to 0.11 
lower)  
⨁◯◯◯ 
VERY LOW  
CI: Confidence interval; MD: Mean difference 
a. High risk of performance and reporting bias; selection and detection bias unclear; b. Wide confidence interval; c. Serious bias due to confounding, d. Small 
study size; e. High risk of performance, attrition and reporting bias; unclear risk of bias in majority of domains in one of the studies; f. High risk of performance, 
detection and reporting bias; g. High risk of attrition and reporting bias; unclear risk of bias in most other domains; h. High risk of selection, performance and 
attrition bias; unclear risk of detection ans reporting bias.  
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Appendix 6: Studies excluded from NIPH supplementary review, with reasons 
Editorial, letter or commentary 
1. Kalenak JW. Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glau-
coma at 12 Months. American Journal of Ophthalmology 2018;188:185-6.  
2. Voykov B, Blumenstock G, Leitritz MA, Dimopoulos S, Alnahrawy O. Treatment efficacy and 
safety of canaloplasty for open-angle glaucoma after 5 years. Clinical and Experimental Oph-
thalmology 2015;43(8):768-71.  
3. Buys YM. Re: Samuelson et al.: A Schlemm canal microstent for intraocular pressure reduction 
in primary open-angle glaucoma and cataract: The HORIZON study (Ophthalmology. 
2019;126:29-37). Ophthalmology 2019;126(1):e5-e6.  
 
Included in CADTH HTA 
1. Glaukos C. Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With 
Primary Open-angle Glaucoma (POAG). https://ClinicalTrials.gov/show/NCT00913029; 2009. 
2. Fdez-Barrientos Y, Martinez-de-la-Casa JM, Garcia-Feijoo J, Olea-Zorita G, Mendez-Hernandez 
C, Fdez-Vidal A, et al. Fluorophotometric Study of the Effect of Cataract Surgery and Trabecu-
lar Micro-Bypass on Aqueous Humor Dynamics, Preliminary Results. IOVS 2007;48:ARVO E-
Abstract 823.  
3. Nct, University of Turin I. A Clinical Trial of Phacoemulsification Versus Phacoemulsification 
&amp; the iStent Implantation in POAG Patients. 2009. 
4. Glaukos C. A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open 
Angle Glaucoma or OH Patients. https://ClinicalTrials.gov/show/NCT00326066; 2005. 
5. Nct. Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hyperten-
sion Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents 
(iStent)or Travoprost. Https://clinicaltrialsgov/show/nct01443988 2011.  
6. Nct, Glaukos C. A Study of the Trabecular Micro-bypass Stent in Combination With Cataract 
Surgery in Subjects With Open Angle Glaucoma. 2006. 
 
Can not translate 
1. Jo S. Glaucoma Schlemm's canal stent insertion: A systematic review. [Korean]. Journal of the 
Korean Medical Association 2016;59(8):637-43.  
 
Duplicate 
1. Buffault J, Baudouin C, Labbe A. XEN<sup></sup> Gel Stent for management of chronic open 
angle glaucoma: A review of the literature. Journal Francais d Opthalmologie 2019;42(2):e37-
e46.  
2. Gao LD, Ge YR, Cheng JW, Shen Y, Wang H, Wei RL. Efficacy of nonpenetrating glaucoma sur-
gery in the treatment of open angle glaucoma: a systematic review. Academic Journal of Sec-
ond Military Medical University 2014;35(2):129-35.  
3. Samuelson TW, Chang DF, Marquis R, Flowers B, Lim KS, Ahmed IIK, et al. A Schlemm Canal 
Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: 
The HORIZON Study. Ophthalmology 2019;126(1):29-37.  
4. Samuelson TW, Sarkisian SR, Lubeck DM, Stiles MC, Duh YJ, Romo EA, et al. Prospective, Ran-
domized, Controlled Pivotal Trial of iStent inject Trabecular Micro-Bypass in Primary Open-
Angle Glaucoma and Cataract: two-Year Results. Ophthalmology 2019.  
5. Jprn U, Hiroshima U. A Randomized Study of Efficacy of trabecular micro bypass stent with 
cataract surgery for open angle glaucoma <Acronym />. 2017. 
6. University of Turin I. A Clinical Trial of Phacoemulsification Versus Phacoemulsification & the 
iStent Implantation in POAG Patients. https://ClinicalTrials.gov/show/NCT00847158; 2006. 
7. Jprn U, Sato E, Internal Medicine C. Outcomes of 360-degree suture trabeculotomy ab interno 
with cataract surgery in patient with open-angle glaucoma coexisting cataract: a 2-year pro-
spective, randomized, comparative study <Acronym />. 2016. 
8. Nct. Safety and Efficacy of Three Variants of Canaloplasty With Phacoemulsification to Treat 
Glaucoma and Cataract. Https://clinicaltrialsgov/show/nct02908633 2016.  
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9. New World Medical I. A Comparison of Two Ab Interno Procedures in the Treatment of Glau-
coma in Patients Undergoing Cataract Extraction. https://ClinicalTri-
als.gov/show/NCT02784249; 2016. 
10. Nct, Solx I. SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glau-
coma. 2006. 
11. Nct, Ivantis I. Safety &amp; Effectiveness Study of the Hydrus Microstent for Lowering IOP in 
Glaucoma Patients Undergoing Cataract Surgery (HORIZON). 2012. 
12. Nct, Ivantis I. Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Under-
going Cataract Surgery. 2012. 
13. Nct, Ivantis I. Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower 
IOP in Phakic Eyes. 2013. 
14. Nct, Ivantis I. Comparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma 
Patients Undergoing Cataract Surgery. 2013. 
15. Nct, Glaukos C. Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabecu-
loplasty <Acronym />. 2014. 
16. Nct, Sight Sciences I. Randomized Study of the Safety and Effectiveness of the Sight Sciences 
VISCO™360 Viscosurgical System Versus SLT in Primary Open Angle Glaucoma (VISCO360 
Study). 2016. 
17. Nct, Center for Eye Research A, Glaukos C. A Comparison of Cataract Surgery Alone and Cata-
ract Surgery With iStent. 2017. 
18. Nct, Johns Hopkins U. Trabeculectomy Versus 2-iStent and Prostaglandin Study. 2017. 
19. Nct, Military Institute of Medicine P. Safety and Efficacy of Canaloplasty and Non-penetrating 
Deep Sclerectomy With Phacoemulsification to Treat Glaucoma and Cataract. 2012. 
 
Poster 
1. Fea A, Lacroix G, Ghennadian S, Brogliatti B, Grignolo F. A Prospective, Randomized, Double 
Blind 15-Month Pilot Study on the Efficacy of Trabecular Stent (iStent) Implantation With 
Combined Phacoemulsification. American academy of ophthalmology 2008:214.  
2. Harasymowycz P. Results from the horizon trial: a randomized study of a schlemm'scanal mi-
crostent for reduction ofiop in primary open angle glaucoma. Clinical & Experimental Oph-
thalmology 2018;46:66-.  
 
Retrospective study 
1. Kostanyan T, Shazly T, Kaplowitz KB, Wang SZ, Kola S, Brown EN, et al. Longer-term Baerveldt 
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Appendix 7: Characteristics of studies included in NIPH supplementary review  
 
 
 
 
Study characteristics  Study: Ahmed 2019,  
Country: 12 centers across 9 countries 
Publication title: A prospective randomized trial comparing hydrus 
and iStent microinvasive glaucoma surgery implants for standalone 
treatment of open-angle glaucoma. The COMPARE study.  
Methods  Study design: Multicenter randomised clinical trial 
Inclusion criteria: Open –angle glaucoma   
Exclusion criteria: Secondary  glaucoma, angle closure, previous inci-
sional glaucoma surgery, significant ocular pathology, agerelated 
macular degeneration, diabetic retinopathy 
Study population  Total: 152 patients, 152 eyes, age 45 to 84 years, 55% female,  
 
Intervention group: Hydrus N= 75 
Control group: 2iStents N=77 
  
96% POAG* in Hydrus group, 92,2% in 2iStents group.  
65,3% Phakic in Hydrus group, 62,3% in 2iStents group  
Follow up time 
Study duration  
One year follow up postoperative 
March 2013 to May 2015 
Conflicts of interest 
Funding  
Funding: Glaukos, Ivantis (?) 
“The study data were 100% source document verified by independ-
ent clinical monitors with funding provided by study sponsor.” Finan-
cial disclosures authors are given at the end of paper.  
Study characteristics  Study: Best 2019 
Country: Germany 
Publication title: “Mikroinvasive Glaukomchirurgie– Wirksamkeit 
von trabekulären Stents bei kombinierten Eingriffen. Eine kli-
nische Studie an 65 Augen” 
Methods  Study design: RCT 
Inclusion criteria: chronic open-angle glaucoma with at least 2 dif-
ferent pressure-lowering drugs  
Exclusion criteria: low-tension glaucoma, secondary glaucoma 
and ocular hypertension 
Study population  Total: 56 patients, 65 eyes. Aged between 66 and 81 years 
Intervention group: Phako+iStent group (31 eyes, 27 individuals) 
Control group: Phako (34 eyes, 29 individuals) 
Type of glaucoma: primary chronic open-angle glaucoma. 
Glaucoma  severity/stage : The phako+iStent group had preopera-
tive mean IOP 25,1 mmHg, the Phako group 22,0 mmHg 
Follow up time 
Study duration  
Mean follow-up time 14 months (up to 38 months) 
Inclusion and intervention October 2014 to March 2017 
Follow up October 2014 to December 2017 
Conflicts of interest 
Funding  
The authors declare no conflicts of interest 
Not funded by or connected to the industry.  
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Study characteristics  Study: Jones 2019 
Country: USA, 26 investigational sites 
Publication title: “Results from the United States cohort of the HORI-
ZON trial of a Schlemm canal microstent to reduce intraocular pres-
sure in primary open-angle glaucoma” 
Methods  Study design: RCT 
Inclusion criteria: age related cataract or moderate primary open-an-
gle glaucoma  
Exclusion criteria: angle-closure glaucoma, any secondary glaucoma, 
and other diagnoses of various diseases and complications related to 
the eye.  
Study population  Total: 331 eyes (US population) (Total in HORIZON (N=556)) 
Intervention group: Hydrus Microstent implantation (n=219 eyes) 
mean age 70, 52% female. 
Control group: phacoemulsification (n=112 eyes), mean age 71, 55% 
female.  
Type of glaucoma: age-related cataract and mild to moderate pri-
mary open angle glaucoma 
Glaucoma severity/stage: mild to moderate visual field loss 
Follow up time 
Study duration  
Two years follow up 
Conflicts of interest 
Funding  
Disclosures at the end of paper.  
Ivantis Inc., Glaukos Corp., Alcon laboratory Inc., and Allergan Inc. 
The dataset was audited by the sponsor. 
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Study characteristics  Study: Rekas 2015  
Country: Poland 
Publication title: “Canaloplasty versus non-pnetrating deep 
sclerectomy – a prospective, randomised study of the safety and effi-
cacy of combined cataract and glaucoma surgery; 12-month follow-up” 
                           
Methods  
Study design: RCT 
Inclusion criteria: uncontrolled primary open-angle glaucoma and a 
cataract; primary open-angle glaucoma (POAG), pseudo-exfoliation 
glaucoma (PEX), and pigmentary glaucoma (PG), with unsatisfac-
tory intraocular pressure (IOP) control despite maximally tolerated 
topical and systemic medication.   
Exclusion criteria: any previous surgical procedure within the eye, 
closed or narrow angle glaucoma, neovascular glaucoma, poorly 
controlled diabetes mellitus with diabetic retinopathy, advanced 
macular degeneration, and active inflammatory disease. 
Study population  Total: 59 patients 
Intervention group: 29 eyes phaco-canaloplasty (mean age 74,5 years, 
female/male 12/17) 
Control group: 30 eyes phaco-non-penetrating deep sclerectomy 
(mean age 73 years, female/male 14/16) 
Type of glaucoma: majority POAG 
Glaucoma severity/stage: LOCS III scale 24/35 
Follow up time 
Study duration  
One year  
Conflicts of interest 
 
“The authors have no proprietary interest in any of the materials, 
products, or methods mentioned in this article”. 
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Funding 
 
  
“No financial support was received for this submission”.  
Study characteristics  Study: Samuelson 2019 
Country: USA 
Publication title: “Prospective, randomized, controlled pivotal trial of 
Ab Interno Implanted Trabecular Micro-bypass in primary open-angle 
glaucoma and cataract” 
Methods  Study design: RCT 
Inclusion criteria: primary mild to moderate open angle glaucoma Ex-
clusion criteria: a.o. angle-closure glaucoma, glaucoma associated 
with vascular disease, visual field MD worse than -12dB, div ocular or 
systemic conditions 
Study population  Total: 505 eyes, 41 sites, multicentre trial, USA population 
Intervention group: cataract surgery with stent implantation (n=387 
eyes, mean age 69 years, 58% women) 
Control group: cataract surgery (n=118 eyes, mean age 70 years, 54% 
women) 
Type of glaucoma: POAG, pre op IOP ≤ 24mmHg, on 1 to 3 medica-
tions or unmedicated diurnal IOP 21 to 36 mmHg 
Glaucoma severity/stage:BSCVA 0.234 at baseline 
Follow up time 
Study duration  
Two years 
Investigation initiated in September 2011 
Conflicts of interest 
 
Funding  
Financial disclosures at the end of paper (mainly Glaukos and Ivantis) 
Glaukos Corporation  
Study characteristics  Study: Sato 2018 
Country: Japan 
Publication title: “360-degree suture trabeculotomy ab interno with 
phacoemulsification in open-angle glaucoma and coexisting cataract: 
a pilot study” 
Methods  Study design: RCT 
Inclusion criteria: open-angle glaucoma and coexisting cataract 
Exclusion criteria: neovascular, uveitic or angle recession glau-
coma; had previous glaucoma, vitrectomy, buckling surgery or re-
fractive surgery; were known to be corticosteroid responders; 
had severely uncontrolled IOP or severe glaucomatous field de-
fects or had ocular disease that would affect safety or interfere 
with the tests 
Study population  Total: 18 patients/eyes (total 24 patients, six excluded at study start 
before randomisation) Mean age 74 years 
Intervention group: n=9, 360-degree suture trabeculotomy ab in-
terno with phacoemulsification  
Control group: n=9, phacoemulsification alone  
Type of glaucoma: primary open-angle glaucoma, exfoliation glau-
coma  
Glaucoma severity/stage: Best-corrected visual acuity (logMAR) 
0.24±0.25 (intervention) 0.88±0.69 (control) 
Follow up time Two years 
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Study duration  October 2014 to April 2015 
Conflicts of interest 
Funding  
None declared. 
“The authors have not declared a specific grant for this research 
from any funding agency in the public, commercial or not-for-
profit sectors.” 
Study characteristics  Study: Skaat 2016  
Country: Israel 
Publication title: “Gold micro-shunt implants versus Ahmed Glau-
koma Valve: long-term outcomes of a prospective randomized clini-
cal trial” 
Methods  Study design: 3-armed RCT 
Inclusion criteria: primary open-angle  glaucoma,  pseudoexfolia-
tion glaucoma, or pigmentary dispersion glaucoma in 1 or both 
eyes; average baseline IOP of ≤22 mm Hg while on maximally tol-
erated medical treatment  
Exclusion criteria: a.o. best-corrected visual acuity (BCVA) worse 
than finger counting in 1 or both eyes; the presence of uveitic 
glaucoma, iridocorneal endothelial syndrome, traumatic glau-
coma, or neovascular glaucoma 
Study population  Total: 29 patients, 29 eyes, mean age 72 years, equal men/women 
Group 1: an Ahmed glaucoma valve (AGV) n=9 
Group 3: a 24mm Gold Micro-Shunt (GMS) n=9 
Group 3: a 48mm Gold Micro-Shunt (GMS) n=11 
Type of glaucoma: primary open angle (n=21) or pseudoexfoliative 
(n=8)  
Glaucoma severity/stage: Phakic (n=10), Pseudophakic (n=19) 
Follow up time 
Study duration  
Five years 
January 2006 to July 2007 
Conflicts of interest 
Funding  
“The authors declare no conflicts of interest” 
None declared 
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Appendix 8: Organizational aspects: questionnaire 
1. What type of MIGS is used in your Regional Health Authority today (at the specific 
hospital)? Which ,ethod is most appropriate to use in Norway? 
 
 
2. We have received a list (attached below) presetning the type of MIGS, name and 
provider. Which of these do you think may be relevant to our assessment regards to 
the questions above? 
  
  
TYPE OF SURGERY   BRAND NAME   COMPANY   
Subconjunctival space         
   Xen Gel Stent   Allergen   
   Express Alcon 
   Microshunt   Santen   
   
  
Suprachoridal space         
   Gold   Solx    
   iStent Supra  Glaukos   
   Cypass  Alcon   
Trabecular meshwork/ schlemm canal         
   Abic (iTrack)   Ellex   
   Kahook Dual Blade   New World Medical   
   Visco360   Sight Sciences   
   Hydrus  Ivantis   
   iStent   Glaukos   
   Trabectome    Neomedix    
 
3. What type of MIGS is appropriate to use in Norway? Is every MIGS device equally 
relevant? (see table for three types of MIGS). 
 
4. Which suppliers are on the Norwegian market? 
 
5. Are “Sykehusinnkjøp HF” involved in procurement processes related to this area? 
 
6. How many patients received MIGS surgery at hospitals in your region in 2016, 2017 
and 2018? 
 
7. How do you select patients? 
 
8. Describe the use of cataract surgery and trabeculectomy. 
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9. Do you use operating room when performing MIGS? 
 
10.  What about the capacity? 
 
11. Will an extension of the indication for MIGS lead to organizational consequences for 
their hospitals and if so, what kind of consequences (investements, equipments, 
buildings (establishing of special rooms), need for staff with specialized expertise, 
training, number of hospitals performing MIGS, changed need for follow-up in 
hospitals and primary health care)? 
 
12. Are there any results from, is it ongoing, or are there relevant research projects 
planned in the region/hospital? 
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